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Background: Asthma is a common chronic inflammatory respiratory disease that 
disproportionately affects children and African Americans residing in urban, low 
socioeconomic status communities. Polycyclic aromatic hydrocarbons (PAH) are 
products of incomplete combustion of organic materials and are found in gas phase, and 
on fine and ultrafine particulate matter (PM). In vitro, animal and human studies have 
shown PAHs to be associated with increased oxidative stress, allergen-mediated 
inflammatory responses and asthma exacerbation. 
Methods: In this study, we examined whether internal dose of PAHs (urinary 1-OHPG) 
was associated with early effect biomarkers of oxidative stress, inflammation, and 
asthma-related symptoms in the DISCOVER/Asthma-Diet study (children with asthma in 
Baltimore) and the Nasal Challenge to Indoor Particulate Matter study (adults with atopic 
asthma in Baltimore). 
Results: We found that children spending time in homes with low air nicotine 
concentrations showed inverse associations between time spent indoors and urinary 1-
OHPG concentrations. In addition, time spent outdoors was independently associated 
with increased 1-OHPG in boys. Atopy modulated the associations between urinary 1-
OHPG and peripheral blood eosinophils and neutrophils, with significantly stronger 
positive associations among atopic asthmatic children compared to non-atopic asthmatic 
children. Children with high urinary 1-OHPG concentrations were also at an increased 
risk for nighttime waking due to asthma symptoms and nighttime rescue medication use. 
We also found that GSTM1 genotype modified the associations between 1-OHPG and 




atopic asthmatics, with significantly stronger positive associations among GSTM1-null 
participants compared to GSTM1-present participants. 
Conclusion: Our results suggest that exposures to second hand smoke, and combustion 
products in outdoor ambient air are major contributors to internal dose of PAHs in inner 
city children. In addition, PAH exposures may contribute to allergen-mediated systemic 
inflammatory responses (with possible adjuvant effects by PAHs in atopic asthmatics), 
and to asthma exacerbation in inner city children with asthma. Our results also suggest 
that PAH exposures contribute to increased local and systemic inflammation in adults 
with atopic asthma in Baltimore, and that individuals with the GSTM1-null 
polymorphism may be more susceptible to inflammatory responses associated with PAH 
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This thesis dissertation is comprised of six chapters. The first chapter is an introduction to 
the studies performed, with background, specific aims and hypotheses. The second, third 
and fourth chapters are the extended draft manuscripts for each of the aims. The fifth, and 
final, chapter discusses the public health relevance and implications of these studies, and 
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CHAPTER 1: Introduction 
 
Background 
Asthma is a common chronic inflammatory respiratory disease with an increasing 
disease burden in the United States. Asthma prevalence in the US has increased from 
7.3% (20 million people) in 2001 to 8.4% (25.7 million people) in 2010, with higher rates 
among children ages 0-17 (9.5%) compared to adults 7.7% for 2008-2010 (CDC 2011; 
Akinbami et al. 2012). The medical and social burden of asthma is considerable, with a 
disproportionate impact on vulnerable groups including young children, African-
Americans, and those who are living in inner cities. African American children are 
especially at risk, as they have double the asthma prevalence (17%) compared to white 
children (8.5%) (CDC 2011). Sociodemographic disparities in asthma are also evident, as 
people living in urban environments, and children from families of low socioeconomic 
status experience higher asthma burdens–11.2% asthma prevalence compared to the 
national average for children, 9.5% (CDC 2011; Akinbami et al. 2012). Atopy, an allergic 
phenotype characterized by increased production of IgE in response to specific allergens, 
is associated with asthma pathogenesis and asthma severity (Pearce et al. 1999; Suh and 
Koh 2013). Most asthmatics have an atopic constitution and are vulnerable to 
inflammatory responses from multiple environmental stimuli (Nelson et al. 1999; 
Eggleston 2000; Lau et al. 2000), as co-exposures to allergens and environmental air 
pollutants (such as second hand smoke (SHS), particulate matter (PM), ozone (O3) and 
nitrogen dioxide (NO2)) may lead to increased frequency of asthma exacerbations in 




Inner city residents experience increased exposures to agents and conditions (such 
as PM, allergens, NO2, O3, rodent and cockroach infestations and dilapidated housing) 
that are linked to asthma morbidity (Breysse et al. 2005; McCormack et al. 2009). 
Exposures to PM from indoor air sources (e.g. cooking, tobacco smoking, and infiltration 
from outside air) are of particular concern, as people spend over 85% of their day 
indoors, and the potency (per unit mass) and concentrations of indoor particulates can be 
significantly greater than outdoor particulates (Klepeis et al. 2000; Wallace et al. 2003; 
Koenig et al. 2005). Contrasting indoor air exposures in city and suburban settings, 
Simons et al. (2007) found 2-3 fold higher exposure to indoor PM, and mouse and 
cockroach allergens in asthmatic children living in inner city Baltimore compared to 
asthmatic children living in the surrounding suburbs. Sources of ambient air pollution in 
urban environments include proximity to high vehicular traffic volume on streets and 
highways, bus and truck depots, waste incinerators and industrial operations (Perera et al. 
2002). Urban, inner city populations are therefore more vulnerable due to 
disproportionately high exposures to PAHs, PM, SHS, and other indoor and ambient air 
pollutants, and concurrently experiencing disproportionately higher asthma, allergy, 
cancer and other environmentally related disease burdens (Perera et al. 2002; Breysse et 
al. 2005; Simons et al. 2007). In addition, the combination of disproportionately higher 
environmental exposures and generally higher asthma disease burden in urban areas 
supports the longstanding premise that children living in urban settings are exposed to a 
more asthmagenic environment (Breysse et al. 2005). These findings highlight both the 




importance of elucidating the complex factors that link environmental exposures to 
asthma exacerbation and increased disease burden. 
This study will focus on investigating the links between internal dose of 
polycyclic aromatic hydrocarbons (PAHs) and biological responses associated with 
asthma using biomarkers of oxidative stress and allergic and non-allergic inflammatory 
responses in children living in inner city Baltimore. PAHs are formed from the 
incomplete combustion or pyrolysis of organic materials (e.g. coal, wood, fuel and oil) 
and are commonly found on fine (aerodynamic diameter <2.5 µm) and ultrafine 
particulates (aerodynamic diameter <0.1 µm) (Rosa et al. 2011). Sources of ambient 
PAHs include motor vehicle emissions (combustion products from diesel and 
conventional gasoline engines), burning fossil fuels (e.g. coal and oil), and wood burning 
(ATSDR 1995; Larsen et al. 2003). Tobacco smoking, cooking with gas stoves, heating 
appliances (e.g. kerosene space heaters), and incense burning are major sources of indoor 
PAHs (ATSDR 1995; Larsen et al. 2003). Individual PAHs and PAH mixtures have been 
classified as human carcinogens (e.g. benzo[a]pyrene and coal tar pitch), probable 
carcinogens, and possible carcinogens by the International Agency for Research on 
Cancer (IARC), the Agency for Toxic Substances and Disease Registry (ATSDR) 
(ATSDR 1995; IARC 2010). Our study, however, will focus on the non-mutagenic, 
irritant (i.e. oxidative potential) properties of PAHs. In general, particle size is inversely 
related to the temperature of combustion, surface area to mass ratio, PAH content, and 
redox activity (Li et al. 2003). Our study is based on the following proposed toxicologic 
mechanism: exposures to the organic components of PM (i.e. PAHs) increase oxidative 




related symptoms and exacerbation (Xia et al. 2005) (Figure 1-1). Recent studies suggest 
that PAHs may be associated with development of asthma (Miller et al. 2004; Jung et al. 
2012), neurodevelopmental deficiencies (Perera et al. 2006), and low birth weight (Perera 
et al. 2003) in inner city urban populations. In addition, experimental evidence suggests 
that pyrene, a common PAH, enhances allergic immunoglobulin E (IgE) responses in 
mice (Kanoh et al, 1996; Bommel et al, 2000). Thus, finding significant associations 
between PAHs, oxidative stress and inflammatory response biomarkers, and asthma 
exacerbation in our study would support this mechanistic hypothesis. 
 
Figure 1-1. Environmental health paradigm with biomarkers of PAH exposure, effects, 
and asthma exacerbation 
 
Previous studies have assessed exposure by measuring PAHs isolated from 
filtered airborne PM samples gathered using personal, active (portable or stationary), 
and/or outdoor air monitors and estimating internal dose (Choi et al, 2008; Dubowsky et 
al, 1999; Jedrychowski et al, 2005; Rosa et al, 2011; Tonne et al, 2004). These methods, 
however, do not assess internal dose or biologically effective dose, as estimates of time 




indoor PM concentrations can lead to inaccurate assessments of individual exposures 
(Breysse et al. 2010). Therefore, we measured the most common urinary metabolite of 
pyrene, 1-hydroxypyrene-glucuronide (1-OHPG), as a biomarker of internal dose. 
Urinary 1-OHPG is an accepted biological indicator of PAH exposure, as its parent 
compound, pyrene, is present in virtually all environmental PAH mixtures and it is a 
reliable biomarker of low-level exposure (Buchet et al. 1992; Strickland et al. 1994; 
Strickland et al. 1999; Jongeneelen 2001, Hansen et al, 2008). Previous studies have 
demonstrated increased urinary 1-OHPG associated with recent exposures through 
inhalation, ingestion and dermal absorption of PAHs from environmental, occupational, 
dietary or medicinal sources.  
Predictors of urinary 1-OHPG concentrations in the general population include 
gender: higher in males (Huang et al. 2004, CDC 2005; Lee et al. 2009; Sul et al. 2012), 
dietary exposures (Fiala et al. 2001; Bostrom et al. 2002; Kang et al. 2005; Lee KH et al. 
2009), exposures to SHS (Jongeneelen et al. 1994, van Wijnen et al. 1996; Siwinska et al. 
1999; Mucha et al. 2004; Lee KH et al. 2009), exposures to high traffic volume 
(Taniawiroon et al. 2007; Martinez-Salinas et al. 2010; Fan et al. 2012), and living in an 
large cities/urban environments (Hansen et al. 2005; Bae et al. 2010). 1-OHPG, or its 
deconjugated derivative, 1-OHP, have been associated with a variety of exposure/internal 
dose biomarkers including urinary cotinine (Leem et al. 2010); early effect biomarkers of 
oxidative stress (8-deoxy-hydroxyguanine and malondialdehyde) (Kang et al. 2005; Hong 
et al. 2009; Bae et al. 2010); and diseases related to environmental exposures. For 
example, increased levels of 1-OHPG in children are associated with having asthma (Kim 




dose of 1-OHPG therefore allowed us to assess the short-term body burden of PAHs and 
provide a better understanding of the relationship between these exposures and adverse 









Specific Aim 1 
Quantify PAH internal dose in children from the DISCOVER/Asthma-Diet study by 
measuring urinary 1-OHPG; and examine associations between indoor air pollutants, 
time spent indoors (at home) or outdoors and urinary 1-OHPG concentrations, and 
evaluate whether a child’s gender and/or adults smoking in the home are effect modifiers 
of these relationships. 
Hypothesis 
We hypothesized that urinary 1-OHPG concentrations would be associated with time 
spent indoors and exposure to indoor air pollutants (such as PM and indoor air nicotine), 
with more pronounced positive associations between time spent indoors and 1-OHPG 
among children residing in smoking households. 
 
Specific Aim 2 
Examine associations between internal dose of PAHs (by urinary 1-OHPG) and oxidative 
stress (by analyzing urinary MDA), as well as associations between PAH internal dose 
and peripheral blood biomarkers of inflammation, asthma-related symptoms, and 
medication use in children from the DISCOVER/Asthma-Diet study. Evaluate whether 
atopic constitution is an effect modifier of the associations between internal dose PAHs 
and inflammatory biomarkers, and asthma symptoms in asthmatic children.  
Hypothesis 
We hypothesized that urinary 1-OHPG concentrations would be associated with urinary 




increased risk for asthma-related symptoms. We also hypothesized that atopic asthmatics 
would have stronger associations between urinary 1-OHPG and peripheral blood 
biomarkers and asthma-related symptoms, based on synergistic properties of PAHs on 
allergic inflammatory responses in allergen sensitized individuals. 
 
Specific Aim 3  
Evaluate associations between internal dose of PAHs (measured by urinary 1-OHPG) and 
biomarkers of oxidative stress (urinary isoprostane), gene expression of antioxidants, and 
peripheral blood, serum and nasal lavage biomarkers of inflammation in the Nasal 
Challenge to Indoor Particulate Matter study, a study of atopic asthmatic adults in 
Baltimore City. Evaluate whether GSTM1 genotype was an effect modifier of the 
associations between internal dose PAHs and oxidative stress and inflammatory 
biomarkers. 
Hypothesis 
We hypothesized that PAH internal dose would be associated with increased internal 
dose of oxidative stress, increased induction of antioxidant genes (HO-1, NQO1, GCLC 
and GCLM), increased serum mediators (ECP, MIP-1α, eotaxin, CCL20, and RANTES), 
and increased local and systemic inflammation (nasal lavage and peripheral white blood 
cells, and nasal lavage cytokines and chemokines). We also hypothesized that GSTM1 
genotype would be a significant effect modifier, with GSTM1-null participants having 
stronger positive associations between 1-OHPG and oxidative stress and inflammatory 
biomarkers compared to GSTM1-present participants, due to less antioxidant capacity in 




CHAPTER 2. Predictors of polycyclic aromatic hydrocarbon exposure 





Background: Polycyclic aromatic hydrocarbons (PAH) are products of incomplete 
combustion of organic materials (oil, tobacco, fuel, etc.) and are found in gas phase, and 
on fine and ultrafine PM. 1-Hydroxypyrene-glucuronide (1-OHPG) is the most common 
urinary metabolite of pyrene, a semi-volatile PAH that is present in most PAH mixtures. 
Children spend most of their time indoors and may be exposed to higher PM 
concentrations than outdoor ambient exposures. These exposures may play an important 
role in asthma morbidity. We examined time spent indoors and outdoors as predictors of 
PAH internal dose in inner city Baltimore, and whether a child’s gender and/or adults 
smoking in the home modify the association between urinary 1-OHPG and time spent 
inside the home or outdoors. 
Methods: The DISCOVER/Asthma-Diet study is a longitudinal (panel) study with at 
total of 118 participants ages 5-13 from Baltimore City.  Children were followed for one-
week periods in each of four seasons. Urine specimens were collected on day 3 and day 7 
of each week, and analyzed for 1-OHPG. Indoor PM and air nicotine were monitored 
over the week using passive samplers, and questionnaires assessing time spent 
indoors/outdoors and smoking frequency in the home were administered each day of the 
week-long study periods. 
Results: Most of the children were female (52%), African American (95%), atopic 
asthmatics (63%), and 53% of the households reported smoking in the home. Time spent 




in urine collected on day 7 (ß=-0.045, p=0.005). Spending time in homes with low air 
nicotine concentrations was associated with low 1-OHPG concentrations (ß=-0.075, 
p=0.003), whereas spending time in homes with high air nicotine concentrations was not 
associated with changes in 1-OHPG concentration (ß=0.005, p=0.835) (p-value for 
interaction=0.076). Time spent outdoors on day 4-6 (ß=0.097, p=0.002) was associated 
with increased 1-OHPG concentrations in urine collected on day 7 in boys only. 
Conclusion: Our results suggest that time spent in the home is inversely associated with 
1-OHPG concentrations in children’s urine and is modified by smoking in the home. 
Spending time in a non-smoking home confers a more “protective” effect for 1-OHPG 
concentrations than spending time in a smoking home. In addition, spending time 
outdoors is positively associated with 1-OHPG, and the effect is more pronounced in 
boys. Our results suggest that SHS and outdoor ambient air PAH sources contribute to 







Polycyclic aromatic hydrocarbons (PAHs) are formed from the incomplete 
combustion or pyrolysis of organic materials (e.g. coal, wood, fuel and oil) and are 
commonly found on fine and ultrafine particulates, PM2.5 (aerodynamic diameter <2.5 
µm) and PM0.1 (aerodynamic diameter <0.1 µm), respectively (Rosa et al. 2011). Sources 
of ambient PAHs include motor vehicle emissions (combustion products from diesel and 
conventional gasoline engines), burning fossil fuels (e.g. coal and oil), and wood burning 
(ATSDR 1995; Larsen et al. 2003). Tobacco smoking, cooking with gas stoves, heating 
appliances (e.g. kerosene space heaters), and incense burning are major sources of indoor 
PAHs (ATSDR 1995; Larsen et al. 2003). Individual PAHs and PAH mixtures have been 
classified as human carcinogens (e.g. benzo[a]pyrene and coal tar pitch), probable 
carcinogens (e.g. dibenz[a,h]anthracene and dibenzo[a,l]pyrene) and possible carcinogens 
(e.g. benz[a]anthracene, benzo[b]fluoranthene and indeno[1,2,3-cd]pyrene) by the 
International Agency for Research on Cancer (IARC), and the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the National Toxicology Program (NTP) 
(ATSDR 1995; IARC 2010; NTP 2011). PAHs have also been associated with 
development of asthma (Miller et al. 2004; Jung et al. 2012), neurodevelopmental 
deficiencies (Perera et al. 2006), and low birth weight (Perera et al. 2003) in urban and 
inner city populations. 
Urinary1-hydroxypyrene-glucuronide (1-OHPG) is an accepted biological 
indicator of PAH exposure, as its parent compound, pyrene, is present in virtually all 
environmental PAH mixtures and is a reliable biomarker of low-level exposure (Buchet 




through inhalation, ingestion, and dermal absorption (from contaminated air and soil) 
(Jongeneelen 2001). Both 1-hydroxypyrene (1-OHP) and 1-OHPG are commonly used 
urinary biomarkers of PAH exposure, however 1-OHPG is more sensitive, as the addition 
of glucuronide confers 3-5 times more fluorescence than 1-OHP alone (Singh et al. 1995; 
Strickland et al. 1996; Kang et al. 2005). Predictors of 1-OHPG concentrations include 
gender: higher in males (Huang et al. 2004, CDC 2005; Lee et al. 2009; Sul et al. 2012), 
dietary exposures (Fiala et al. 2001; Bostrom et al. 2002; Kang et al. 2005; Lee KH et al. 
2009), exposures to second hand smoke (Jongeneelen et al. 1994, van Wijnen et al. 1996; 
Siwinska et al. 1999; Mucha et al. 2004; Lee KH et al. 2009), exposures to high traffic 
volume (Taniawiroon et al. 2007; Martinez-Salinas et al. 2010; Fan et al. 2012), and 
living in an large cities/urban environments (Hansen et al. 2005; Bae et al. 2010). 1-
OHP(G) is associated with exposure/internal dose biomarkers including urinary cotinine 
(Leem et al. 2010) and other urinary PAH metabolites (Kang et al. 2005; Fan et al. 2012; 
Yoon et al. 2012); and biomarkers of oxidative stress and damage (8-deoxy-
hydroxyguanine and malondialdehyde) (Kang et al. 2005; Hong et al. 2009; Bae et al. 
2010). Elevated levels of 1-OHPG in children are also associated with having asthma 
(Kim et al. 2005), and experiencing an asthma attack (Leem et al. 2006). 
PAHs are commonly found on the surface of fine particulates (PM2.5), and are 
among the most biologically relevant organic constituents of PM2.5 because of irritant (i.e. 
oxidative potential) and carcinogenic properties (Squadrito et al. 2001). Exposure to PM 
from indoor air sources (such as cooking and smoking) are of particular concern, as 
people may spend over 85% of their day indoors, and the potency (per unit mass) and 




(Klepeis et al. 2000; Koenig et al. 2005; Wallace et al. 2003). Sources of ambient air 
pollution in urban environments include proximity to high vehicular traffic volume on 
streets and highways, bus and truck depots, waste incinerators and industrial operations 
(Perera et al. 2002). Urban, inner city populations are therefore more vulnerable due to 
disproportionately high exposures to PAHs, PM, SHS, and other indoor and outdoor 
ambient air pollutants, and concurrently experiencing disproportionately higher disease 
burdens of asthma, allergy, cancer and other environmentally related disease burdens 
(Perera et al. 2002; Breysse et al. 2005; Simons et al. 2007). 
Our overall goal is to quantify PAH internal dose using urinary 1-OHPG, and 
examine the relationship between predictors of PAH exposure and internal dose of PAHs 
in inner city Baltimore children participating in the DISCOVER/Asthma Diet study. We 
also examine associations between indoor air pollutants, time spent indoors (at home) or 
outdoors and urinary 1-OHPG concentrations, and evaluate whether a child’s gender 
and/or adults smoking in the home are effect modifiers of the these relationships. 
 
 
MATERIALS AND METHODS 
The Role of Particulate Matter and Allergens in Oxidative Stress in Asthma 
(DISCOVER) and Asthma-Diet (A Study to understand The Mechanisms of Asthma-
Dietary Interventions to protect against Environmental Triggers) studies have the same 
study design, as the Asthma-Diet study is an extension of the DISCOVER study (with a 
dietary component). The DISCOVER/Asthma-Diet study is a panel study that enrolled 




12, from nine contiguous zip codes in inner city Baltimore. Indoor PM and allergen 
exposures, diet, lung function, asthma symptoms, and biomarkers of oxidative stress, and 
inflammation were assessed for a one week period, in each of four seasons (Figure 2-1) 
(Dr. Greg Diette, personal communication). Inclusion criteria included: age 5-12 years, 
physician diagnosis of asthma, symptoms of asthma and/or reliever medication use in 
past 6 months, and residence in Baltimore city. Children were excluded from the study if 
they had a current diagnosis of another major pulmonary disease, if they were planning to 
relocate residence during the study period, were currently taking antioxidant 
supplements, had a known food allergy, had metabolic or dietary disorders or were 
pregnant. Each season, the children’s homes were monitored for 8 days (labeled as days 
0-7); indoor air nicotine, PM, NO2 concentrations were measured, daily activity 
questionnaires were administered, and urine was collected on the fourth (day 3) and eight 
day (day 7). Daily activity diaries asked questions about smoking in the home and where 
the child spent his/her time (hours spent inside the home, outdoors, and indoors in other 
buildings and vehicles) (Appendix A: Daily Diary Questionnaire). 
 
Figure 2-1. DISCOVER/Asthma-Diet study framework  
 
                 
                                                                          
 
 
Seasonal collection time points 
 
Baseline ------------- 3 months ------------ 6 months ----------- 9 months 
                       
Questionnaire data and samples collected during 1 week of monitoring at each seasonal time point 
           Day:       0 (Sat)      1 (Sun)      2 (Mon)      3 (Tue)      4 (Wed)       5 (Thu)      6  (Fri)      7 (Sat) 
               PM/NO2/Nicotine ----------------------------------------------------------------------------- 
                       Symptoms -------------------------------------------------------------------------------- 
                                           FEV1 ----------------------------------------------------------------------- 
                                          FeNO ----------------------------------------------------------------------- 
                                                                     urine     urine 




Urinary 1-OHPG  
Spot urine samples were analyzed for urinary 1-OHPG concentrations using 
immunoaffinity chromatography (IAC) and synchronous fluorescence spectroscopy 
(SFS) as previously described (Strickland et al. 1994). Urine samples (2ml) were treated 
with 0.1N HCl (90°C, 60 min), neutralized, and loaded onto Sep-pak C18 cartridges 
(Waters). After washing with 30% methanol, the relatively non-polar metabolites were 
eluted with 4 ml of 80% methanol and the volume of eluate is reduced to 0.5ml by 
evaporation on a Speedvac. The concentrated samples were diluted to 4ml with 15mM 
phosphate buffered saline (PBS) and loaded onto immunoaffinity columns prepared with 
0.8ml cyanogen bromide activated sepharose 4B (Sigma) coupled with monoclonal 
antibody 8E11 that recognizes several PAH-DNA adducts and metabolites (Santella et al. 
1986). We have previously shown that 1-OHPG binds to these columns (Strickland et al. 
1994). After washing the columns three times with 4 ml 15 mM PBS, bound compounds 
were eluted with 2 ml of 40% methanol in three fractions. Eluate fractions were analyzed 
by SFS with a Perkin-Elmer LS50 fluorescence spectrometer. The excitation-emission 
monochromators are driven synchronously with a wavelength difference of 34 nm. Under 
these conditions 1-OHPG produces a characteristic fluorescence excitation maximum at 
347 nm with emission maximum at 381 nm (Strickland et al. 1994). Fluorescence 
intensity was used to quantify 1-OHPG; in our laboratory the limit of detection was about 
0.03 pmol/ml. This level of sensitivity is sufficient to detect urinary 1-OHPG in >90% of 
subjects with low-level exposure to PAHs (such as in the U.S.), and in 100% of subjects 
with high exposure. The coefficient of variation of the assay is typically 6-10% 




Urinary Creatinine  
Creatinine concentrations were determined using a modified version of the Jaffe 
reaction using the Creatinine Assay Kit (Cayman Chemical Company; Ann Arbor, MI). 
Briefly, 150 µl of alkaline picrate solution was added to wells containing 15 µl creatinine 
standard or urine samples in duplicate, and the solution was mixed for 10 minutes. The 
absorbance of the solution (due to the reaction between the alkaline picrate and urinary 
creatinine metabolites) was read at 450-500 nm using a Biotek ELx800 Absorbance 
Microplate Reader. 5 µl of acid solution was then added to the assay and the absorbance 
was read again at 450-500 nm, 20 minutes after mixing. The difference in color intensity 
before and after acidification is proportional to urinary creatinine concentration. Urinary 
creatinine levels were determined using a creatinine standard curve, which was estimated 
in each batch from analysis of the standard creatinine. 
Particulate matter 
Airborne particulate matter monitoring was conducted in the child’s bedroom 
using integrated sampling methods for a 5-7 day period. Air samples for both particulate 
matter ≤10 microns (PM10) and ≤ 2.5 microns (PM2.5) were collected on Teflon® filters 
(Pall Gelman, Ann Arbor, MI) using SKC Personal Environmental Monitors (SKC, Inc., 
Eighty-four, PA) and BGI 400S pumps (BGI, Inc., Waltham, MA).  
Air nicotine  
Two passive sampling badges were placed in the child’s bedroom and the 
TV/family room at 3-5 feet off the floor. The passive air samplers consist of a sodium-
bisulfate- treated filter contained in a 37-mm polystyrene cassette covered with a 




chromatography with a nitrogen-phosphate detector. The limit of detection for the passive 
air nicotine badges was 0.003 µg/m3. 
Statistical analysis 
Summary statistics were reported for urinary1-OHPG, and indoor PM2.5, PM10, 
PM2.5-10 and air nicotine concentrations. 1-OHPG, PM2.5, PM10, PM2.5-10 and air nicotine 
concentrations were log-transformed to adjust for positively skewed distributions. 
Urinary 1-OHPG concentrations on day 3 (Tuesday; n=255) and day 7 (Saturday; n=339) 
and averages for the monitoring period (n=359) were analyzed separately. Multivariate 
linear regressions with generalized estimating equations (GEE) were used to assess 
associations between potential predictors (independent variables) and individual 1-OHPG 
concentrations (dependent variable), while adjusting for repeated measurements (i.e. 
monitoring periods) and possible confounders. Explanatory variables were considered 
possible confounders if the ß coefficient changed by more than 10% after inclusion of the 
exposure variable (e.g. time spent in the home) in the model or if the variable was 
significantly associated with the exposure or outcome. Our final models for multivariate 
linear regression with GEE were adjusted for age, gender, season, atopic status and 
caregiver educational attainment. Duplicate measures for indoor air nicotine 
concentration were averaged. PM2.5 and PM10 measurements were excluded if airflow 
through the passive monitor was not sufficient, PM2.5 concentrations were greater than 
PM10 concentrations or if there were equipment malfunctions. Race was not included in 
models because 95% of the participants were African American. Urinary 1-OHPG 
concentrations were adjusted for urinary creatinine by including creatinine concentrations 




nicotine, PM2.5, PM10, PM2.5-10, and self-reported exposure variables (e.g. average time in 
the home and average time outdoors) were measured as continuous variables; gender and 
health insurance were binary variables; BMI percentile and season were categorical 
variables; and caregiver education and annual household income were measured as 
ordinal variables. Seasons were defined based on calendar days and heating season was 
defined as November 1 through March 1 (Jung et al. 2010). Atopic constitution was 
defined as having allergic responses to at least one of 13 aeroallergens from a skin prick 
test or by radioallergosorbent test (RAST).  
Effect modification was assessed using pairwise interaction terms for independent 
variables (e.g. the product of average time indoors and smoking in the home). 
Comparisons of two groups of exposure variables were performed using Wilcoxon sign-
rank test and Mann-Whitney U test. Pearson’s correlation coefficient and Spearman’s rho 
were used to examine correlations between internal dose biomarkers and indoor air 
concentrations. Urine collected in the afternoon or early evening of day 3 (Tuesday) was 
compared to pooled estimates of exposures on days 0-2, representing exposures from 24-
96 hours prior to urine collection (24-48 hours for day 2, Monday; 48-72 hours for day 1, 
Sunday; and 72-96 hours for day 0, Saturday). Urine collected in the morning to early 
afternoon on day 7 (Saturday) was compared to pooled estimates of exposures on days 4-
6, representing exposures from 18-88 hours prior to urine collection. Urinary 1-OHPG 
concentrations were reported as pmol/ml and µmol/mol creatinine, and concentrations for 
indoor air nicotine, PM2.5, PM10, and PM2.5-10 were reported as µg/m3. Missing data 
varied by the exposure metric (4%-28%) and did not differ substantially by gender 




contact the caregiver and obtain urine samples from the child (especially during the 
weekday (day 3) and on the first day of the monitoring period (day 0)), incorrect or 
unusable questionnaire data (e.g. daily time apportionment exceeded 24 hours), and 
technical problems with the air nicotine and PM monitors. Missing values were not 






 Children in the DISCOVER/Asthma-Diet study were between 5 and 13 years of age 
(mean: 10 years of age), and most were female (52%), African American (95%), and 
from low socioeconomic status households (66% of caregivers had up to a high school 
diploma, 88% had public health insurance, and 77% had annual household incomes 
below $25,000) (Table 2-1). Most children were atopic (70%) and asthmatic (86%) and 
resided in households with adults smoking in the home at some time during the study 
(53%). Approximately half of the children (46%) were overweight or obese (BMI 
percentile ≥85%) and about a third (32%) of the children were obese (BMI percentile 
≥95%). Most of the obese children (62%) were girls. 
Urinary 1-OHPG concentration 
1-OHPG concentrations were analyzed in 594 spot urine samples and urinary 
creatinine (Cr) was measured to adjust for differences in urine dilutions (Table 2-2). 




pmol/ml, geometric mean (GM) of 0.88 pmol/ml, median (interquartile range (IQR)) of 
1.24 (0.42-2.43) pmol/ml, 95th percentile of 5.35 pmol/ml, and range of 0.05-14.59 
pmol/ml. Sixty-seven samples (11%) were below the limit of detection (LOD) of 0.05 
pmol/ml. Log-transformed urinary creatinine was significantly associated with age 
(ß=0.123, p<0.001; 95% CI [0.088-0.158]) and inversely associated with being asthmatic 
(ß=-0.267, p=0.001; 95% CI [-0.411-(-0.123)]), but was not associated with gender, 
atopic status, BMI percentile (continuous), season or caregiver’s educational attainment 
(Supplemental Table 2-1). Urinary 1-OHPG concentration (pmol/ml) was divided by 
urinary creatinine (µmol/ml) to adjust for urine dilution differences, and was reported as 
µmoles 1-OHPG per mole creatinine (µmol/mol creatinine).  
Day 3 vs. Day 7 urine 
 Urine samples were collected on day 3 (Tuesday) in the afternoon to early evening 
(3:00-7:00 PM), and day 7 (Saturday) in the morning (8:30 AM-12:00 PM). Diurnal 
differences in 1-OHPG and creatinine output may therefore be reflected in day 3 and day 
7 spot urine samples. GM and median creatinine corrected 1-OHPG concentrations were 
similar for day 3 (n=255) and day 7 (n=339) samples (Wilcoxon sign-rank test p=0.422) 
(Supplemental Table 2-2). Individual 1-OHPG concentrations on day 3 and day 7 were 
correlated using parametric (Pearson’s correlation coefficient=0.20, r2=0.04; p=0.003) 
and non-parametric (Spearman’s rho=0.34; p<0.001) analyses. Log-transformed 1-OHPG 
concentrations were also significantly associated in multivariate linear regression with 
GEE to account for repeated measurements in crude (adjusted for urinary creatinine; 
ß=0.190, p=0.003; 95% CI [0.065-0.316]) and adjusted models (adjusted for urinary 




p=0.001; 95% CI [0.085-0.323]).  
Predictors of 1-OHPG 
 Overall, girls had higher 1-OHPG concentrations than boys (ß=-0.385; p=0.010; 
95% CI [-0.680-(-0.091)]) and the gender difference remained in models without 
creatinine adjustment (ß=-0.378, p=0.016; 95% CI [0.686-(-0.069)]) (Table 2-3). This 
translates to 42% higher GM of 1-OHPG concentrations in girls than boys. Significant 
gender differences within age groups were also reported. Among 13 year olds, gender 
differences in creatinine adjusted 1-OHPG were more pronounced (ß=-1.821; p<0.001) 
and remained in analyses of creatinine unadjusted 1-OHPG concentrations (ß=1.511; 
p<0.001). This translates into 4.5 fold higher GM of creatinine adjusted 1-OHPG 
concentrations, and 6 fold higher GM of creatinine unadjusted 1-OHPG concentrations in 
13 year-old girls than 13 year-old boys. Overall, age, asthma status and atopic 
constitution, BMI percentile (continuous) and being obese (compared to normal weight) 
were not significantly associated with 1-OHPG concentrations (Table 2-3). There were 
also no differences in 1-OHPG levels by season. Comparing individual seasons, 1-OHPG 
concentrations were highest in the fall, followed by winter and spring, and were lowest in 
summer (Supplemental Table 2-3). Heating season, defined as November 1 through 
March 1, was not significantly associated with urinary 1-OHPG concentrations. Type of 
heating in the home, opening windows in the house, distance from the curb to the street, 
and type of curb (i.e. parking lot, arterial street or side street) were also not associated 
with 1-OHPG concentrations (Supplemental Table 2-4). Most homes used a gas stove 
(85%), and having a gas stove was inversely, though non-significantly associated with 





Fine particulate matter (PM2.5) was measured over the course of the monitoring 
week using passive monitors, located predominantly in the child’s bedrooms (Table 2-2). 
Overall, indoor PM2.5 concentrations had an arithmetic mean (SD): 28.4 (22.8) µg/m3, 
median (IQR): 21.8 (13.0-34.9) µg/m3, 95th%ile: 72.1 µg/m3, and range: 3.7-133.2 µg/m3. 
Indoor PM2.5 concentrations were associated with adults smoking in the home (ß=0.275, 
p=0.001; 95% CI [0.119-0.431]) and number of cigarettes smoked in the home each day 
(ß=0.037 p<0.001; 95% CI [0.023-0.051]) (Supplemental Table 2-5). Daily time with 
windows open, daily stove use, burning incense or candles, and burning something on the 
stove were not associated with indoor PM2.5 concentrations. Indoor PM2.5 concentrations 
were also not associated with urinary 1-OHPG concentrations from urine collected on 
day 3, urine collected on day 7 or averaged 1-OHPG concentration (Table 2-4).  
Indoor PM10 
Particulate matter (PM10) was measured using stationary passive monitors located 
predominantly in the child’s bedroom (Table 2-2). Indoor PM10 concentrations had an 
arithmetic mean (SD): 41.1 (29.0) µg/m3, median (IQR): 32.6 (21.6-52.5) µg/m3, 
95th%ile: 97.5 µg/m3, and range: 5.8-268.8 µg/m3. Smoking in the home (ß=0.306, 
p<0.001; 95% CI [0.162-0.450]) and number of cigarettes smoked in the home daily 
(ß=0.030, p<0.001; 95% CI [0.018-0.041]) were significantly associated with increased 
indoor PM10 (Supplemental Table 2-5). Daily stove use was moderately associated with 
indoor PM10 (ß=0.115, p=0.087), however, daily time with windows open, burning 
something on the stove and burning incense or candles were not associated with indoor 




1-OHPG concentrations, however the associations between 1-OHPG and indoor PM10 
were stronger than 1-OHPG and indoor PM2.5 (Table 2-4).  
Indoor PM2.5-10 
Indoor PM2.5-10 (coarse PM) was calculated by subtracting PM2.5 from PM10 
concentrations (Table 2-2). Overall, indoor PM2.5-10 concentrations had an arithmetic 
mean (SD): 12.7 (14.3) µg/m3, median (IQR): 9.8 (5.4-15.8) µg/m3, 95th%ile: 30.8 µg/m3, 
and range: 0.71-215.3 µg/m3. The highest value, 215.3 µg/m3 (over 20-fold higher than 
the median) was considered an outlier and was therefore not included in these analyses. 
Smoking in the home (ß=0.176, p=0.064; 95% CI[-0.011-0.362]) and stove use (ß=0.158, 
p=0.072; 95% CI [-0.014-0.330]) were moderately associated with increased PM2.5-10 
(Supplemental table 2-5). Time with windows open, number of cigarettes smoked in the 
home, and burning incense or candles, and burning something on the stove were not 
associated with indoor PM2.5-10 concentrations. Indoor PM2.5-10 was significantly 
associated 1-OHPG from urine collected on day 7 (ß=0.177, p=0.021; 95% CI [0.027-
0.326]) moderately associated with averaged urinary 1-OHPG (ß=0.117, p=0.074; 95% 
CI [-0.011-0.246]), but not associated with 1-OHPG from day 3 urine (Table 2-4). 
Time spent in the home 
Children spent an average of 16 hours in the home each day, with no differences 
for boys and girls (Table 2-5). More time was spent in the home on days 0-2 (Saturday, 
Sunday and Monday) (median 17.0 hours), compared to days 4-6 (Wednesday, Thursday 
and Friday) (median 15.7 hours) (Wilcoxon sign-rank test p=0.005). Spending time in the 
home on days 4-6 (Wednesday-Friday) showed an inverse association with 1-OHPG 




(Table 2-6). This translates into a 5% decrease in GM of 1-OHPG concentrations for each 
hour spent in the home. Spending time in the home on days 0-2 (Saturday-Monday) was 
moderately associated with decreased 1-OHPG concentrations in urine on day 3 
(Tuesday) (ß=-0.026, p=0.076). Associations between time spent in the home and 1-
OHPG concentrations were similar, but slightly attenuated, after individually adjusting 
for indoor PM2.5, PM2.5-10, and PM10 (Supplemental Table 2-7). 
Air nicotine 
Smoking in the home may contribute to the high levels of 1-OHPG in this cohort, 
as most households self-reported smoking in the home at some time during the study. 
Indoor air nicotine concentrations were measured throughout the monitoring week using 
passive monitors located predominantly in the child’s bedroom (Table 2-2). Indoor air 
nicotine concentrations had an arithmetic mean (SD): 0.76 (1.26) µg/m3, median (IQR): 
0.13 (0.03-0.96) µg/m3, 95th%ile: 3.4 µg/m3, and range: 0.005-8.8 µg/m3. Using bivariate 
linear regression analysis with GEE, log transformed air nicotine concentrations were 
associated with self-reported number of cigarettes smoked in the home per day (ß=0.083, 
p<0.001; 95% CI [0.055-0.110]) and smoking in the home (ß=1.037, p<0.001; 95% CI 
[0.703-1.371]) (Supplemental Table 2-6). Air nicotine concentrations were also 
correlated with indoor PM2.5 concentrations (Pearson’s correlation coefficient (both log-
transformed) r= 0.55, p<0.001; Spearman’s rho=0.53, p<0.001), and significantly 
associated with indoor PM2.5 concentrations (ß=0.795, p<0.001; 95% CI [0467-1.124]). 
Air nicotine and 1-OHPG 
Indoor air nicotine concentrations were correlated with urinary 1-OHPG 




(Spearman’s rho=0.12, p=0.031) analyses (Supplemental Table 2-6). Indoor air nicotine 
was also significantly associated with increased 1-OHPG from urine collected on day 3 
(ß=0.129, p=0.007; 95% CI [0.035-0.233]), but not associated with 1-OHPG collected on 
day 7 and averaged 1-OHPG concentration (Table 2-4). Similar associations between 
indoor air nicotine and urinary 1-OHPG were found using multivariate linear regression 
analysis without GEE. 
Air nicotine, average time spent in home and 1-OHPG 
Overall, average time spent in the home was inversely associated with urinary 1-
OHPG in homes with low air nicotine concentration (below the median: 0.13 µg/m3) (ß=-
0.075, p=0.003; 95% CI [-0.124-(-0.026)]), with a significant trend of decreasing 1-
OHPG concentrations with increasing time spent in homes with low air nicotine 
concentration (Cusick’s test for trend p-value=0.029) (Table 2-7, Figure 2-2). Spending 
time in homes with low air nicotine concentration on days 4-6 was associated with 
significantly lower urinary 1-OHPG concentrations in urine collected on day 7 (ß=-0.081, 
p<0.001) (Table 2-8, Figure 2-3). Air nicotine was an effect modifier of the relationship 
between spending time in the home on days 4-6 and urinary 1-OHPG concentrations 
from urine collected on day 7, with more pronounced inverse associations between 
spending time in the home and 1-OHPG in homes with low air nicotine concentration (p-
interaction=0.074). Indoor air nicotine concentration also modified the associations 
between average time spent in the home and 1-OHPG in boys (p-interaction=0.014), but 
not girls (Table 2-8). Gender differences in effect modification by indoor air nicotine 
were evident despite lack of gender differences in time spent in the home. Inverse 




urinary 1-OHPG were strongest among boys (exposures on days 4-6, 1-OHPG from day 
7 urine: ß=-0.088, p=0.005; exposures over the week, averaged 1-OHPG: ß=-0.085, 
p=0.008), and effect modification by indoor air nicotine concentration was found in boys 
only (p-interaction=0.014) (Table 2-7).  
Indoor air nicotine was significantly associated with indoor PM2.5 concentrations 
and self-reported smoking in the home (Supplemental Table 2-6). These SHS surrogates 
may therefore have similar interactions with time spent in the home and urinary 1-OHPG 
concentrations. Models stratified by indoor PM2.5 concentrations (dichotomized at the 
median, 21.57 µg/m3) showed significant interactions with time spend in the home, with 
more pronounced inverse associations between spending time in the home on days 4-6 
and 1-OHGP from urine collected on day 7 in homes with low PM2.5 concentrations (p-
interaction=0.003) (Supplemental Table 2-8). However, indoor PM2.5 concentrations did 
not modify associations between time in the home and 1-OHPG from urine collected on 
day 3 or averaged urinary 1-OHPG. Self-reported adult smoking in the home also showed 
effect modification patterns similar to indoor air nicotine and PM2.5 (Supplemental Table 
2-8). 
Time spent outdoors  
Children spent approximately 2 hours outdoors each day, and overall boys spent 
more time outdoors daily than girls (Wilcoxon rank-sum test p=0.053) (Table 2-5). 
Overall, time spent outdoors on days 0-2 was similar to time spent outdoors on days 4-6 
(Wilcoxon sign-rank test p=0.404). Boys spent more time outdoors on days 0-2 and days 
4-6 than girls (Wilcoxon sign-rank test p=0.053 and p=0.026, respectively). Average time 




Table 2-9). Children spent the most amount of time outdoors in spring, followed by 
summer and fall, and were outdoors least during the winter. 
The two urine collection days, day 3 (Tuesday) and day 7 (Saturday) may reflect 
different patterns of exposure because of behavioral and activity differences on the 
weekday and weekend. The children in the DISCOVER/Asthma-Diet study are of school 
age (5-13 years old) and will likely spend up to 8 hours in school during the weekday. 
This is reflected by the difference in average time spent in the home on weekdays 
(median: 15.4 hours) and weekends (median: 18.0 hours) (Wilcoxon rank sum p<0.001); 
and the corresponding difference in time spent in indoor environments other than the 
home (including other buildings and vehicles) during weekdays (median: 6.2 hours) 
compared to weekend (median=1.5 hours) (Wilcoxon rank sum p<0.001) (Supplemental 
Table 2-10). Average time spent outdoors, however, did not differ on weekdays and 
weekends (Wilcoxon rank sum p=0.792).  
Average time spent outdoors on days 4-6 (Wednesday, Thursday and Friday) was 
associated with moderately significant increased urinary 1-OHPG concentrations from 
urine on day 7 (Saturday) (ß=0.048, p=0.054; 95% CI [-0.001-0.098]) (Table 2-9, Figure 
2-4). However, time spent outdoors on days 0-2, and average time spent outdoors during 
the week were not associated with urinary 1-OHPG. 
Time spent outdoors and 1-OHPG by gender 
 Boys spending time outdoors on days 4-6 had statistically significantly increased 1-
OHPG concentration from urine collected on day 7 (ß=0.097, p=0.002; 95% CI [0.037-
0.157]) (Table 2-9). Each hour that boys stayed outdoors on Wednesday through Friday 




for urine collected on Saturday. Spending time outdoors was not associated with urinary 
1-OHPG in girls. These associations remained after adjusting for indoor air nicotine and 
PM2.5 concentrations (Supplemental Tables 2-11 and 2-12). The gender differences may 
be explained by differences behaviors, as boys spent more time outdoors than girls during 
the weekday (median: 2 vs. 1.4 hours; Wilcoxon rank sum p<0.001) (Supplemental Table 
2-10).  
Time spent outdoors and 1-OHPG concentrations by season 
The associations between spending time outdoors and urinary 1-OHPG 
concentrations differed seasonally. Spending time outdoors in the summer (compared to 
other seasons) was associated with significantly increased urinary 1-OHPG 
concentrations (ß=0.147, p=0.003; 95% CI [0.048-0.246]) (Supplemental Table 2-13). In 
addition, summer modulated associations between spending time outdoors and 1-OHPG, 
as children had significantly higher associations between spending time outdoors and 
urinary 1-OHPG concentrations in summer than in the other seasons (p-
interaction=0.001). During winter, associations were in the opposite direction, with 
moderately significantly inverse associations between time spent outdoors and urinary 1-
OHPG, compared to the other seasons (p-interaction=0.060). Interactions between season 
and time outdoors for associations with urinary 1-OHPG in spring and fall were not 
significant. These seasonal interactions remained after individually adjusting for indoor 








 Urinary 1-OHPG concentrations in this study were higher than a representative 
sample of the US population (NHANES) and similar international studies, and was 
influenced by second hand smoke and time spent indoors. 1-Hydroxypyrene-glucuronide 
(1-OHPG), a urinary metabolite of pyrene, is a short-term biomarker with an estimated 
half-life of 4-35 hours (Huang et al. 2007). Most 1-OHPG is eliminated in urine in 24-48 
hours (Strickland and Kang 1999). The half-life of 1-OHPG may also depend on route of 
exposure, as the reported half-life from inhalation of pyrene, 6.0-29 hours, is longer than 
the reported half-life from ingestion, 4.4-12 hours (Jongeneelen et al. 1990; Buchet 1992; 
Buckley and Lioy 1992; Hu et al. 2006; Li et al. 2012). Our exposure metric, self-
reported time apportionment in different environments (e.g. time spent in the home and 
time spent outdoors) was obtained from daily activity diaries. Time spent in those 
environments over three days prior to urine collection was averaged to adequately capture 
the range of attributes (e.g. weekend vs. weekday) and normalize inter-day variability. 
We hypothesized that having asthma would be associated with 1-OHPG concentrations, 
as previous studies have shown higher 1-OHP(G) in asthmatics than non-asthmatics (Kim 
et al. 2005; Cavanaugh et al. 2006). However, in this cohort of mostly asthmatic children, 
1-OHPG concentrations did not significantly differ by asthma status. Despite the lack of 
differences in internal dose PAH biomarkers by asthma status in this study, asthmatics 
may be more susceptible to adverse health effects from inhaled PAHs (Cho and Moon 
2010). 
Creatinine correction 




differences in spot urine dilutions were used in some studies (Kang et al. 2002; Epton et 
al. 2008; Hu et al. 2011; Leyorer et al. 2011; Deziel et al. 2013), and not others (Becker 
et al. 2003; Leem et al. 2005; Lai et al. 2012; Sul et al. 2012), and some reported both 
adjusted and unadjusted concentrations (Huang et al. 2004; Huang et al. 2006; Lee et al. 
2009; Islami et al. 2012). Urine creatinine output is influenced by age, gender, lean 
muscle mass, diet (especially meat intake), and kidney function (Boeniger et al. 1993). In 
our study, urinary 1-OHPG concentrations increased, though not significantly, with age. 
However, when corrected for urinary creatinine (dividing urinary 1-OHPG by urinary 
creatinine concentrations to adjust for differences in spot urine dilution) these adjusted 
values showed an inverse relationship with age. Similar trends were seen in children ages 
6-19 years old in NHANES III (1999-2000) (Huang et al. 2004), children ages 1-13 years 
old in Taiwan (Hu et al. 2012), and in a German cohort of children ages 3-17 years old 
(Heudorf and Angerer 2001). Assuming the children in this study did not have renal 
dysfunction, the inverse associations between age and creatinine corrected 1-OHPG (1-
OHPG/creatinine) were likely influenced by increased PAH burden in younger children 
(per kilogram body weight) compared to older children, and increased creatinine output 
in older children (due to increased lean muscle mass, especially during puberty) 
(Vyskocil et al. 2000). We included urinary creatinine in the model as an independent 
variable to properly adjust for the relationship between creatinine and the dependent 
variable (urinary 1-OHPG concentrations), while adjusting for the influence of creatinine 
on other independent variables (e.g. age and gender) (Barr et al. 2005). 1-OHPG is 
primarily eliminated from the kidney through the same pathway as creatinine (glomerular 




model may also adjust for variations in 1-OHPG excretion patterns (Viau et al. 2004). 
Short-term fluctuations in creatinine elimination due to physiological changes in renal 
functions (e.g. decreased glomerular filtration and increased reabsorption during 
dehydration events) may also affect 1-OHPG output, and improper or lack of creatinine 
adjustment may skew analyses of 1-OHPG concentrations. Therefore, we adjusted for 
urinary creatinine by dividing by urinary creatinine in comparative analyses, and included 
urinary creatinine as an independent variable in multivariate linear regressions to ensure 
proper analyses of urinary 1-OHPG concentrations.  
Diurnal differences 
There were no differences in day 3 (Tuesday) and day 7 (Saturday) urinary 1-
OHPG concentrations despite being collected at different times of the day (morning vs. 
late afternoon, respectively). Diurnal differences in urine 1-OHP(G) concentrations have 
been previously reported, including higher 1-OHP first void urine concentrations than 
average daily (24 hour composite) urine (Han et al. 2008), and greater intra-individual 
variability of 1-OHP concentrations than inter-individual variability (Siwinska et al. 
1998; Li et al. 2005). Although 1-OHPG concentrations from Tuesday and Saturday 
urines were not different, there were differences in urine dilution, as urinary creatinine 
was significantly higher on day 3. Differences in creatinine excretion throughout the day 
may reflect dietary and behavioral factors, as creatinine excretion concentration was 
reported to be higher in late afternoon than early morning, and creatinine elimination 
rates were significantly higher at night than during the day (Boeniger et al. 1993). 




therefore normalized urinary 1-OHPG concentrations between the more concentrated 
Tuesday urine and, the more dilute, Saturday urine.  
Comparison to other studies 
 The geometric mean 1-OHPG concentration for children in this study was higher 
than that observed in the second (1999-2000), third (2001-2002) and fourth (2003-2004) 
National Health and Nutrition Examination Surveys (NHANES), nationally 
representative cross-sectional studies in the United States (Table 2-10, Figure 2-5). 
Urinary 1-OHPG levels were also higher than most international studies in children. 
Studies with 1-OHP(G) concentrations that exceeded our study’s levels were mostly 
conducted in regions with major industrial activities (e.g. steel mills, coal-fired power 
plants and oil refineries) (Kim et al. 2005; Tuntawiroon et al. 2007; Martinez-Salinas et 
al. 2010; Hu et al. 2011) or high vehicular traffic volume (Kang et al. 2002). 
 Gender  
Urinary 1-OHPG levels were higher in girls than boys in our study. Gender 
differences remained a significant determinant of 1-OHPG after including creatinine in 
the model to adjust for urinary dilution. Many studies have higher levels for males 
(Huang et al. 2004, CDC 2004, CDC 2007, Sul et al. 2012). Similar to our results, a study 
of South Korean children living close to a steel mill showed higher creatinine corrected 
1-OHP concentrations in girls than boys (Lee et al. 2007). The differences, however, 
were not significant for unadjusted concentrations–highlighting the likely influence of 
higher urinary creatinine excretion for boys on adjusted 1-OHPG concentrations (Lee et 
al. 2007). Other studies by Yoon et al. (2012), and Merlo et al. (1998), also showed 




age, we found that 13 year-old girls in our study had much higher 1-OHPG levels than 
boys of the same age. These stark gender differences among 13 year-old children may be 
due to firsthand cigarette smoking. However, neither the smoking habits of the children 
or internal dose biomarkers of cigarette smoke exposure (e.g. cotinine) were measured in 
our study. 
Time spent indoors 
Time spent indoors showed a “protective” effect for urinary 1-OHPG 
concentrations. This effect was stronger for urine collected on Saturday (day 7), which 
reflects weekday (i.e. Wednesday, Thursday and Friday) exposures.  Differences in types 
of exposures, amount of time spent outdoors, and where the children spent time outside 
of home on the weekday (Saturday urine) and weekend (Tuesday urine) may explain the 
inverse associations between 1-OHPG and time spent indoors. Children were more likely 
to be in school for up to 8 hours on the weekdays during the school year. Schools are 
presumably smoke-free and will likely increase the “protective” effect if the main 
exposures to PAHs are second hand smoke and outdoor ambient air. In addition, most of 
the children live in homes with gas or electric heating. Contributions to indoor PAHs 
from gas furnaces may be less than burning fuels associated with higher PAH 
concentrations (such as heating oil, coal or kerosene), especially during heating season.  
Most of the children (53%) lived in households that reported adults smoking 
during the study period, which is higher than the US average for children living with a 
smoker (18%) (CDC 2011), but comparable to the percentage of low-income asthmatic 
children living with at least on smoker in the home (47-69%) (Butz et al. 2011a). Median 




asthmatic children in Baltimore, MD (median (IQR): 0.13 (0.03-0.96) µg/m3 vs. 0.12 
(0.01-0.61) µg/m3, respectively) (Matsui et al. 2013). However, mean air nicotine levels 
in our study were about half as high as a randomized control study in smoking 
households (at least 5 cigarettes per day) with asthmatic children in Baltimore City (mean 
(SD): 0.76 µg/m3 (1.26) vs. 1.43 µg/m3 (2.16), respectively) (Butz et al. 2011b). 
Overall, 1-OHPG levels differed for children exposed to SHS compared to non-
exposed children. Similarly, a study by Suwan-ampai et al. (2009) reported that 
exposures to secondhand smoke were associated with 56-58% higher geometric mean of 
1-OHP in children ages 6-19 in the 1999-2000 NHANES. Children spending time in 
homes with little or no cigarette smoking had significantly lower urinary 1-OHPG 
concentrations. Residing in non-smoking homes was therefore protective for PAH 
exposures. Children spending time in smoking homes during the late weekday 
(Wednesday to Friday) had significantly higher 1-OHPG concentrations (in urine 
collected on Saturday morning) than children spending time in non-smoking homes. 
Residing in smoking homes therefore attenuated the “protective” effect. 
Indoor air nicotine was significantly associated with elevated 1-OHPG 
concentrations from day 3 (Tuesday) urine. Indoor air nicotine, however, was not 
associated with 1-OHPG concentrations from day 7 (Saturday) urine. Trends similar to 
the associations between tobacco smoke exposures (measured by indoor air nicotine) and 
1-OHPG were found using self-reported smoking in the home attained through daily 
activity questionnaires (i.e. smoking in the home at any time, and average number 
cigarettes smoked in the home per day) as the SHS exposure metric. These strong 




reported household smoking) and increased 1-OHPG concentrations in our study suggest 
that SHS contributes to urinary 1-OHPG concentrations. Similar associations between 
SHS exposure and 1-OHP(G) in children from have been previously reported (van 
Wijnen et al. 1996, Mucha et al. 2004; Huang et al. 2004; Lee KH et al. 2009; Yoon et al. 
2012), while other studies have reported no association (Siwinska et al. 1999; Kang et al. 
2002; Lee SM et al. 2009; Hansen et al. 2005). Logistical and behavioral factors may 
have contributed to the significant influence SHS exposures (as measured by indoor air 
nicotine) on 1-OHPG in urine collected on an early weekday only. Associations between 
air nicotine and 1-OHPG in Tuesday urine only may be due to increased exposures to 
SHS in the home on the weekend and early weekday (Saturday- Monday). Children spent 
significantly more time in the home during the weekend and early weekday (Saturday-
Monday) than during the latter part of the week (Wednesday-Friday). Therefore, 
increased SHS exposures from increased time spent in smoking homes, may have been 
reflected in elevated 1-OHPG concentration in Tuesday urine. In addition, the 
“protective” effect (inverse relationship between spending time in homes with little or no 
smoking and 1-OHPG concentration) was stronger for Saturday urine (reflecting 
Wednesday-Friday exposures) than Tuesday urine (reflecting Saturday-Monday 
exposures), suggesting that children may have been exposed to less cigarette smoke later 
during the latter half of the week. These intra-week differences in exposure-internal dose 
relationships may also be due to differences in weekday activities (i.e. children attending 
school during the day), as well as different behavioral choices by smokers during the 
weekday/weekend, such as smoking while the child is at school or away from home, 




during or after smoking, and smoking by open windows. In addition, children may have 
been exposed to SHS by spending time in other smoking environments (for example, 
homes of smoking friends and relatives or in vehicles with smokers), particularly over the 
weekend, which were not captured by air nicotine monitors in the child’s home. 
Self-reported smoking in the home and number of cigarettes smoked may give a 
quantitative assessment of relative frequency and magnitude of smoking. These metrics 
may, however, introduce reporting bias, which may bias SHS exposure/1-OHPG 
concentration associations toward the null. In our study, 23 (7%) of the air nicotine 
samples had levels above the median (0.128 µg/m3) despite reporting no cigarette 
smoking in the home (Figure 2-6a). In addition, 39 samples (13%) had air nicotine levels 
above 1 µg/m3 but reported smoking less than half a pack of cigarettes (10 cigarettes) in 
the home daily (Figure 2-6b). Similarly, Butz et al. (2011b) reported that 17% of the 
respondents reported smoking less than 10 cigarettes per day yet had high air nicotine 
concentrations (≥1 µg/m3) in a cohort of asthmatic children from Baltimore, Maryland. In 
conclusion, self-reported smoking frequency yielded unreliable assessments of second 
hand smoke exposure. Monitoring of PM2.5 and/or air nicotine concentrations (as done in 
our study) are better metrics for SHS exposure assessment. Internal dose biomarkers of 
SHS exposure (e.g. urinary cotinine, 3-ethynyl pyridine (3-EP), and 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)) are best for cigarette smoke 
exposure assessments because exposures to sources outside of the stationary monitoring 
sites (e.g. other people’s homes, vehicles, and firsthand smoking) are reflected in internal 






Indoor PM2.5 concentrations were not correlated or associated with 1-OHPG 
concentrations (using multivariate analysis with GEE). Mean (28.5 µg/m3) and median 
(21.7 µg/m3) indoor PM2.5 concentrations in our study were comparable to other studies 
in inner city Baltimore, mean: 20.9-45 µg/m3 (Breysse et al. 2010; Butz et al. 201lb; 
McCormack et al. 2009; Sarnet et al. 1999), and median: 20.6-35 µg/m3 (Hansel et al. 
2008; Hansel et al. 2011). Mean indoor PM2.5 levels were below the US Environmental 
Protection Agency’s (EPA) National Ambient Air Quality Standard (NAAQS) for 
maximum PM2.5 concentrations in a 24-hour period, 35 µg/m3 (EPA 2013). However, one 
quarter of the samples, and 36% of the households had PM2.5 levels that exceeded the 24-
hour standard. Mean indoor PM2.5 levels were also about twice the annual standard for 
ambient PM2.5 concentrations, 15 µg/m3 (EPA 2013). Nearly 75% of the samples, and 
81% of the households had indoor PM2.5 levels that exceeded the EPA annual standard 
during the study. Most children in this study lived in homes that would consistently fail 
the EPA’s standard for maximum annual ambient PM2.5 exposure, which may have major 
implications for health, especially in vulnerable populations such as inner city asthmatic 
children. Based on the high indoor air PM levels in our study and the correlative 
associations between PAHs and PM2.5, we expected PM2.5 concentrations to predict 
urinary 1-OHPG in multivariate analyses. The absence of an association between indoor 
PM2.5 and 1-OHPG levels may be due to low PAH content on indoor particulates, a 
possible threshold for airborne PAHs to be reflected in urinary metabolites (that was not 
reached in this study), or indoor PM2.5 concentrations measured in the home did not 




monitored areas for time periods that were sufficient to influence 1-OHPG levels. Our 
findings of an inverse relationship between children spending time in the home and 
urinary 1-OHPG in this study therefore suggest that exposures to indoor air PAHs from 
PM2.5 (quantified by indoor air PM2.5 concentration) likely had little influence on urinary 
1-OHPG concentration. 
Time spent outdoors 
Overall, time spent outdoors was associated with increased 1-OHPG 
concentrations, with the strongest associations among day 7 urine samples, reflecting 
weekday exposures. Specifically, boys who spent time outdoors late in the week had 
significantly elevated 1-OHPG levels in urine collected on Saturday. The primary source 
for inhaled PAHs may therefore be outdoors. Similarly, a study of children in 
Copenhagen, Denmark, showed positive correlations between spending time outdoors on 
Monday-Thursday and 1-OHP in urine collected the following day (Hansen et al. 2005).  
We expected exposures to indoor air pollution (i.e. indoor PM) to be primary 
predictors of increased urinary 1-OHPG, however we observed the opposite effect, an 
inverse relationship in non-smoking homes. Exposure to outdoor air may be more potent 
than indoor air because of higher concentrations of semi-volatile PAHs and particles 
containing PAHs, and higher PAH content on each particle (i.e. diesel exhaust and 
particulates from burning of wood and fuel) (Squadrito et al. 2001). Vehicular exhaust, 
especially diesel exhaust particulates (DEP), are common components of air pollution 
and are rich in PAH content (Srogi et al. 2007). Larsen et al. (2003) reported that diesel 
exhaust contributes to 16-26% of the PAH in ambient air in Baltimore City. Exposures to 




concentrations from high traffic roads around kindergarten schools were 3-12 times 
higher than low traffic roads, and indoor PAH concentrations were 6 times higher in 
kindergarten schools around high traffic roads than low traffic roads in the summertime 
(Vyskocil et al. 2000; Fiala et al. 2001). Personal monitors measuring PAHs in inner city 
New York City also reported that hours per day spent outdoors significantly predicated 
pyrene exposures (Tonne et al. 2004). Inner cities and urban areas, especially poor and 
mostly African American communities (such as Baltimore City), may therefore 
experience disproportionately high exposures to ambient air pollution (Miranda et al 
2011).  
Seasonally, spending time outdoors in summer only, was associated with 
significantly increased 1-OHPG concentrations in our study. Boys may be driving these 
associations, as they spend twice as much time outdoors in the summer compared to girls 
and were likely exposed to more air ambient pollution. A study by Tonne et al. (2004) 
reported that personal monitors measured higher concentrations of airborne pyrene in the 
summer compared to the winter in inner city New York City (Tonne et al. 2004). Low 
molecular weight PAHs (e.g. pyrene and phenanthrene) volatilize with increasing 
temperature and are found predominantly in gaseous phase (Dimashki et al. 2001). 
Gaseous phase PAHs and ultrafine particulates are readily deposited in the small airways 
and alveoli, and have high surface areas per mass, thereby increasing the PAH carrying 
capacity, making them potent toxicants (Squadrito et al. 2001). Exposures to outdoor 
ambient PAHs may therefore be a significant factor in predicting 1-OHPG levels, as 
increased exposure to outdoor PAHs (as measured by time spent outdoors) was 





To our knowledge, this is the only panel study that examines predictors of 1-
OHPG concentrations in inner city Baltimore children. The longitudinal design of the 
study allowed us to address temporality, seasonal influences, and intra-individual 
differences. Daily questionnaire administration, measurement of indoor air pollutants 
throughout the one week monitoring period, and urine specimen collection at multiple 
time points allowed us to characterize temporally relevant exposures for the outcome, 
PAH internal dose, measured by urinary 1-OHPG.  
Limitations 
One drawback to our study is that we did not estimate PAH exposures though 
ingestion. Dietary intake (e.g. eating roasted, charbroiled or smoked foods) has been 
shown to explain some of the internal dose of PAH, as ingested PAHs can account for a 
significant portion of total PAH exposure (Fiala et al. 2000; Vyskocil et al. 2000). In 
addition, urinary monohydroxylated metabolites of low molecular weight PAHs, 
including 2-naphthol (naphthalene), 3-hydroxyphenanthrene (phenanthrene) and 9-
hydroxyflurorene (fluorine) were not analyzed. These 2-3 ring PAH are predominantly 
found in gas phase with inhalation as the primary route of exposure, whereas pyrene is 
introduced to the body through inhalation and ingestion exposures. Incorporation of gas 
phase PAH metabolites would allow for better assessment of PAH inhalation exposures. 
Urinary 1-OHPG is a short-term marker of internal dose (half-life of 6-35 h) and may not 
directly reflect long-term exposure to PAHs. 
Outdoor ambient PM and PAHs were also not measured during the one week 




outdoor air pollutants may have had a substantial impact on internal dose biomarkers. 
There also were no assessments of exposures to traffic related pollution, such as 
geospatial analyses of proximity of the children’s homes and schools to major roads, 
highways, bus and truck depots, and other areas with high traffic volume. Urinary 
cotinine was also not measured in this study. In addition to quantifying internal dose and 
SHS exposures, urinary cotinine analysis may identify first hand smokers (which may be 
a confounder of associations between 1-OHPG and environmental predictors). Finally, 
gene-environment interactions, such as genetic polymorphisms, were also not assessed in 
this study. Polymorphisms in phase I (e.g. CYP1A1, CYP1A2) and phase II enzymes 
(e.g. GSTP1, GSTT1, and GSTM1) may be useful in explaining inter-individual 
differences in PAH metabolism and urinary 1-OHPG elimination.  
Conclusion 
Urinary 1-OHPG concentrations in our study was higher than the US national 
average and many international studies, reflecting the disproportionate burden of 
exposures to environmental toxicants for inner city predominantly African American 
communities of low SES. Residing in a non-smoking household confers a “protective” 
effect for 1-OHPG concentrations compared to residing in a smoking household, as 
exposures to second hand cigarette smoke contribute to urinary 1-OHPG. Exposures to 
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Table 2-2. Descriptive statistics for urinary 1-OHPG, indoor PM and indoor air nicotine 
concentrations 
 
Participant characteristics, total (n=118) No. (%) 
Female   61 (52) 
Age, years 10 (5-13)* 
Race  
    African American 112 (95) 
Atopic status  
    Non-atopic 33 (30) 
    Atopic 83 (70) 
Asthma status   
    Non-Asthmatic 16 (14) 
    Asthmatic 102 (86) 
Caregiver education level (n=116)  
    Less than high school 29 (25) 
    HS diploma 47 (41) 
    College or higher 40 (34) 
Health Insurance (n=113)  
    Public 100 (88) 
    Private or other  16 (12) 
Smoking in the house  
    No smoking in the house 55 (47) 
    Smoking in the house 63 (53) 
BMI percentile (n=116)  
    Normal (BMI percentile 5-85%) 55 (47) 
    Overweight (BMI percentile 85-95%) 16 (14) 
    Obese (BMI percentile >95%) 37 (32) 













Air nicotine  
(μg/m3) 
Number of samples 594 594 309 308 280 346 
Arithmetic Mean (SD) 1.8 (1.9) 0.17 (0.22) 28.4 (22.8) 41.1 (29.0) 12.7 (14.3) 0.76 (1.26) 
Geometric Mean 0.9 0.09 21.8 33.3 9.0 0.17 
Median (IQR) 1.2 (0.4-2.4) 0.11 (0.05-0.22) 21.6 (13.0-34.9) 32.6 (21.6-52.5) 9.8 (5.4-15.8) 0.13 (0.03-0.96) 
95%ile 5.4 0.54 72.1 97.5 30.8 3.4 
Range 0.05-14.59 0.003-2.13 3.7-133.2 5.8-268.8 0.71-215.3 0.005-8.8 



























































*13 year olds only; Adjusted for atopic/asthma status, season, caregiver’s education, BMI percentile 









Coef. (β) P-value [95% Conf. Interval] 
Urinary creatinine 0.403 <0.001 0.259 0.547 
Gender (reference: girls)     
   Unadjusted for Cr -0.378 0.016 -0.686 -0.069 
   Adjusted for Cr -0.385 0.010 -0.680 -0.091 
Age  -0.023 0.566 -0.100 0.055 
Atopic and asthma statuses     
   Atopic non-asthmatic (reference) - - - - 
   Non-atopic asthmatics -0.110 0.665 -0.609 0.389 
   Atopic asthmatic -0.459 0.057 -0.932 0.014 
BMI percentile (continuous) 0.001 0.833 -0.004 0.005 
BMI percentile categories     
   Normal weight (reference) - - - - 
   Overweight 0.007 0.979 -0.495 0.508 
   Obese -0.025 0.877 -0.344 0.294 
   Underweight -0.162 0.614 -0.790 0.467 
Season     
   Winter (reference) - - - - 
   Spring 0,752 0.572 -0.186 0.336 
   Summer -0.072 0.645 -0.377 0.234 
   Fall 0.079 0.514 -0.158 0.316 
Heating season (Nov 1-March 1) 0.081 0.464 -0.135 0.297 
Caregiver education     
   Some HS (reference) - - - - 
   HS diploma -0.172 0.327 -0.517 0.172 
   Attended college/college degree -0.334 0.058 -0.680 0.011 
Insurance (ref: public insurance) -0.071 0.624 -0.356 0.214 
     
Gender; 13 year olds only     
   Gender (unadjusted for Cr)* -1.821 <0.001 -2.469 -1.174 




Table 2-4. Associations between indoor PM2.5, PM10, PM2.5-10 and air nicotine concentrations and 














































*Adjusted for urinary creatinine 








 Crude*  Adjusted** 
 PM2.5 β P>z [95% CI]  β P>z [95% CI] 
All samples 0.049 0.605 -0.137 0.235  0.038 0.711 -0.162 0.238 
Urine collected on Day 3 0.040 0.757 -0.211 0.290  0.020 0.888 -0.257 0.296 
Urine collected on Day 7 0.014 0.902 -0.215 0.244  0.046 0.711 -0.199 0.292 
          
 PM10          
All samples 0.140 0.129 -0.041 0.322  0.085 0.385 -0.107 0.278 
Urine collected on Day 3 0.143 0.364 -0.165 0.450  0.094 0.580 -0.240 0.429 
Urine collected on Day 7 0.142 0.220 -0.085 0.370  0.104 0.390 -0.133 0.342 
          
PM2.5-10          
All samples 0.121 0.057 -0.003 0.245  0.117 0.074 -0.011 0.246 
Urine collected on Day 3 0.113 0.297 -0.100 0.326  0.083 0.437 -0.127 0.293 
Urine collected on Day 7 0.144 0.055 -0.003 0.291  0.177 0.021 0.027 0.326 
          
 Air nicotine          
All samples 0.050 0.212 -0.028 0.128  0.028 0.464 -0.047 0.103 
Urine collected on Day 3 0.157 0.001 0.061 0.252  0.129 0.007 0.035 0.223 
Urine collected on Day 7 0.007 0.923 -0.131 0.144  -0.006 0.928 -0.147 0.134 
          
Air nicotine (MLR, without GEE)         
All samples 0.063 0.049 0.000 0.125  0.046 0.171 -0.020 0.111 
Urine collected on Day 3 0.117 0.008 0.031 0.203  0.097 0.035 0.007 0.188 




Table 2-5. Average time (hours) spent in the home and time spent outdoors (median (IQR)), and 
differences by gender 
a Wilcoxon sign-rank test for difference by gender 





Table 2-6. Associations between average time (hours) spent in the home and 1-OHPG 
concentrations 
*Adjusted for urinary creatinine 






In the Home All samples Boys Girls P-valuea 
P-
valueb 
Avg. time spent in the home on days 0-6 (Sat-Fri) 16.1 (13.6-18.1) 15.9 (12.7-18.0) 16.4 (14.7-18.3) 0.067 0.161 
Avg. time spent in the home on days 0-2 (Sat-Mon) 17.0 (13.7-20.3) 16.7 (11.5-19.5) 17.8 (14.3-20.3) 0.059 0.089 
Avg. time spent in the home on days 4-6 (Wed-Fri) 15.7 (13.7-17.7) 15.6 (14.0-17.6) 15.7 (13.7-18.0) 0.733 0.704 
Difference between days 0-2 and days 4-6 p=0.005     
      
Outdoors      
Avg. time spent outdoors on days 0-6 (Sat-Fri) 1.9 (0.7-3.9) 2.1 (0.8-4.7) 1.6 (0.7-3.3) 0.053 0.028 
Avg. time spent outdoors on days 0-2 (Sat-Mon) 2.0 (0.5-4.3) 2.0 (0.7-5.3) 1.7 (0.3-3.7) 0.053 0.033 
Avg. time spent outdoors on days 4-6 (Wed-Fri) 1.5 (0.3-4.0) 1.9 (0.7-4.3) 1.0 (0.3-3.3) 0.026 0.044 
Difference between days 0-2 and days 4-6 p=0.404     
All Samples Crude*  Adjusted** 
 β P>z [95% CI]  β P>z [95% CI] 
Avg. time in the home all samples -0.018 0.267 -0.051 0.014  -0.019 0.221 -0.050 0.012 
Avg. time in the home days 0-2 (urine day 3) -0.024 0.105 -0.054 0.005  -0.026 0.076 -0.055 0.003 
Avg. time in the home days 4-6 (urine day 7) -0.038 0.024 -0.072 -0.005  -0.045 0.005 -0.076 -0.013 
          
          
By Gender          
  Boys          
Avg. time in the home all samples -0.030 0.176 -0.073 0.013  -0.029 0.209 -0.073 0.016 
Avg. time in the home days 0-2 (urine day 3) -0.043 0.022 -0.079 -0.006  -0.045 0.010 -0.079 -0.011 
Avg. time in the home days 4-6 (urine day 7) -0.041 0.105 -0.090 0.008  -0.051 0.038 -0.099 -0.003 
          
  Girls          
Avg. time in the home all samples -0.014 0.543 -0.059 0.031  -0.023 0.275 -0.065 0.019 
Avg. time in the home days 0-2 (urine day 3) 0.014 0.555 -0.033 0.061  0.011 0.668 -0.038 0.059 




Table 2-7.  Associations between time spent in the home (continuous and tertiles) and urinary 1-
OHPG, stratified by indoor air nicotine 





Figure 2-2. Comparison of associations between urinary 1-OHPG concentration and tertiles of 











Low air nicotine  High air nicotine 
Average time spent in the home β P>z [95% CI]  β P>z [95% CI] 
Average time spent in the home (continuous) -0.075 0.003 -0.124 -0.026  0.005 0.835 -0.039 0.048 
          
Average time spent in the home         
5-12 hours (reference) - - - -  - - - - 
13-18 hours -0.231 0.417 -0.789 0.327  0.117 0.263 -0.258 0.612 
19-24 hours -0.451 0.108 -1.001 0.099  0.372 0.134 -0.083 0.827 




Table 2-8. Associations between time spent in the home and 1-OHPG, stratified by indoor air 
nicotine 





Figure 2-3. Comparison of 1-OHPG concentrations by time spent in the home (days 0-2 and 4-6), 






 Low air nicotine  High air nicotine  
 β P>z [95% CI]  β P>z [95% CI] Pinteraction 
Avg. time in home days 0-2 (urine day 3) -0.034 0.167 -0.083 0.014  -0.008 0.658 -0.041 0.026 0.357 
Avg. time in home days 4-6 (urine day 7) -0.081 <0.001 -0.121 -0.041  -0.024 0.285 -0.069 0.020 0.074 
           
By Gender           
 Boys           
Avg. time in the home all samples -0.085 0.008 -0.148 -0.022  0.018 0.583 -0.047 0.083 0.014 
Avg. time in home days 0-2 (urine day 3) -0.055 0.078 -0.116 0.006  -0.023 0.221 -0.061 0.014 0.264 
Avg. time in home days 4-6 (urine day 7) -0.088 0.005 -0.149 -0.027  -0.053 0.164 -0.127 0.021 0.623 
           
 Girls           
Avg. time in the home all samples -0.008 0.837 -0.080 0.065  -0.038 0.166 -0.092 0.016 0.693 
Avg. time in home days 0-2 (urine day 3) 0.011 0.743 -0.056 0.079  0.032 0.442 -0.049 0.113 0.478 




Table 2-9. Associations between average time spent outdoors and urinary 1-OHPG 
* Adjusted for urinary creatinine 





Figure 2-4. Comparison of 1-OHPG concentrations by time spent outdoors (days 0-2 and 4-6), 
stratified by gender 
 
 
 Crude*  Adjusted** 
All Samples β P>z [95% CI]  β P>z [95% CI] 
Avg. time in the home all samples -0.001 0.971 -0.048 0.047  0.014 0.618 -0.040 0.067 
Avg. time in home days 0-2 (urine day 3) 0.002 0.939 -0.061 0.066  0.019 0.635 -0.058 0.096 
Avg. time in home days 4-6 (urine day 7) 0.030 0.178 -0.014 0.075  0.048 0.054 -0.001 0.098 
          
By Gender          
 Boys          
Avg. time in the home all samples -0.006 0.854 -0.074 0.061  0.004 0.919 -0.073 0.081 
Avg. time in home days 0-2 (urine day 3) -0.009 0.798 -0.082 0.063  -0.008 0.861 -0.095 0.080 
Avg. time in home days 4-6 (urine day 7) 0.085 0.005 0.026 0.144  0.097 0.002 0.037 0.157 
          
 Girls          
Avg. time in the home all samples 0.020 0.545 -0.046 0.087  0.031 0.426 -0.045 0.108 
Avg. time in home days 0-2 (urine day 3) 0.034 0.585 -0.088 0.156  0.060 0.417 -0.085 0.206 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2-5. Comparison of geometric means of 1-OHPG concentrations  
 
Adjusted for urinary creatinine, gender, age, atopic status, season, caregiver’s education 
 
 
Figure 2-6a.  Comparison of indoor air nicotine concentration (µg/m3) with average number of 
cigarettes per day. Subjects identified in the square have high air nicotine concentrations (> 0.128 






Figure 2-6b.  Comparison of indoor air nicotine concentration (µg/m3) with average number of 
cigarettes per day. Subjects identified in the square have air nicotine concentrations >1 µg/m3and 
average ≤10 cigarettes smoked per day.  




CHAPTER 3: Polycyclic aromatic hydrocarbon internal dose, oxidative 




Background: Polycyclic aromatic hydrocarbons (PAH) are products of incomplete 
combustion of organic materials. PAH internal dose is commonly measured using urinary 
1-hydroxypyrene-glucuronide (1-OHPG) or its deconjugated derivative, 1-hydroxypyrene 
(1-OHP), the most common urinary metabolite of pyrene. PAHs have been reported to 
have adjuvant activity in allergic inflammatory responses, and PAHs have been 
associated with increased oxidative stress, inflammation and asthma-related symptoms. 
We examined whether PAH internal dose was associated with systemic oxidative stress 
and systemic inflammation in inner city asthmatic children in Baltimore, and whether 
being atopic modified these associations. 
Methods: The DISCOVER/Asthma-Diet study is a longitudinal (panel) study with a total 
of 118 participants ages 5-14 from Baltimore City. Children were followed for one-week 
periods in each of four seasons. Urine specimens were collected on day 3 and day 7 of 
each week, and analyzed for 1-OHPG and malondialdehyde (MDA); blood was collected 
on day 7 and analyzed for peripheral blood biomarkers. Day and nighttime asthma-
related symptoms and medication use were assessed for using daily diary questionnaires. 
Results: Urinary 1-OHPG was not significantly associated with the oxidative stress 
biomarker, urinary MDA, but was associated with biomarkers of systemic inflammation: 
peripheral white blood cell count (ß=0.019, p=0.030), and eosinophil count (ß=0.061, 
p=0.012) and percent (ß=0.415, p=0.002). Atopy modified the associations between 




associations among atopic asthmatic children compared to non-atopic asthmatic children 
(p-interaction=0.052, and p-interaction=0.057, respectively). Children with high urinary 
1-OHPG concentration were at a three to four-fold higher risk of waking during the night 
due to asthma symptoms in the 2-4 days prior to urine collection, and had a three to five-
fold higher risk of nighttime waking due to asthma symptoms during the 2-4 days after 
urine collection (on Tuesday) than children with low 1-OHPG concentration. Having 
high 1-OHPG concentration also was also associated with a two-fold higher risk of 
nighttime rescue medication (ß-agonist) use both during the 2-4 days prior to urine 
collection and over the 4 days following urine collection. 
Conclusions: Exposures to PAHs were associated with biomarkers systemic 
inflammation, and were modulated by atopy, with more pronounced inflammatory 
responses among atopic asthmatic children compared to non-atopic asthmatic children. In 
addition, PAH exposures were associated with increased risk of nighttime waking due to 
asthma symptoms and rescue medication use. Our results suggest that exposures to 











Asthma is a chronic inflammatory disease of the airways characterized by 
reversible airway obstruction, sensitivity of the nerve endings and an influx of 
inflammatory cells and cellular elements (i.e. eosinophils, neutrophils, macrophages, 
mast cells and T-lymphocytes) (Delfino et al. 2002, Dozor et al. 2010). Asthma is the 
most prevalent chronic disease in children, afflicting 7 million children (9.5%) in the 
United States in 2010 (Akinbami et al. 2012). African-American children have a 
disproportionate asthma burden, with higher prevalent asthma (11.1%) than the national 
average (Akinbami et al. 2012). Atopy is an allergic phenotype characterized by 
increased production of IgE in response to specific allergens, and diagnosed with skin 
prick test (Pearce et al. 1999; Suh and Koh 2013). Most asthmatic children have an atopic 
constitution and are therefore vulnerable to inflammatory responses from multiple stimuli 
(Nelson et al. 1999; Eggleston 2000; Lau et al. 2000; Breysse et al. 2005). Co-exposures 
to allergens and asthma triggers (such as second hand smoke (SHS), particulate matter 
(PM), ozone and nitrogen dioxide (NO2)) in atopic asthmatics may lead to increased 
frequency of asthma exacerbations (D’Amato et al. 2002; Diaz-Sanchez et al. 2006). 
Inner city children are a particularly vulnerable population, as they experience both 
higher asthma burden and increased exposures to substances associated with asthma 
exacerbation and severity, including SHS, indoor and outdoor PM, indoor allergens (e.g. 
mouse, cockroach, and dust mite allergens), endotoxin, mold and fungus (Wallace et al. 





Oxidative stress and MDA 
Oxidative stress, caused by an abundance of reactive oxygen species (ROS) (such 
as superoxide, peroxide and hydroxyl radicals), is associated with asthma pathogenesis 
and exacerbation (Saleh et al. 1998; Leem et al. 2005; Ercan et al. 2006; Nadeem et al. 
2008; Cho et al. 2010; Dozor et al. 2010). Malondialdehyde (MDA), a by-product of lipid 
peroxidation of polyunsaturated fatty acids, is commonly analyzed in urine and serum to 
assess oxidative stress (Kang et al. 2005). Systemic oxidative stress, measured by serum 
MDA, is associated with asthma and increased asthma severity, with asthmatics having 
higher concentrations than non-asthmatics (Jacobson et al. 2007; Ercan et al. 2006; 
Nadeem et al. 2003). Urinary MDA is also correlated with internal dose polycyclic 
aromatic hydrocarbons (PAHs), measured by urinary 1-hydroxypyrene-glucuronide (1-
OHPG) (Kang et al. 2005; Bae et al. 2010; Yoon et al. 2012). Mechanisms for asthma 
exacerbations due to PAH exposures (from PM and diesel exhaust particles (DEP)), that 
are mediated by oxidative stress, have also been reported (Pandya et al. 2002; Li et al. 
2003). The proposed mechanism for biomolecular and physiological responses to 
oxidative stress is multi-tiered, depending on levels oxidative stress generated and the 
capacity to counteract oxidative stress through antioxidant pathways. Low levels of 
oxidative stress may lead antioxidant responses through the induction of the Nrf2 
pathway and phase II enzymes. At moderate levels, oxidative stress may overwhelm 
antioxidant responses and trigger pro-inflammatory activator protein-1 (AP-1) and 
nuclear factor kappa-B (NF-kB) pathways, which are associated with increased 
cytokines, chemokines and immune mediators (e.g. interleukin (IL)-8, IL-13, macrophage 




regulated on activation, normal T-cell expressed and secreted (RANTES)) (Li et al. 
2003). High levels of oxidative stress may lead to superoxide generation, mitochondrial 
damage, necrosis and apoptosis (Nel et al. 2001; Gilmour et al. 2006; Li and Nel 2006; 
Reidl et al. 2008; Cho and Moon 2010). Moderate to high ROS burdens from PAH 
exposures may therefore elicit inflammatory cascades and cytotoxicity, which may 
contribute to airway inflammation and asthma exacerbations. 
PAHs  
Polycyclic aromatic hydrocarbons are formed from the incomplete combustion or 
pyrolysis of organic materials (e.g. coal, wood, fuel and oil) and are commonly found on 
fine and ultrafine particulates, PM2.5 (aerodynamic diameter <2.5 µm) and PM0.1 
(aerodynamic diameter <100 ng), respectively (Rosa et al. 2011). Sources of airborne 
PAH exposures include motor vehicle emissions (combustion products from diesel and 
conventional gasoline engines), burning fossil fuels (e.g. coal and oil), wood burning, 
tobacco smoking, cooking with gas stoves, heating appliances (e.g. kerosene space 
heaters), and incense burning (ATSDR 1995; Larsen et al. 2003). Diesel exhaust 
particulates (DEP), which are present in the fine (PM2.5) and ultrafine (PM0.1) particulate 
fractions have high concentrations of volatile and semi-volatile PAHs (i.e. naphthalene, 
fluorine, phenanthrene, pyrene) on the particulate surface. DEP are potent inducers of 
allergic and non-allergic inflammatory responses due to high oxidation potential of 
activated PAHs, formed through the conversion of PAHs to oxidative reactive 
intermediates (such as quinones, semiquinones and epoxides) by cytochrome P450 (CYP) 
(Nel et al. 2001; Reidl et al. 2008). PAHs are primarily known for their carcinogenicity, 




benzo[a]pyrene and coal tar pitch), probable carcinogens (e.g. dibenzo[a,l]pyrene and 
dibenz[a,h]anthracene) and possible carcinogens (e.g. benz[a]anthracene, 
benzo[b]fluoranthene and indeno[1,2,3-cd]pyrene) by the International Agency for 
Research on Cancer (IARC), and the Agency for Toxic Substances and Disease Registry 
(ATSDR) (ATSDR 1995; IARC 2010). PAHs, have also been associated with the 
development of asthma (Miller et al. 2004; Jung et al. 2012), neurodevelopmental 
deficiencies (Perera et al. 2006), and low birth weight (Perera et al. 2003) in inner city 
children, most likely through non-mutagenic inflammatory mechanisms.  
1-OHPG 
Urinary 1-hydroxypyrene-glucuronide (1-OHPG) is an accepted biological 
indicator of PAH exposure, as its parent compound, pyrene, is present in virtually all 
environmental PAH mixtures and is a reliable biomarker of low-level exposure (Buchet 
et al. 1992; Jongeneelen 2001). Urinary 1-OHPG concentrations reflect exposures 
through inhalation, ingestion, and dermal absorption (from contaminated air and soil) 
(Jongeneelen 2001). 1-hydroxypyrene (1-OHP) and 1-OHPG are commonly used urinary 
biomarkers, however 1-OHPG is more sensitive, as the glucuronide molecule confers 3-5 
times more fluorescence than 1-OHP (Strickland et al. 1996; Kang et al. 2005). 1-OHPG 
levels have been associated with increased levels of oxidative stress biomarkers (i.e. 
urinary MDA and 8-OHdG), decreased lung function, and having asthma, and higher 1-
OHP concentrations have been reported in asthmatic children than non-asthmatic children 
(Kim et al. 2005; Leem et al. 2005; Bae et al. 2010; Hong et al. 2009). Molecular 
pathways for (oxidative stress and allergic inflammation mediated) asthma-related 




in vivo and human studies. The proposed mechanism for PAH-asthma exacerbation is 
thought to involve high concentrations of quinones, semiquinones and epoxides derived 
from biotransformed PAHs overriding protective pathways (i.e. antioxidants and phase II 
enzymes), leading to increased oxidative damage in cells and the surrounding tissues, and 
subsequent biomolecular, immunological and physiological responses (e.g. airway 
inflammation and airway hyperreactivity) associated with asthma exacerbations (Nel et 
al. 2001; Ercan et al. 2006; Park et al. 2006; Cho and Moon 2010). PAHs can also target 
eosinophils, basophils, neutrophils, and antigen presenting cells, and act as adjuvants for 
allergic sensitization (Nel et al. 1998; Delfino et al. 2002). In epidemiologic studies, 
exposures to PAHs early in life have been shown to act as adjuvants to the development 
of allergies to cockroach proteins (Bla g 2) in an inner city birth cohort (Perzanowski et 
al. 2009); and adjuvant activities by PAHs have been shown to increase allergic 
inflammatory responses among atopic individuals challenged with PAH-rich DEP and 
allergens intranasally in randomized crossover studies (Diaz-Sanchez et al. 1997; Diaz-
Sanchez et al. 1999). 
Our overall goal was to evaluate associations between internal dose of PAHs (i.e. 
1-OHPG) and oxidative stress (by analyzing urinary MDA), as well as associations 
between PAH internal dose and peripheral blood biomarkers of inflammation, and 
asthma-related symptoms and medication use. We also evaluated whether atopic 
constitution is an effect modifier of the associations between internal dose PAHs and 
inflammatory biomarkers, and asthma symptoms in asthmatic children. We hypothesize 
that urinary 1-OHPG concentrations will be associated with urinary MDA concentrations, 




related symptoms. We also hypothesize that atopic asthmatics will have stronger 
associations between urinary 1-OHPG and peripheral blood biomarkers and asthma-
related symptoms, based on synergistic properties of PAHs on allergic inflammatory 





The Role of Particulate Matter and Allergens in Oxidative Stress in Asthma 
(DISCOVER) and Asthma-Diet (A Study to understand The Mechanisms of Asthma-
Dietary Interventions to protect against Environmental Triggers) studies have the same 
study design, as the Asthma-Diet study is an extension of the DISCOVER study (with a 
dietary component).  The DISCOVER/Asthma-Diet study is a panel study that enrolled 
100 atopic asthmatic and 50 non-atopic asthmatic, and 30 non-asthmatic children ages 5-
12, from nine contiguous zip codes in inner city East Baltimore. Indoor PM and allergen 
exposures, diet, lung function, asthma symptoms, and biomarkers of oxidative stress and 
inflammation were assessed for a one week period, in each of 4 seasons (Figure 3-1) (Dr. 
Greg Diette, personal communication). Inclusion criteria included: age 5-12 years, 
physician diagnosis of asthma, symptoms of asthma and/or reliever medication use in 
past 6 months, and residence in Baltimore city. Children were excluded from the study if 
they had a current diagnosis of another major pulmonary disease, if they were planning to 
relocate residence during the study period, were currently taking antioxidant 




pregnant. Each season, the children’s homes were monitored for 8 days (day 0-7), air 
nicotine, PM2.5, PM2.5-10, PM10, and NO2 concentrations were measured. Asthma-related 
symptom questionnaires were administered (in the morning and evening); urine was 
collected on the fourth (day 3, Tuesday) and eighth day (day 7, Saturday), and blood was 
collected on the eighth day (day 7). The morning (AM) and night (PM) symptom diaries 
asked questions about sleep interruption due to asthma, inhaler use, trouble breathing, 
doctor of emergency room (ER) visits for asthma, prednisone treatment, and physical 
activity limitation due to asthma (see Appendix B).    
 
 
Figure 3-1. DISCOVER/Asthma-Diet study framework  
                 
 
Malondialdehyde 
Malondialdehyde (MDA) concentrations were analyzed using high-performance liquid 
chromatography (HPLC) with fluorescence detection measured as modified from Giera et 
al. (2011).  
MDA standard preparation 
10mM malondialdehyde standard was prepared using a modified method previously 
described by Kang et al. (2006). 0.084 ml 1,1,3,3-tetramethoxypropane (TMP) was 
 
Seasonal collection time points 
 
            Baseline ------------- 3 months ------------ 6 months ----------- 9 months 
                       
Questionnaire data and samples collected during 1 week of monitoring at each seasonal time point 
           Day:       0 (Sat)      1 (Sun)      2 (Mon)      3 (Tue)      4 (Wed)       5 (Thu)      6  (Fri)      7 (Sat) 
               PM/NO2/Nicotine ----------------------------------------------------------------------------- 
                       Symptoms -------------------------------------------------------------------------------- 
                                           FEV1 ----------------------------------------------------------------------- 
                                          FeNO ----------------------------------------------------------------------- 
                                                                     urine     urine 




mixed with 1ml 1.0N HCl in a 40°C bath for 10 minutes, with frequent shaking. 1mL 
1.0N NaOH was added to increase the pH. 48 ml of 0.1M phosphate buffer was then 
added to bring the total volume to 50 ml. 
2-Aminoacridone preparation 
5nM stock solution 2-aminoacridone (2-AA) was prepared weekly. Briefly, 9 mg of 2-
AA was mixed with 860 acetonitrile (ACN).  
Assay 
MDA concentrations were analyzed with HPLC and laser-induced fluorescence 
(LIF). 0.5 ml of the urine sample was mixed with 40µL 2-AA and 460 µL 0.1M citrate 
buffer (pH 4.0) and incubated in a water bath for 90 minutes at 40°C. Five microliters of 
the sample were injected into an HPLC system consisting of a Rheodyne injector with a 5 
mm loop, Agilent 1100 series pumps, Series 56 helium-cadmium Omnichrome laser, and 
a Picometrics Zetalif LIF detector (P/N1701- 201) set to 325 nm. Separation was 
achieved with a Zorbax SB C18 5 mm, 150 0.5 mm column. The sample was eluted using 
a 20-minute linear gradient with acetylnitrile (ACN) and water (25%–90% ACN) 
followed by a cleaning regimen (90% ACN over 5 minutes). This system was operated at 
a flow rate of 5 mL/min. Area under the peak at the retention time of 12 minutes was 
determined by manually integrating the peaks using ChemStation Software Rev. A.08.04 
(Agilent Technologies). MDA concentrations, reported as pmol/ml, were calculated by 
dividing fluorescence peak area by the slope of 1.5 from MDA standard curves (water 
spiked with 0, 50, 100 and 200 pmol/ml). The limit of detection was 33 pmol/ml. The 
MDA range in our study was <33-726 pmol/ml (mean: 96.2 pmol/ml). Giera et al. (2011) 




communication with Giera). 
Urinary 1-OHPG  
Spot urine samples were analyzed for urinary 1-OHPG concentrations using 
immunoaffinity chromatography (IAC) and synchronous fluorescence spectroscopy 
(SFS), as previously described (Strickland et al. 1994). Urine samples (2ml) were treated 
with 0.1N HCl (90°C, 60 min), neutralized, and loaded onto Sep-pak C18 cartridges 
(Waters). After washing with 30% methanol, the relatively non-polar metabolites were 
eluted with 4 ml of 80% methanol and the volume of eluate is reduced to 0.5ml by 
evaporation on a Speedvac. The concentrated samples were diluted to 4ml with 15mM 
phosphate buffered saline (PBS) and loaded onto immunoaffinity columns prepared with 
0.8ml cyanogen bromide activated sepharose 4B (Sigma) coupled with monoclonal 
antibody 8E11 that recognizes several PAH-DNA adducts and metabolites (Santella et al. 
1986). We have previously shown that 1-OHPG binds to these columns (Strickland et al. 
1994). After washing the columns three times with 4 ml 15 mM PBS, bound compounds 
were eluted with 2 ml of 40% methanol in three fractions. Eluate fractions were analyzed 
by SFS with a Perkin-Elmer LS50 fluorescence spectrometer. The excitation-emission 
monochromators are driven synchronously with a wavelength difference of 34 nm. Under 
these conditions 1-OHPG produces a characteristic fluorescence excitation maximum at 
347 nm with emission maximum at 381 nm (Strickland et al. 1994). Fluorescence 
intensity was used to quantify 1-OHPG; in our laboratory the limit of detection was about 
0.03 pmol/ml. This level of sensitivity is sufficient to detect urinary 1-OHPG in >90% of 




with high exposure. The coefficient of variation of the assay is typically 6-10% 
(interbatch) in our laboratory.  
Complete blood counts 
Peripheral blood total cell counts, differential counts and platelet counts and were 
done using an automated counter. 
Urinary creatinine  
Creatinine concentrations were determined using a modified version of the Jaffe 
reaction using the Creatinine Assay Kit (Cayman Chemical Company; Ann Arbor, MI). 
Briefly, 150 µl of alkaline picrate solution was added to wells containing 15 µl creatinine 
standard or urine samples in duplicate, and the solution was mixed for 10 minutes. The 
absorbance of the solution (due to the reaction between the alkaline picrate and urinary 
creatinine metabolites) was read at 450-500 nm using a Biotek ELx800 Absorbance 
Microplate Reader. 5 µl of acid solution was then added to the assay and the absorbance 
was read again at 450-500 nm, 20 minutes after mixing. The difference in color intensity 
before and after acidification is proportional to urinary creatinine concentration. Urinary 
creatinine levels were determined using a creatinine standard curve, which was estimated 
in each batch from analysis of the standard creatinine. 
Air nicotine 
Two passive sampling badges were placed in the child’s bedroom or TV/family 
room at 3–5 feet off the floor. The passive air samplers consist of a sodium-bisulfate 
treated filter contained in a 37-mm polystyrene cassette covered with a polycarbonate 




nitrogen-phosphate detector. The limit of detection for the passive air nicotine badges 
was 0.003 µg/m3. 
Statistical analysis 
Summary statistics were reported for urinary1-OHPG and MDA concentrations. 
1-OHPG and MDA concentrations were log-transformed to adjust for positively skewed 
distributions. Urinary 1-OHPG and MDA concentrations on day 3 (Tuesday; n=255) and 
day 7 (Saturday; n=339) and averages for the monitoring period (n=359) were analyzed 
separately. Individual day (day 3 or day 7) 1-OHPG and MDA values were used instead 
of the average when urine samples for both days were not collected. Multivariate linear 
regressions with generalized estimating equations (GEE) were used to assess associations 
between the primary predictor (e.g. urinary 1-OHPG) and outcome (dependent) variables 
(i.e. urinary MDA, peripheral blood biomarkers, asthma-related symptoms) while 
adjusting for repeated measurements (i.e. monitoring periods) and possible confounders. 
Analyses of relationships between 1-OHPG and peripheral blood biomarkers and asthma 
symptoms were performed for asthmatics only. Explanatory variables were considered 
possible confounders if the ß-coefficient changed by more than 10% after inclusion of the 
exposure variable (e.g. time spent in the home) in the model or if the variable was 
significantly associated with the exposure or outcome. Our final models for multivariate 
linear regression with GEE were adjusted for age, gender, season, atopic status and 
caregiver educational attainment. Asthma symptom analyses were also adjusted for 
indoor air nicotine concentration. Urinary 1-OHPG and MDA concentrations were 
adjusted for urinary creatinine by including creatinine concentrations in the model as an 




peripheral blood biomarkers were measured as continuous variables; asthma symptoms, 
gender and atopic status were binary variables; BMI percentile and season were 
categorical variables; and caregiver education was measured as ordinal variables. Atopic 
constitution was defined as having allergic responses to at least one of 13 common 
aeroallergens (dust mite mix, rat and mouse epithelia, dog hair/dander, cat dander, 
American and German cockroach, three pollens (Eastern Oak mix, grass mix, ragweed 
mix) and four molds (Helminthosporium, Alternariam, Penicillium and Aspergillus)) 
from skin prick tests or having anti-mouse IgE using radioallergosorbent test (RAST).  
Effect modification was assessed using pairwise interaction terms for independent 
variables (e.g. the product of 1-OHPG concentrations and atopic status) and interaction 
terms were considered statistically significant at p-value<0.1. Comparisons of two groups 
were performed using Wilcoxon sign-rank test and Mann-Whitney U test was used for 
comparisons of exposure variables. Pearson’s correlation coefficient and Spearman’s 
correlation coefficient examined correlations between internal dose biomarkers and 
indoor air concentrations. Two-tailed p-value<0.05 was used to determine statistical 
significance. Urine was collected in the afternoon or early evening of day 3 (Tuesday), 
and in the morning to early afternoon on day 7 (Saturday). 1-OHPG and MDA 
concentrations were reported as both pmol/ml and µmol/mol creatinine, and 
concentrations for air nicotine was reported as µg/m3, and blood biomarkers were 
reported as percent or count density (cells/mm3). Reasons for missing data included 
inability to contact the caregiver or obtain urine samples (especially during the weekday 




Missing values were not included in analyses. All data were analyzed using STATA 11.1 





Urinary malondialdehyde concentrations were analyzed for 594 spot urine 
samples (Table 3-1). Urinary MDA had an arithmetic mean (standard deviation (SD)) of 
10.4 (9.6) µmol/mol creatinine (Cr) and a median (IQR) of 7.6 (4.4-12.9) µmol/mol Cr. 
Fifty-nine samples (10%) were below the limit of detection of 33 pmol/ml. Log-
transformed creatinine corrected MDA concentrations from urine collected on day 3 
(Tuesday) and day 7 (Saturday) were significantly correlated (Pearson’s r: 0.25, p<0.001) 
and associated (ß=0.204, p=0.001; 95% CI [0.086-0.322]) (Tables 3-2 and 3-3). Using 
multivariate linear regression analyses with GEE to account for repeated measurements, 
log transformed urinary MDA concentrations were associated with urinary creatinine 
(ß=0.246, p<0.001; 95% CI [0.153-0.339]), and obesity (ß=0.151, p=0.054; 95% CI [-
0.003-0.305]), particularly in asthmatics, but not with gender, age, atopic status, season, 
or caregiver’s educational status (Table 3-2).   
Overall MDA and 1-OHPG 
Urinary 1-OHPG concentrations from 594 spot urine samples had an arithmetic 
mean (SD) of 0.17 (0.22) µmol/mol Cr and a median (IQR) of 0.11 (0.05-0.22) µmol/mol 
Cr (Table 3-1). Creatinine-corrected urinary MDA was correlated with urinary 1-OHPG 




associated with 1-OHPG concentrations in urine collected on day 3, day 7 or in the 
averaged urinary measurements, using multivariate linear regression analysis (accounting 
for repeated measurements and adjusting for possible confounders) (Table 3-5). 
MDA in asthmatics  
Urinary MDA concentrations were analyzed in 532 spot urine samples from 
asthmatic children (Table 3-1). Urinary MDA had an arithmetic mean (SD) of 10.6 (9.8) 
µmol/mol Cr and a median (IQR) of 7.8 (4.6-13.0) µmol/mol Cr. Forty-nine samples 
(9%) were below the limit of detection of 33 pmol/ml. Log-transformed creatinine 
corrected MDA concentrations from urine collected on day 3 were significantly 
correlated (Pearson’s r: 0.25, p<0.001) and associated (ß=0.187, p=0.004; 95% CI 
[0.061-0.314]) with MDA concentrations from day 7 (Tables 3-2 and 3-4). Log 
transformed MDA concentrations were also associated with urinary creatinine (ß=0.248, 
p<0.001; 95% CI [0.155-0.340]) and being obese (compared to normal weight) (ß=0.181, 
p=0.024; 95% CI [0.024-0.338]), but not with gender, age, atopic status, asthma status, or 
caregiver’s educational status (Table 3-2).  
MDA and 1-OHPG in asthmatics 
Urinary 1-OHPG concentrations in 532 spot urine samples from asthmatic 
children had an arithmetic mean (SD) of 0.17 (0.21) µmol/mol Cr and a median (IQR) of 
0.11 (0.05-0.23) µmol/mol Cr. (Table 3-1). Creatinine adjusted urinary MDA 
concentrations were correlated with urinary 1-OHPG concentrations (Pearson’s 
correlation coefficient: 0.12, p=0.033) (Table 3-4). MDA concentrations were not 
associated with 1-OHPG concentrations in urine collected on day 3, day 7 or in the 




for repeated measurements and adjusting for possible confounders) (Table 3-5). 
However, creatinine unadjusted urinary MDA was significantly associated with 
creatinine unadjusted 1-OHPG concentration in urine collected on day 3 in asthmatic 
children (ß=0.089, p=0.024; 95% CI [0.012-0.165]) (Table 3-5). 
Peripheral blood biomarkers summary 
Peripheral blood eosinophil count (Wilcoxon rank-sum test: p<0.001), and 
eosinophil, basophil and leukocyte percent were higher in atopic asthmatic children than 
non-atopic asthmatic children (Wilcoxon rank-sum test: p<0.001, p<0.001 and p=0.045, 
respectively) (Table 3-6). Peripheral blood neutrophil count and percent (Wilcoxon rank-
sum test: p=0.024 and p=0.001, respectively) and monocyte count (Wilcoxon rank-sum 
test: p=0.037), were higher in non-atopic asthmatics than atopic asthmatics. 
1-OHPG and peripheral blood biomarkers 
Peripheral blood biomarkers from blood draws on day 7 (Saturday) were 
compared to urinary 1-OHPG concentrations from urine collected on day 3 (Tuesday) 
and day 7 (Saturday), and an average of the two samples (averaged 1-OHPG) (Table 3-7). 
Urinary 1-OHPG concentrations on day 3 were significantly associated with increased 
peripheral blood eosinophil counts (ß=0.061, p=0.012; 95% CI [0.014-0.108]), eosinophil 
percent (ß=0.415, p=0.002; 95% CI [0.154-0.676]), and white blood cell count (ß=0.019, 
p=0.030; 95% CI [0.002-0.035]) from blood collected on day 7 (Table 3-7). A dose-
dependent relationship between quartiles of 1-OHPG from day 3 urine and peripheral 
blood eosinophil counts was also observed (Table 3-8, Figure 3-2). 1-OHPG 




one-week monitoring period, however, were not associated with peripheral blood 
biomarkers (Table 3-7).  
Effect modification by atopic status 
Atopy was examined as a possible effect modifier of associations between urinary 
1-OHPG concentrations and peripheral blood inflammatory biomarkers in asthmatic 
children only (Tables 3-9 to 3-11; Figures 3-3 to 3-6).  
Associations with 1-OHPG from urine collected on day 3 
1-OHPG concentrations in urine from day 3 were significantly associated with 
increased peripheral blood eosinophil counts (ß=0.079, p=0.001; 95% CI [0.033-0.125]) 
and eosinophil percent (ß=0.524, p<0.001; 95% CI [0.258-0.790]) in atopic asthmatic 
children (Table 3-9; Figure 3-3 and 3-4). Urinary 1-OHPG concentrations were also 
significantly associated with decreased monocyte percent (ß=-0.229, p=0.030; 95% CI [-
0.436-(-0.022)]) and marginally associated with decreased basophil percent (ß=-0.017, 
p=0.096; 95% CI[-0.037-(-0.003)]) in non-atopic asthmatic children.  
Atopic status modified associations between urinary 1-OHPG and peripheral 
blood eosinophil percent, with atopic asthmatics experiencing more pronounced increases 
in eosinophil percent associated with urinary 1-OHPG (ß=0.524, p<0.001) than non-
atopic children (ß=0.016, p=0.860) (p-interaction=0.052) (Table 3-9, Figure 3-4). Similar 
patterns were seen with 1-OHPG concentrations and peripheral blood neutrophil counts 
(atopic asthmatic children: ß=0.019, p=0.343; non-atopic asthmatic children: ß=0.004, 
p=0.864) (p-interaction=0.062). Atopy also modified the associations between urinary 1-
OHPG concentration on day 3 and peripheral blood monocyte count and percent, with 




positively (though non-significantly) associated with peripheral blood monocyte counts 
in atopic asthmatics (ß=0.018, p=0.294; 95% CI [-0.016-0.053]), whereas non-atopic 
asthmatics had inverse (though non-significant) associations between 1-OHPG and 
peripheral blood monocyte counts (ß=-0.021, p=0.152; 95% CI [-0.049-0.008]) (p-
interaction=0.083). Similarly, atopy modified the associations between 1-OHPG and 
peripheral blood monocyte percent, with non-atopic asthmatic children showing 
significantly stronger inverse associations than atopic asthmatic children (non-atopic 
asthmatics: ß=-0.229, p=0.030; atopic asthmatics: ß=-0.013, p=0.864) (p-
interaction=0.001) (Table 3-9).   
Associations with 1-OHPG from urine collected on day 7 
Atopy modified associations between urinary 1-OHPG concentration and 
peripheral blood monocyte percent from urine and blood samples collected on the same 
day (day 7 (Saturday)), with associations in opposite directions (Table 3-10, Figure 3-6). 
Atopic asthmatics showed marginally significant positive associations between 1-OHPG 
and monocyte percent (ß=0.131, p=0.085; 95% CI [0.018-0.279]), whereas 1-OHPG and 
monocyte percent were non-significantly inversely associated in non-atopic asthmatics 
(ß=0.072, p=0.618; 95% CI [-0.354-0.210]) (p-interaction=0.016). Atopic status also 
modified inverse associations between urinary 1-OHPG concentration and peripheral 
blood neutrophil counts (Figure 3-5). Atopic asthmatics had stronger non-significant 
inverse associations between 1-OHPG and neutrophil counts (ß=-0.023, p=0.322; 95% CI 






1-OHPG and symptoms  
Asthma-related symptoms and medicine use were assessed each day of the 
weeklong monitoring period, days 0-7 and compared to urinary 1-OHPG concentrations. 
Associations were analyzed for creatinine adjusted 1-OHPG (dichotomized at the 
median) and symptoms two, three and four days prior to spot urine collection on day 3 
(Tuesday) and day 7 (Saturday); two and four days after urine collection on Tuesday; as 
well as over the entire week (Tables 3-12 and 3-13; Supplemental Tables 3-1 to 3-5). 
High 1-OHPG concentrations from urine collected on Tuesday were associated with 
approximately 3-4 times higher risk of waking during the night due to asthma symptoms 
(such as wheeze) in the 2-4 days prior to urine collection, and children with high 1-
OHPG were 3-5 times more likely to wake during the night due to asthma symptoms 
during the 2-4 days after urine collection (Table 3-12, Figure 3-7). Children with high 
urinary 1-OHPG concentration from urine collected on Saturday were approximately 3 
times more likely to be woken at night due to asthma during the previous 4 nights 
(Thursday-Saturday) than children with low 1-OHPG (OR=2.98, p=0.015; 95% CI 
[1.239-7.147]). Children with high 1-OHPG from the weekly averaged urine 
concentration were 3 times as likely to be woken due to asthma symptoms from 
Wednesday to Saturday (days 4-7) than children with low urinary 1-OHPG (OR=3.36, 
p=0.019; 95% CI [1.223-9.214]) (Table 3-12, Figure 3-8). 
1-OHPG concentrations from urine collected on Tuesday were also associated 
with 2 times higher risk of nighttime rescue medication (ß-agonist) use during the 
previous 2-4 days compared to children with low 1-OHPG (OR=2.05, p=0.048; 95% CI 




were also approximately two times more likely to use rescue medication during the night 
or early morning over the next 4 days (Tuesday-Saturday) (OR=2.48, p=0.014; 95% CI 
[1.201-5.104]) (Table 3-13, Figure 3-9). 
There was little evidence for associations between 1-OHPG and other asthma-




Urinary 1-OHPG and MDA 
The proposed mechanism for exacerbation of asthma-related symptoms involves 
exposures to PAH (measured as internal dose, urinary 1-OHPG) inducing oxidative stress 
(measured by urinary MDA) leading local and systemic inflammation and subsequently 
asthma exacerbation. Although urinary 1-OHPG and MDA were correlated in our study, 
they were not associated using both cross-sectional multivariate linear regression (MLR) 
and longitudinal analyses (MLR with GEE, with urinary creatinine included in the model 
as an independent variable, and adjusting for possible confounders). Leem et al. (2003) 
reported similar lack of a relationship between internal dose PAHs (urinary 1-OHPG) and 
urinary MDA in asthmatic children. Other studies have reported associations between 1-
OHP(G) and MDA (Kang et al. 2005; Bae et al. 2010; Yoon et al. 2012), however, these 
reports may be misleading because the thiobarbituric acid reactive substances (TBARS) 
(used to measure urinary MDA) is a non-specific assay and may underestimate 
concentrations and suggest relationships that are not representative of oxidative stress. In 




fluorescence of 2-aminoacridone (2-AA) covalently bound to MDA (2-AA-MDA) (Giera 
et al. 2011). TBARS assays were commonly used to analyze urinary MDA concentrations 
because the assay is time and cost efficient (i.e. TBARS can be measured using 
fluorescence from multi-welled plates) (Janero et al. 1990; Esterbauer et al. 1991; Kang 
et al. 2005). The 2-AA-MDA assay is more specific for MDA than TBARS because 2-
thiobarbituric acid (TBA) may cross-react with other aldehydes, sugars, amino acids, 
oxidized lipids, and by-products resembling MDA–formed through the breakdown of 
various compounds from the harsh conditions of TBA reactions (incubation in acidic 
solution at high temperatures (90°C) for up to an hour) (Esterbauer et al. 1991; Draper et 
al. 2001; Giera et al. 2011). MDA can be measured in two forms, free (unbound) MDA–
as measured in this study, and total MDA (free MDA+bound MDA)–measured by 
TBARS (de Vecchi et al. 2009). Analysis of urinary free MDA concentration quantifies 
recent lipid peroxidation activity and current oxidative stress, whereas TBARS 
concentrations, although up to 10 fold higher, are less specific and reflect old oxidative 
stress events (de Vecchi et al. 2009). Analysis of short-term biomarkers of internal dose 
PAHs (urinary 1-OHPG) and oxidative stress biomarkers (free MDA concentrations) may 
therefore give a snapshot of recent PAH exposures and early biologic effects. Analysis of 
other oxidative stress biomarkers, such as urinary isoprostane (8-iso-PGF2α) and urinary 
8-hydroxy-deoxyguanosine (8-OHdG), in conjunction with urinary free MDA analysis 
(using urinary 2-AA-MDA) may improve assessments of systemic oxidative stress and 
oxidative damage, and better reflect early biological effects in individuals exposed to 





1-OHPG and peripheral blood biomarkers 
In this study, 1-OHPG concentrations from urine collected on Tuesday showed 
more significant associations with peripheral blood biomarkers collected on Saturday 
than urinary 1-OHPG and peripheral blood markers both collected on Saturday. 
Peripheral blood biomarkers assess systemic inflammation, and the short half-lives of 
circulating neutrophils (6-8 hours), eosinophils (8-18 hours), and basophils (a few days) 
are similar to urinary 1-OHPG (6-35 hours, mean 15.4 hours) (Stock et al. 2000; Hu et al. 
2006; Stone et al. 2009). Associations between urinary 1-OHPG and peripheral blood 
biomarkers may therefore reflect short-term inflammatory responses to exogenous 
exposures. 
Urinary 1-OHPG concentration was independently associated with increased 
peripheral white blood cell count, highlighting the relationships between internal dose 
PAHs and systemic inflammation. Similar positive associations were found in cross-
sectional, nationally representative studies in the United States from 1999-2004 (the 
National Health and Nutrition Surveys (NHANES II, III and IV)) (Alshaaraway et al. 
2013). In our study, PAH internal dose (from urine collected on Tuesday) was also 
independently associated with increased peripheral blood eosinophil counts and percent 
in atopic asthmatics children, and atopy modified these associations, with significantly 
stronger PAH-eosinophil count associations in atopic asthmatics than non-atopic 
asthmatics. This relationship between PAH internal dose and peripheral eosinophils 
supports the concept of PAH induced inflammation mechanisms and has implications for 
asthma exacerbation, as eosinophilic inflammation (eosinophilia) is an integral 




related symptoms (Stone et al. 2009). Peripheral blood eosinophils are associated with 
total serum IgE and positive skin prick test responses, which is consistent with an allergic 
phenotype in children (Oryszczyn et al. 2007). Eosinophilia is also an integral component 
of asthma attacks and asthma severity in children. A meta-analysis showed half of 
childhood asthma cases were attributed to eosinophilic airway inflammation (Douwes et 
al. 2002).  Bossley et al. (2012) reported that severe asthmatic children overwhelmingly 
present eosinophilic asthma phenotype. In this study, significant independent associations 
between internal dose PAHs and increased peripheral blood eosinophils suggest that 
PAHs influence eosinophilia in atopic asthmatic children, and effect modification by 
atopy also suggests significant interaction between PAHs and allergen-mediated 
inflammatory responses in atopic asthmatic children.  
We did not measure exposures to aeroallergens in this study, however, previous 
studies quantifying allergen exposures in the homes of inner city asthmatic children in 
New York City and Baltimore City have reported high background levels of mouse 
urinary protein (Mus m 1), dust mite allergen (Der f 1), and cockroach allergen (Bla g 2) 
(Perzanowski et al. 2009; Matsui et al. 2006; Matsui et al. 2010). It is therefore likely that 
the participants in our study (inner city asthmatic children from Baltimore City) 
experienced similarly high exposures to aeroallergens, and co-exposures with indoor and 
ambient outdoor PAHs. The significantly increased levels of peripheral blood eosinophils 
in atopic asthmatic children with high PAH exposures, and comparatively higher 
peripheral neutrophils and monocytes in atopic asthmatics than non-atopic asthmatics 
suggests a synergistic relationship between PAHs and allergens, with PAHs acting as 




reported in human nasal provocation studies with (PAH rich) diesel exhaust particulates 
and allergens (e.g. ragweed and keyhole limpet hemocyanin (KLH)) in atopic individuals. 
In those studies, allergic inflammatory responses were enhanced in individuals exposed 
to both DEP and allergens, leading to marked increases in allergen specific IgE, increases 
in Th2-type cytokines (IL-4, IL-5, IL-6, IL-10 and IL-13), and induction of chemokines 
related to eosinophil recruitment (RANTES, MIP-1α, and MCP-3) (Diaz-Sanchez et al. 
1994; Diaz-Sanchez et al. 1997a; Diaz-Sanchez et al. 1997b; Nel et al. 1998; Bastain et 
al. 2003). PAHs can also target macrophages, leading to increased IL-8, RANTES, and 
MIP-1α, induction of adhesion molecules, initiation of chemokine and cytokine cascades, 
and recruitment of pro-inflammatory cells (e.g. eosinophils and neutrophils) (Nel et al. 
1998; Nel et al. 2001; Pandya et al. 2002). The comparatively higher peripheral blood 
monocyte levels in atopic asthmatic children in our study may therefore reflect 
interactions between PAHs and monocytes. Peripheral blood monocytes differentiate into 
antigen presenting cells (macrophages and dendritic cells) in the tissues and are integral 
in enhancing allergen-mediated inflammatory responses.  
Among non-atopic asthmatic children in our study, 1-OHPG was independently 
associated with decreased peripheral blood monocytes, and atopic status modified the 
associations, with non-atopic asthmatics showing stronger inverse associations than 
atopic asthmatics. Interactions between PAHs and suppression of blood monocytes in 
non-atopic asthmatics likely has a different mechanism than the adjuvant activities of 
PAH among atopic individuals, however, further research is needed to explore the 
mechanism. Fahy et al. (1999) reported that peripheral blood mononuclear cells (PBMC) 




increases in IL-8 and RANTES (which are associated with neutrophil and eosinophil 
recruitment, respectively), suggesting a preference for neutrophils and eosinophils 
induction, and a suppression of monocytes and macrophages in response to DEP-PAH 
exposures. In non-atopic asthmatics, asthma pathogenesis and exacerbation have been 
associated with a neutrophilic inflammatory phenotype, which differs from the mostly 
eosinophilic inflammatory phenotype in atopic asthmatics (Douwes et al. 2002). 
Neutrophilic inflammation and airway obstruction is characterized by non-allergenic, 
innate immune inflammatory responses, and has been shown to be induced by PM, NO2, 
ozone, endotoxin and viruses. Exposures to DEP have also been shown to increase 
neutrophil mobilization and neutrophilic inflammation through the NF-kB inflammatory 
pathway (Nightinggale et al. 2000; Mukae et al. 2001; Douwes et al. 2002). 
Associations between internal dose of PAHs and peripheral blood monocytes 
were modified by atopic status in our study. On both urine collection days, monocyte 
percent was significantly modified by atopy, with more pronounced positive associations 
between 1-OHPG and peripheral blood monocytes in atopic asthmatics than non-atopic 
asthmatics. In vitro studies have shown diminished differentiation and maturation of 
monocyte derived dendritic cells (Laupeze et al. 2002) and macrophages (van 
Grevenynghe et al. 2003) after PAH exposures, suggesting altered trafficking of 
monocytes. However, the mechanism for altered peripheral blood monocyte levels by 
PAH exposures, and the influence of atopy on this pathway, is not known. Similarly, 
atopy marginally modified the positive associations between peripheral blood eosinophil 
counts and urinary 1-OHPG, with more pronounced associations in atopic asthmatics 




blood biomarker associations involving urine collected four days prior to blood 
collection, but not for urine and blood collected on the same day. These differences in 
effect modification by sample collection day (for statistically similar 1-OHPG 
concentrations in Tuesday and Saturday urines) may be due to differences in the types of 
PAH exposures (e.g. outdoor, indoor or SHS exposures), differences in the relative 
potencies of the PAH mixtures (such as, inflammatory, adjuvant and immunotoxicity 
potentials), and differences in routes of PAH exposures (inhalation or ingestion) on those 
days. PAHs reflected in urine collected on Tuesday may be largely from airborne sources 
with high oxidative potential (i.e. from DEP and SHS), which may confer increased local 
and systemic inflammatory responses, and increased adverse pulmonary outcomes in 
asthmatic children. These differences in PAH internal dose-peripheral blood biomarker 
associations by urine collection day may also reflect differences in temporality of the 
inflammatory responses to PAH exposures. Acute inflammatory responses may be 
captured in urine and blood collected on the same day, while longer-term inflammatory 
responses may be captured in blood collected four days after urine collection. 
Inflammation may last for hours to days after PAH exposures, and may increase over 
time, especially if the PAH exposures persist and if there are co-exposures to 
aeroallergens–which may potentiate the effects of PAHs in atopic asthmatics.  
1-OHPG and asthma-related symptoms 
In this study, significant associations were found between urinary 1-OHPG and 
nighttime and early morning asthma symptoms. Children with high exposures to PAHs 
were at an increased risk to wake up during the night due to wheezing and other asthma 




morning. Associations between PAH internal dose and symptoms were found on days 
prior to, and after urine collection on Tuesday, suggesting both prolonged exposures to 
PAHs in the beginning of the week (i.e. Saturday through Tuesday), and lasting effects of 
those exposures on asthma related outcomes for the rest of the week (Wednesday through 
Saturday). In a study of the effects of daily PAH exposures on asthma symptoms, Gale et 
al. (2012) reported that increased exposures to ambient PAHs were associated with 
higher odds of wheeze in asthmatic children ages 6-11 years old in Fresno, CA (Gale et 
al. 2012). Exposures to phenanthrene, a semi-volatile PAH, were associated with 
significant increases in odds of wheeze with lags for 1-4 days, and for 2 day and 5 day 
moving averages (Gale et al. 2012). Nighttime asthma symptoms and medication use may 
be particularly important to the health and well being of asthmatic children, as nighttime 
awakening is a predictor of poor asthma control and may lead to decreased sleep, missed 
school and poor performance in school (Diette et al. 2000; Hansel et al. 2011). ß-agonist 
use among asthmatic children was also shown to be an indicator of poorly controlled 
asthma and asthma severity (Diette et al. 2000). 
Asthma-related responses to PAH exposures differed by atopic phenotype, with 
non-atopic asthmatic children at increased risk for asthma symptoms. Internal dose of 
PAHs were independently associated with overall risk of nighttime waking due to asthma 
and ß-agonist use in non-atopic asthmatics only. 1-OHPG from urine collected on 
Saturday and nighttime waking due to asthma and ß-agonist use during the previous 2-3 
days (Thursday and Friday) showed slightly stronger positive associations in non-atopic 
asthmatic children than atopic asthmatic children (with moderate interactions by atopic 




in non-atopic asthmatic children ages 5-6 years old who were repeatedly exposed to 
PAHs (prenatally and during a two week monitoring period at ages 5-6 years old) in an 
inner city birth cohort. Asthma symptoms during the night may involve non-allergen 
mediated mechanisms, which may result in increased symptoms in non-atopic asthmatics 
compared to asthmatic children. In a review of studies characterizing lung eosinophilia in 
asthmatics, Douwes et al. (2002) found that about half of childhood asthma cases were 
attributed to non-eosinophilic inflammation. The mechanism for non-atopic asthma 
exacerbations involved innate immune responses linked to environmental exposures 
(such as particulates, ozone and NO2, eotaxin and viruses) and NF-kB mediated 
neutrophilic inflammation (Douwes et al. 2002). Non-atopic asthmatic children also 
showed greater bronchial hyperresponsiveness after methacholine challenges than atopic 
asthmatics, and may therefore be more susceptible to pulmonary irritants (Mochizuki et 
al. 1999). In addition, Li et al. (2006) showed that cough frequency was associated with 
sputum neutrophil cell counts in atopic children with mild asthma, highlighting the 
importance of possible independent (non-allergen mediated) inflammatory pathways for 
symptoms in asthmatic children (Li et al. 2006). Neutrophilic inflammation may 
therefore be important in both susceptibility to exposures to airborne pollutants such as 
PAHs, and subsequent increased asthma-related outcomes in non-atopic asthmatic 
children. 
Our study showed associations between PAH internal dose and early effect 
peripheral blood biomarkers of inflammation (i.e. eosinophil count and percent, and 
white blood cell count), and an increased risk of nighttime asthma symptoms and rescue 




pathophysiology of asthma–was associated with PAH internal dose in atopic asthmatics, 
suggesting a synergistic relationship between PAH exposures and allergen mediated 
inflammatory responses (e.g. skewing toward Th2-type pathways, increased IgE 
production, and increased cytokine and chemokine production). These findings support 
the proposed mechanisms for PAH-asthma exacerbation involving adjuvant PAH 
activities and allergic inflammation in atopic asthmatics. However, there were no 
significant associations between PAH internal dose and asthma-related symptoms in 
atopic asthmatics. PAH adjuvant activity may therefore predispose atopic asthmatics to 
increased inflammation, but progression to asthmatic symptoms may also include 
mechanisms (such as neutrophilic inflammation) that are not directly related to allergen-
mediated responses. More research is needed to quantify PAH exposures (e.g. airborne 
PAH monitoring and multiple internal dose biomarkers) and inflammation (e.g. 
inflammatory biomarkers from various biospecimens); evaluate allergic and asthma 
related responses in epidemiologic studies of affected populations; and to further 
investigate mechanisms linking PAH exposures, local and systemic inflammatory 
responses, and asthma exacerbation. 
Strengths  
This is the first panel study to examine associations between internal dose of 
PAHs, measured by urinary 1-OHPG concentrations, peripheral blood biomarkers, and 
asthma-related symptoms in inner city Baltimore children. The longitudinal design of the 
study allowed us to assess associations over a one-year period, account for seasonal 
differences, and intra-individual differences over time. Daily diaries of symptoms and 




exposure/outcome relationships for temporally relevant time periods. This study also 
adds to the growing literature on effects of PAHs on inflammation and asthma-related 
outcomes. This study also focuses on a vulnerable population (predominantly African 
American children from low SES neighborhoods in inner city Baltimore) with 
concomitantly high air pollutant exposures and asthma burdens. 
Limitations 
One drawback to our study is that we could not apportion PAH exposures through 
inhalation and ingestion. Dietary intake of PAHs from eating roasted, charbroiled or 
smoked foods can account for a significant portion of total PAH exposure (Fiala et al. 
2000; Vyskocil et al. 2000). In addition, measurement of urinary monohydroxylated 
metabolites of low molecular weight PAHs (predominantly found in gas phase), 
including 2-naphthol (naphthalene), 3-hydroxyphenanthrene (phenanthrene) and 9-
hydroxyflurorene (fluorine) may give a better assessment of internal dose from inhaled 
PAHs. We also did not measure other air pollutants and biological inhalants (such as 
ozone, NO2, endotoxin and aeroallergen) or assess viral infections. These possible co-
exposures are associated with inflammation and asthma exacerbation, and may confound 
the relationships found in our analyses. We did not measure aeroallergen content in 
settled dust or quantitate serum anti-allergen immunoglobulin (i.e. total serum IgE, anti-
mouse IgE, anti-cockroach IgE, anti-dust mite IgE, etc.). More comprehensive exposure 
assessments and early effect biomarker analyses would allow us to better assess the 
influence of allergens and allergic immune responses to inflammation and asthma 
exacerbations. We did not measure biomarkers of inflammation in other fluids (e.g. 




of inflammatory biomarkers in these biospecimens would give insight into local and 
tissue specific inflammatory responses. We also did not account for medications (other 
than ß-agonist use), which may influence frequency and severity of asthma attacks, as 
well as peripheral eosinophil and other blood biomarker levels. Gene-environment 
interactions, such as genetic polymorphisms, were also not assessed in this study. 
Polymorphisms in phase I (e.g. CYP1A1, CYP1A2) and phase II enzymes (e.g. GSTP1, 
GSTT1, and GSTM1) may be important in explaining inter-individual differences in 
PAH metabolism and urinary 1-OHPG elimination. The study cohort was comprised of 
mostly African American children residing exclusively in neighborhoods of low 
socioeconomic status in inner city Baltimore. This study may therefore not be 
generalizable to the pediatric asthmatic populations or children not living in inner city 
neighborhoods of low socioeconomic status. 
Conclusion 
PAH internal dose was not associated with urinary MDA, a marker of oxidative 
stress, but was associated with increased peripheral blood eosinophils, neutrophils, and 
monocytes. Stronger associations were found in PAH internal dose biomarkers collected 
4 days prior to peripheral blood biomarkers than same day comparisons, suggesting 
differences in PAH exposures, differences in inflammatory responses over time or 
sustained effects from prolonged exposures. PAHs may also exhibit adjuvant effects with 
allergens, leading to more pronounced allergic inflammation (e.g. eosinophilia) in atopic 
asthmatic children. Internal dose PAHs were also associated with increased risks of 
nighttime symptoms and rescue medication use in days prior to, and after urine 
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Table 3-2. Predictors of urinary MDA concentrations 
Adjusted for creatinine, age, gender, season, atopic status and caregiver's education 
 All Samples Asthmatics Only 







Number of samples 594 594 532 532 
Arithmetic Mean (SD) 10.4 (9.6) 0.17 (0.22) 10.6 (9.8) 0.17 (0.21) 
Geometric Mean 7.6 0.09 7.8 0.09 
Median (IQR) 7.6 (4.4-12.9) 0.11 (0.05-0.22) 7.9 (4.6-13.0) 0.11 (0.05-0.23) 
95%ile 28.5 0.54 28.8 0.54 
Range 0.7-75.5 0.003-2.13 0.7-75.5 0.003-2.13 
% Below LOD 10% 11% 9% 11% 
 All Samples 
 Asthmatics only 
 β P>z [95% CI]  β P>z [95% CI] 
Urinary creatinine 0.246 <0.001 0.153 0.339  0.248 <0.001 0.155 0.340 
Log-1-OHPG -0.009 0.736 -0.061 0.043  0.011 0.676 -0.041 0.064 
Age 0.010 0.880 -0.122 0.142  0.030 0.680 -0.111 0.170 
Gender -0.023 0.237 -0.060 0.015  -0.027 0.184 -0.067 0.013 
Atopic status 0.055 0.426 -0.080 0.190  0.065 0.349 -0.071 0.200 
Season           
     Winter (reference) - - - -  - - - - 
     Spring 0.058 0.510 -0.115 0.232  0.059 0.543 -0.131 0.248 
     Summer -0.049 0.556 -0.211 0.114  -0.076 0.379 -0.247 0.094 
     Fall -0.145 0.094 -0.314 0.025  -0.133 0.130 -0.304 0.039 
BMI percentile category    
     
    Normal weight (reference) - - - -  - - - - 
    Overweight 0.139 0.197 -0.072 0.351  0.177 0.173 -0.077 0.431 
    Obese  0.151 0.054 -0.003 0.305  0.181 0.024 0.024 0.338 
    Underweight  0.142 0.195 -0.073 0.357  0.094 0.407 -0.128 0.316 
Caregiver’s education attainment    
     
    Less than HS (reference) - - - -  - - - - 
    HS graduate -0.029 0.695 -0.172 0.114  -0.045 0.544 -0.188 0.099 
    College or higher -0.143 0.091 -0.308 0.023  -0.118 0.178 -0.290 0.054 
Asthma status 0.040 0.703 -0.167 0.247  - - - - 
Constant 4.238 <0.001 3.793 4.683  4.254 <0.001 3.790 4.717 
          
MDA day 3 vs. day 7 samples          
    Cr. adjusted MDA day 3 vs. day 7  0.204 0.001 0.086 0.322  0.187 0.004 0.061 0.314 
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Table 3-5. Associations between urinary log MDA and log 1-OHPG concentrations (urine 
samples from day 3, day 7 and averaged values) 
*Adjusted for, air nicotine, age, gender, atopic status, season, and caregiver's education (and creatinine ) 
**creatinine included in model as an independent variable 
 
* Adjusted for air nicotine, age, gender, atopic status, season, and caregiver's education 





All Samples (n=594) Crude  Adjusted* 
Cr adjusted** log MDA and 1-OHPG β P>z [95% CI]  β P>z [95% CI] 
Log 1-OHPG day 3 0.034 0.379 -0.041 0.109  0.028 0.445 -0.045 0.101 
Log 1-OHPG day 7 0.013 0.635 -0.040 0.066  0.000 0.997 -0.054 0.054 
Log 1-OHPG (average) 0.002 0.937 -0.057 0.062  -0.003 0.922 -0.058 0.052 
          
Cr unadjusted log MDA and 1-OHPG        
Log 1-OHPG day 3 0.053 0.167 -0.022 0.127  0.049 0.195 -0.025 0.122 
Log 1-OHPG day 7 0.034 0.188 -0.017 0.085  0.026 0.335 -0.027 0.079 
Log 1-OHPG (average) 0.046 0.123 -0.012 0.105  0.040 0.156 -0.015 0.096 
Asthmatics only (n=532) Crude  Adjusted*  
Cr adjusted** log MDA and 1-OHPG β P>z [95% CI]  β P>z [95% CI] 
Log 1-OHPG day 3 0.062 0.129 -0.018 0.143  0.064 0.107 -0.014 0.142 
Log 1-OHPG day 7 0.016 0.585 -0.042 0.074  0.008 0.790 -0.051 0.067 
Log 1-OHPG (average) 0.014 0.661 -0.048 0.075  0.012 0.663 -0.043 0.068 
          
Cr unadjusted log MDA and 1-OHPG       
Log 1-OHPG day 3 0.087 0.027 0.010 0.164  0.089 0.024 0.012 0.165 
Log 1-OHPG day 7 0.042 0.131 -0.013 0.096  0.033 0.272 -0.026 0.091 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3-8. Associations between quartiles of urinary 1-OHPG and peripheral blood eosinophil 












* Adjusted for urinary creatinine 
** Adjusted for urinary creatinine, air nicotine, age, gender, atopic status, season, and caregiver's education 
 
 






Table 3-9. Atopic status as an effect modifier of associations between 1-OHPG concentrations 
from urine collected on day 3 (Tuesday) and peripheral blood biomarkers from blood collected on 
day 7 (Saturday) in asthmatic children 
 Adjusted for urinary creatinine, air nicotine (continuous), age, gender, atopic status, season, and caregiver's education 
Log Eosinophil counts Crude*  Adjusted** 
 β P>z [95% CI]  β P>z [95% CI] 
1-OHPG quartile 1 (ref.) - - - -  - - - - 
1-OHPG quartile 2 0.080 0.462 -0.132 0.291  0.094 0.315 -0.089 0.277 
1-OHPG quartile 3 0.230 0.076 -0.024 0.485  0.342 0.013 0.074 0.610 
1-OHPG quartile 4 0.325 0.026 0.039 0.611  0.398 0.002 0.146 0.650 
 
Non-atopic  Atopic  
 β P>z [95% CI]  β P>z [95% CI] P-interaction 
White blood cell count 0.014 0.069 -0.001 0.029  0.024 0.066 -0.002 0.050 0.638 
Platelet count 0.005 0.281 -0.004 0.013  0.008 0.469 -0.014 0.029 0.916 
Monocyte percent -0.229 0.030 -0.436 -0.022  -0.013 0.870 -0.168 0.142 0.001 
Lymphocyte percent 0.315 0.632 -0.975 1.604  -0.492 0.141 -1.146 0.163 0.995 
Neutrophil percent -0.444 0.502 -1.739 0.851  -0.019 0.958 -0.732 0.693 0.143 
Eosinophil percent 0.016 0.860 -0.164 0.196  0.524 <0.001 0.258 0.790 0.052 
Basophil percent -0.017 0.096 -0.037 0.003  -0.011 0.504 -0.042 0.021 0.836 
Lymphocyte count 0.008 0.567 -0.020 0.036  0.017 0.140 -0.006 0.041 0.753 
Monocyte count -0.021 0.152 -0.049 0.008  0.018 0.294 -0.016 0.053 0.083 
Neutrophil count 0.004 0.864 -0.041 0.048  0.019 0.343 -0.020 0.057 0.062 




Figure 3-3. Associations between 1-OHPG concentration from Tuesday (day 3) urine and 







Figure 3-4. Associations between 1-OHPG concentration from Tuesday (day 3) urine and 








Table 3-10. Atopic status as an effect modifier of associations between 1-OHPG concentrations 
from urine collected on day 7 (Saturday) and peripheral blood biomarkers from blood collected 
on day 7 (Saturday) in asthmatic children 





Figure 3-5. Associations between 1-OHPG concentration from Saturday (day 7) urine and 











Non-Atopic  Atopic  
 β P>z [95% CI]  β P>z [95% CI] P-interaction 
White blood cell count 0.000 0.991 -0.029 0.029  -0.012 0.347 -0.037 0.013 0.284 
Platelet count 0.003 0.783 -0.016 0.021  0.008 0.376 -0.010 0.026 0.214 
Monocyte percent -0.072 0.618 -0.354 0.210  0.131 0.085 -0.018 0.279 0.016 
Lymphocyte percent 0.281 0.720 -1.255 1.817  0.317 0.355 -0.355 0.990 0.171 
Neutrophil percent -0.067 0.931 -1.585 1.451  -0.339 0.370 -1.080 0.402 0.143 
Eosinophil percent -0.177 0.172 -0.430 0.077  -0.126 0.254 -0.342 0.090 0.539 
Basophil percent 0.001 0.960 -0.044 0.047  -0.006 0.527 -0.025 0.013 0.620 
Lymphocyte count -0.019 0.346 -0.058 0.020  -0.003 0.779 -0.024 0.018 0.518 
Monocyte count -0.014 0.410 -0.048 0.020  -0.003 0.807 -0.030 0.023 0.212 
Neutrophil count -0.001 0.968 -0.052 0.050  -0.023 0.322 -0.068 0.022 0.096 




Figure 3-6. Associations between 1-OHPG concentration from Saturday (day 7) urine and 








Table 3-11. Atopic status as an effect modifier of associations between averaged urinary 1-
OHPG concentrations and peripheral blood biomarkers collected on day 7 (Saturday) in asthmatic 
children 
                    Adjusted for urinary creatinine, air nicotine (continuous), age, gender, atopic status, season, and caregiver's education 
 
 
Non-atopic  Atopic  
 β P>z [95% CI]  β P>z [95% CI] P-interaction 
White blood cell count 0.013 0.102 -0.003 0.029  0.006 0.738 -0.028 0.039 0.318 
Platelet count 0.007 0.105 -0.001 0.015  0.016 0.126 -0.005 0.037 0.286 
Monocyte percent -0.209 0.078 -0.441 0.024  0.177 0.056 -0.004 0.358 <0.001 
Lymphocyte percent -0.018 0.980 -1.399 1.363  0.105 0.845 -0.950 1.161 0.186 
Neutrophil percent 0.109 0.871 -1.208 1.426  -0.494 0.330 -1.487 0.499 0.018 
Eosinophil percent -0.048 0.632 -0.243 0.148  0.209 0.285 -0.174 0.592 0.121 
Basophil percent -0.005 0.768 -0.041 0.030  -0.007 0.612 -0.033 0.019 0.994 
Lymphocyte count -0.012 0.424 -0.042 0.018  0.011 0.387 -0.014 0.035 0.337 
Monocyte count -0.011 0.535 -0.045 0.024  0.020 0.199 -0.011 0.051 0.093 
Neutrophil count 0.013 0.594 -0.034 0.060  -0.006 0.842 -0.060 0.049 0.038 






Table 3-12. Associations between urinary 1-OHPG concentrations and waking due to asthma 
symptoms during the night or early morning 
*Unadjusted 




Figure 3-7. Associations between 1-OHPG concentration (from urine collected on Tuesday (day 
3)) and waking due to asthma symptoms during the night or early morning. 
 
Urinary 1-OHPG dichotomized at the median (0.11 µmol/mol Cr) 
 
Crude*  Adjusted** 
1-OHPG conc. day 3 OR P>z [95% CI]  OR P>z [95% CI] 
 Woken by asthma during previous 4 nights (0-3) 2.631 0.013 1.230 5.626  2.950 0.016 1.220 7.132 
 Woken by asthma during previous 3 nights (1-3) 3.667 0.003 1.560 8.621  3.838 0.009 1.395 10.559 
 Woken by asthma during previous 2 nights (2-3) 2.106 0.138 0.787 5.634  2.014 0.219 0.660 6.149 
 Woken by asthma during next 2 nights (4-5) 3.391 0.006 1.419 8.100  3.950 0.004 1.550 10.068 
 Woken by asthma during next 4 nights (4-7) 5.110 0.001 1.922 13.589  5.198 0.004 1.693 15.961 
 Woken by asthma any night (0-7) 3.311 0.003 1.484 7.384  3.368 0.007 1.385 8.192 
          
1-OHPG conc. day 7          
 Woken by asthma during previous 2 nights (6-7) 2.638 0.045 1.020 6.824  1.885 0.299 0.569 6.239 
 Woken by asthma during previous 3 nights (5-7) 1.992 0.088 0.902 4.396  1.643 0.313 0.626 4.313 
 Woken by asthma during previous 4 nights (4-7) 2.872 0.005 1.370 6.021  2.976 0.015 1.239 7.147 
 Woken by asthma any night (0-7)) 1.396 0.317 0.726 2.683  1.425 0.365 0.663 3.062 
          
1-OHPG conc. average of samples          
 Woken by asthma on nights 0-3 1.842 0.056 0.985 3.447  1.863 0.078 0.932 3.724 
 Woken by asthma on nights 4-7 3.290 0.002 1.544 7.012  3.357 0.019 1.223 9.214 




Figure 3-8. Associations between 1-OHPG concentration (from urine collected on Saturday (day 
7)) and waking due to asthma symptoms during the night or early morning. 
 





Table 3-13. Associations between urinary 1-OHPG concentrations and ß-agonist use during the 
night or early morning  
*Unadjusted 
**Adjusted for air nicotine (continuous), age, gender, atopic status, season, and caregiver's education 
  
 
Crude*  Adjusted** 
1-OHPG conc. day 3 OR P>z [95% CI]  OR P>z [95% CI] 
 ß-agonist use during previous 4 nights (0-3) 1.612 0.108 0.900 2.887  2.050 0.048 1.005 4.181 
 ß-agonist use during previous 3 nights (1-3) 1.460 0.195 0.824 2.586  1.978 0.063 0.965 4.055 
 ß-agonist use during previous 2 nights (2-3) 1.068 0.849 0.543 2.098  1.528 0.302 0.683 3.416 
 ß-agonist use during next 2 nights (4-5) 1.902 0.049 1.004 3.604  2.476 0.014 1.201 5.104 
 ß-agonist use during next 4 nights (4-7) 2.197 0.033 1.066 4.528  2.437 0.051 0.994 5.971 
 ß-agonist use any night (0-7) 1.892 0.056 0.983 3.639  2.057 0.077 0.926 4.569 
          
1-OHPG conc. day 7          
 ß-agonist use during previous 2 nights (6-7) 1.219 0.580 0.604 2.463  1.107 0.803 0.497 2.466 
 ß-agonist use during previous 3 nights (5-7) 0.911 0.789 0.459 1.808  0.918 0.825 0.430 1.961 
 ß-agonist use during previous 4 nights (4-7) 0.960 0.905 0.496 1.860  0.966 0.926 0.462 2.018 
 ß-agonist use any night (0-7) 0.967 0.908 0.549 1.705  1.030 0.932 0.521 2.037 
          
1-OHPG conc. average of samples          
 ß-agonist use on nights 0-3 1.269 0.315 0.798 2.018  1.430 0.187 0.840 2.435 
 ß-agonist use on nights 4-7 1.345 0.351 0.721 2.510  1.390 0.366 0.681 2.837 




Figure 3-9. Associations between 1-OHPG concentration (from urine collected on Tuesday (day 
3)) and ß-agonist use during the night or early morning 
 





Figure 3-10. Associations between 1-OHPG concentration (from urine collected on Saturday 
(day 7)) and ß-agonist use during the night or early morning 
 






CHAPTER 4: Polycyclic aromatic hydrocarbon internal dose, oxidative 





Background: Polycyclic aromatic hydrocarbons (PAH) are products of incomplete 
combustion of organic materials (oil, tobacco, fuel, etc.). PAHs have been associated 
with increased oxidative stress, inflammation and asthma exacerbation. The GSTM1-null 
polymorphism, which results in the inability to produce the GSTM1 enzyme, has been 
associated with increased risk of asthma and increased susceptibility to asthma attacks. 
We examined whether PAH internal dose was associated with systemic oxidative stress, 
induction of local antioxidant genes, and local and systemic inflammatory immune 
responses in atopic asthmatic adults in Baltimore. We also evaluated whether the GSTM1 
genotype modified associations between urinary 1-OHPG and biomarkers of oxidative 
stress, gene induction, and inflammation.  
Methods: The Nasal Challenge to Indoor Particulate Matter study enrolled 32 non-
smoking atopic asthmatic adults ages 18-50 to measure inflammatory and oxidative stress 
biomarkers and gene expression, after being challenged intranasally with particulate dust 
suspended in saline. We used the baseline samples only, making our study design cross-
sectional with 2 visits per person. Urine specimens were collected and analyzed for 1-
OHPG and isoprostane; and blood, nasal lavage fluid and nasal epithelium cells were also 
collected and analyzed for induction of antioxidant genes and inflammatory biomarkers. 
Results: Most of the participants were women (75%), African American (84%), between 
18 and 50 years of age (mean: 30 years of age), and 31% of the participants had the 




significantly increased nasal lavage white blood cell count; increased serum 
inflammatory chemokines and mediators: GRO, GRO-α, IL-8, RANTES, and ECP; 
increased peripheral blood inflammatory biomarkers: lymphocytes, and monocytes (both 
activated with PMA), and decreased peripheral blood polymorphonuclear leukocytes 
(PMN) in GSTM1-null participants. GSTM1 genotype modified the associations between 
1-OHPG and urinary isoprostane, serum GRO and GRO-α, peripheral blood 
lymphocytes, with stronger positive associations among GSTM1-null participants 
compared to GSTM1-present participants (interaction p-value <0.1). Among GSTM1-
present participants, urinary 1-OHPG was associated with an up-regulation of GCLC 
mRNA in nasal epithelium cells; increased nasal lavage eosinophil percent; and 
decreased peripheral blood PBMC and monocytes, and PMN (with PMA); and decreased 
serum IL-6 and CCL20. 
Conclusion: PAH exposures were associated with increased local and systemic 
inflammation in adults with atopic asthma, with different responses among GSTM1-null 
and GSTM1-present participants. GSTM1 genotype modulates these associations with 
greater inflammatory responses in participants with the GSTM1-null polymorphism 
compared to participants with GSTM1-present genotype. Our results suggest that 
individuals who are unable to produce the GSTM1 enzyme may be more susceptible to 










Asthma is a complex chronic disease of the airways characterized by reversible 
airway obstruction, sensitivity of nerve endings, and an influx of inflammatory cells and 
cellular elements (i.e. eosinophils, neutrophils, macrophages, mast cells and T-
lymphocytes) (Delfino et al. 2002; Dozor et al. 2010). Asthma prevalence in the United 
States was 8.4% in 2010, with a higher prevalence among children ages 0-17 (9.5%) 
compared to adults (7.7%) (Akinbami et al. 2012). Asthma rates also differ by racial 
group and socioeconomic status (measured by poverty-to-income ratio), with African 
Americans (11.2%) and people living below the poverty level (11.2%) experiencing 
disproportionately higher asthma burden than national average (Akinbami et al. 2012). 
Atopy, an allergic phenotype characterized by increased production of IgE in response to 
specific allergens, is associated with asthma pathogenesis and severity (Pearce et al. 
1999; Suh and Koh 2013). Most asthmatics have an atopic constitution and are vulnerable 
to inflammatory responses from multiple environmental stimuli (Nelson et al. 1999; 
Eggleston 2000; Lau et al. 2000). Co-exposures to allergens and environmental air 
pollutants (such as second hand smoke (SHS), particulate matter (PM), ozone (O3) and 
nitrogen dioxide (NO2)) may lead to increased frequency of asthma exacerbations in 
atopic asthmatics (D’Amato et al. 2002; Diaz-Sanchez et al. 2006). Living in an urban 
environment (such as inner city Baltimore) may also increase asthma morbidity. Residing 
in an urban environment has also been associated with increased exposures to substances 
associated with asthma exacerbation and severity, including SHS, indoor and outdoor 




and fungus (Wallace et al. 2003; Breysse et al. 2005; Simons et al. 2007; Matsui et al. 
2008; McCormack et al. 2009). 
Oxidative Stress 
Inflammation due to reactive oxygen species (ROS) has been associated with the 
development of asthma and asthma exacerbations (Cho and Moon 2010; Dozor et al. 
2010). ROS, which include superoxide radicals (O2-), hydroxyl radicals (OH-), hydrogen 
peroxides (H2O2), peroxynitrites (ONOO-), are formed through the addition of electrons 
to oxygen groups on organic molecules. ROS are formed both endogenously (through 
oxidative phosphorylation, metabolic activation of organic compounds, and production 
by macrophages and other inflammatory mediators), and through exposures to exogenous 
oxidants (such as inhalation of ozone, nitric oxide and cigarette smoke) (Nel et al. 2001; 
Bowler and Crapo 2002). ROS are associated with lipid peroxidation, cell apoptosis, 
damage to cellular structures, tissue damage, DNA and protein adducts, and increased 
inflammation (Li et al. 2004; Nel et al 2001; Wan and Diaz-Sanchez 2007). Oxidative 
stress is the result of an imbalance between ROS and antioxidants, under which 
antioxidant responses cannot adequately counteract an abundance of ROS (Nadeem et al. 
2003). The mechanism for oxidative stress by organic compounds has been well 
characterized. Polycyclic aromatic hydrocarbons (PAH) and other organic air pollutants 
can bind to cytosolic aryl hydrocarbon receptors (Ahr) in the lung and induce expression 
of phase I enzymes, especially cytochrome P450 1A1 (CYP1A1). CYP1A1 and CYP 
enzymes (such as CYP1B1 and CYP1A2) add oxidative groups to PAHs resulting in 
reactive intermediates in the form of quinones, semiquinones and epoxides. These 




ROS and subsequently oxidative stress (Nel et al. 2001; Li et al. 2003; Wan and Diaz-
Sanchez 2007). In this study, we measured urinary isoprostane (8-iso-PGF2α), a by-
product of non-enzymatic lipid peroxidation, as an internal dose biomarker of oxidative 
stress.  
PAHs and 1-OHPG 
PAHs are formed from the incomplete combustion or pyrolysis of organic 
materials (e.g. coal, wood, fuel and oil) and are commonly found on fine and ultrafine 
particulates, PM2.5 (aerodynamic diameter <2.5 µm) and PM0.1 (aerodynamic diameter 
<100 ng), respectively (Rosa et al. 2011). Sources of airborne PAH exposures include 
motor vehicle emissions (combustion products from diesel and conventional gasoline 
engines), burning fossil fuels (e.g. coal and oil), wood burning, tobacco smoking, cooking 
with gas stoves, heating appliances (e.g. kerosene space heaters), and incense burning 
(ATSDR 1995; Larsen et al. 2003). Diesel exhaust particulates (DEP) are present in fine 
(PM2.5) and ultrafine particulates (PM0.1), and have high concentrations of volatile and 
semi-volatile PAHs (e.g. naphthalene, fluorine, phenanthrene, and pyrene) on the surface 
of particulates. DEP are potent inducers of allergic and non-allergic inflammatory 
responses due to high oxidation potential of activated PAHs, formed through conversion 
by CYPs to reactive intermediates (quinones, epoxides, etc.) (Nel et al. 2001; Reidl et al. 
2008). PAHs are primarily know for their carcinogenicity, as PAHs and PAH mixtures 
have been categorized as human carcinogens (e.g. benzo[a]pyrene and coal tar pitch), 
probable carcinogens (e.g. dibenzo[a,l]pyrene and dibenz[a,h]anthracene) and possible 
carcinogens (e.g. benz[a]anthracene, benzo[b]fluoranthene and indeno[1,2,3-cd]pyrene) 




Substances and Disease Registry (ATSDR) (ATSDR 1995; IARC 2010). PAHs have also 
been associated with development of asthma (Miller et al. 2004; Jung et al. 2012), most 
likely through non-mutagenic (i.e. inflammatory) mechanisms.  
Urinary 1-hydroxypyrene-glucuronide (1-OHPG) is an accepted biological 
indicator of PAH exposure, as its parent compound, pyrene, is present in virtually all 
environmental PAH mixtures and is a reliable biomarker of low-level exposure (Buchet 
et al. 1992; Jongeneelen 2001). Urinary 1-OHPG concentrations reflect exposures 
through inhalation, ingestion, and dermal absorption (from contaminated air and soil) 
(Jongeneelen 2001). 1-hydroxypyrene (1-OHP) and 1-OHPG are commonly used urinary 
biomarkers, however 1-OHPG is more sensitive, as the glucuronide molecule confers 3-5 
times more fluorescence than 1-OHP (Singh et al. 1995; Strickland et al. 1996; Kang et 
al. 2005). 1-OHPG levels have been associated with increased levels of oxidative stress 
biomarkers (i.e. urinary MDA, isoprostane and 8-OHdG), decreased lung function, and 
having asthma (Kim et al. 2005; Leem et al. 2005; Bae et al. 2010; Hong et al. 2009; Lai 
et al. 2013). The molecular pathway for oxidative stress and allergic inflammation 
mediated asthma-related responses to PAH exposures (e.g. DEP) has been explored in in 
vitro, animal and human studies. The proposed mechanism for PAH-asthma exacerbation 
involves high concentrations of quinones, semiquinones and epoxides derived from 
biotransformed PAHs overriding protective pathways (i.e. antioxidants and phase II 
enzymes), leading to increased oxidative damage in cells and the surrounding tissues, and 
subsequent biomolecular, immunological and physiological responses (e.g. airway 
inflammation and airway hyperreactivity) associated with asthma exacerbations (Nel et 




neutrophils, and antigen presenting cells, and act as adjuvants for inflammatory responses 
with allergic sensitization (Nel et al. 1998; Delfino et al. 2002). In epidemiologic studies, 
adjuvant activities by PAHs have been shown to increase allergic inflammatory responses 
among atopic individuals exposed to PAH-rich DEP and allergens in randomized 
crossover nasal provocation studies (Diaz-Sanchez et al. 1997; Diaz-Sanchez et al. 1999). 
Urinary 1-OHP(G) has been associated with decreased lung function, and increased 
levels of oxidative stress biomarkers (i.e. urinary isoprostane and MDA) (Leem et al. 
2005; Bae et al. 2010; Hong et al. 2009); and PAHs have been associated with increases 
in pro-inflammatory (e.g. interleukin (IL)-6), and anti-inflammatory cytokines and 
chemokines (i.e. IL-4, IL-5, IL-10 and IL-13, monocyte chemotactic protein-1 (MCP-1), 
and macrophage inflammatory protein-1α (MIP-1α)) (Diaz-Sanchez et al. 1997; Leem et 
al. 2005), and inflammatory mediators in nasal lavage fluid (e.g. eosinophils, monocytes, 
and lymphocytes) (Diaz-Sanchez 1997b; Casillas et al. 1999). 
GSTM1 
Glutathione-S-transferases (GST) are a superfamily of phase II antioxidant enzymes that 
catalyze the conjugation of ROS and reactive oxidative and xenobiotic compounds to 
more stable compounds that can be excreted in urine (Hayes and Pulford 1995). GSTs are 
categorized into three major families, cytosolic GSTs, mitochondrial GSTs and 
microsomal GSTs (Hayes et al. 2005). Cytosolic GSTs are coded at five loci, alpha (A), 
mu (M), pi (P) and theta (T) and zeta (Z), of which GSTM1, GSTP1 and GSTT1 are 
commonly associated with chronic lung diseases (e.g. asthma and COPD) (Geisler and 
Olshan 2001; Tamer et al. 2004). Our study will focus on GSTM1 gene, as the cytosolic 




associated with susceptibility to lung inflammation and asthma (Brasch-Anderson et al. 
2004; Joubert et al. 2011; Wu et al. 2012a). The GSTM1 gene is located on chromosome 
1p13.3 and has two variants, the wild type-GSTM1*1 allele, which expresses GSTM1 
protein, and GSTM1*0 allele which fails to express the GSTM1 protein (Hayes et al. 
2005). GSTM1-null genotype is found in about 50% of the population, with differences in 
polymorphism frequencies by race (To-Figueras et al. 1997). GSTM1-null genotype 
frequencies were 23-46.5% in African Americans, and range from 13.1-54.5% in 
Caucasians, 35-53% people of Hispanic descent, and 40-53% in people of Asian descent 
(Cotton et al. 2000; Geisler and Olshan 2001; Carlsten et al. 2008; Mo et al. 2009). The 
GSTM1-null polymorphism has been associated increased susceptibility and aggravation 
of lung diseases, including an increased risk of developing asthma in children (Gilliland 
et al. 2002; Tamer et al. 2004; Li et al. 2013), increased risk of allergic sensitization 
(Perzanowski et al. 2013), lower lung function (Tamer et al. 2004), and increased airway 
inflammation from exposures to air pollutants (such as DEP, SHS and ozone) (Gilliland 
et al. 2004; Gilliland et al. 2006; Alexis et al. 2009). The GSTM1-null polymorphism, has 
also been associated with an increased risk of lung cancer (Quiñonez et al. 2001; 
Matakova et al. 2009). 
Previous studies examining associations between GSTM1 genotype and urinary 1-
OHP(G) have reported inconsistent results. Some studies have found associations 
between urinary 1-OHP(G) and GSTM1 genotype (Gabbani et al. 1996; Pan et al. 1998; 
Nan et al. 2001; Alexandrie et al. 2000; Lee et al. 2009; Islami et al. 2012), while others 
have reported no difference in 1-OHPG by GSTM1 genotype (Hemminki et al. 1997; 




al. 2003; Wu et al. 2004; Bosso et al. 2006; Moretti et al. 2007). The reported mechanism 
for increases in urinary 1-OHP(G) in GSTM1-null individuals involves an accumulation 
of reactive PAH derivatives (such as quinones, semiquinones and epoxides) due to lack 
of GSTM1 enzyme, thereby reducing antioxidant capacity, and a concomitant induction 
of CYP1A1 through PAH-Ahr activity (Alexandrie et al. 2000). The reactive PAH 
intermediates are readily conjugated by the phase II enzyme, uridine 
diphosphoglucuronosyltransferase (UGT) resulting in increased urinary 1-OHPG output. 
The glutathione GSH conjugation pathway (which is catalyzed by GST) competes with 
the glucuronide pathway for phase II detoxification of activated PAH intermediates. 
Therefore, a lack of GSTM1 enzyme activity (in individuals with GSTM1-null genotype) 
may be compensated through the induction of other phase II enzymes (including UGT, 
GSTP1 and GSTT1) (Rihs et al. 2005). Inter-individual differences in PAH metabolism 
may therefore be partially explained by polymorphisms in genes encoding for phase II 
enzymes, such as GSTM1. 
We evaluated associations between internal dose PAHs (measured by urinary 1-
OHPG) and biomarkers of oxidative stress (urinary isoprostane), gene expression of 
antioxidants, and peripheral blood, serum and nasal lavage biomarkers of inflammation in 
an observational study of atopic asthmatic adults in Baltimore City. We also evaluated 
whether GSTM1 genotype was an effect modifier of the associations between internal 
dose PAHs and oxidative stress and inflammatory biomarkers. We hypothesized that 
PAH internal dose would be associated with increased oxidative stress, increased 
induction of antioxidant genes (HO-1, NQO1, GCLC and GCLM), increased serum 




and increased local and systemic inflammation (whole blood and nasal lavage eosinophils 
and neutrophils, and nasal lavage cytokines and chemokines). We also hypothesized that 
GSTM1 genotype will be a significant effect modifier, with GSTM1-null participants 
having stronger positive associations between 1-OHPG and oxidative stress and 
inflammatory biomarkers compared to GSTM1-present participants, due to less 
antioxidant capacity in individuals who are unable to produce the GSTM1 protein. 
 
 
MATERIALS AND METHODS 
Study design 
Our study was conducted within an ongoing PM nasal exposure study: The Nasal 
Challenge to Indoor Particulate Matter study. The parent study enrolled 32 non-smoking 
atopic asthmatic adults ages 18-50 to measure inflammatory biomarkers and gene 
expression in adults challenged intranasally with particulate dust suspended in saline 
(Ong et al. 2011; Dr. Elizabeth Matsui, personal communication). The parent study 
design is a single blind, placebo-controlled crossover with individuals randomized to 
nasal challenges of PM in saline followed by saline, or saline followed by PM. There was 
a minimum one-week washout period before returning for the second instillation.  
In our study, we used samples from the two baseline time points only. Our study 
design was therefore an observational study with two visits per participants. The time 
between visits ranged from 7-114 days, with a mean of 30 days. Urine, blood, exhaled 
nitric oxide (eNO), nasal lavage fluid, nasal epithelial cells, and measures of lung 




biomarkers were available from the parent study: urinary isoprostane (8-iso-PGF2α); gene 
expression (mRNA) from nasal epithelial cells: HO-1, NQO1, GCLC, GCLM, TFF2, and 
IL-33; whole blood inflammatory markers with and without phorbol 12-myristate 13-
acetate (PMA) activation: PBMC, monocytes, PMN, eosinophils, neutrophils and 
lymphocytes; cytokines and chemokines in serum: IL-6, IL-8, IL-10, IL-13, eotaxin, 
MIP-1α, growth-regulated oncogene (GRO), RANTES, chemokine (C-C motif) ligand 
20 (CCL20), GRO-α, and ECP); and in nasal lavage fluid: IL-6, IL-8, IL-10, IL-13, 
eotaxin, MIP-1α, GRO, RANTES, CCL20 and GRO-α. Atopy was defined as having 
allergic responses to at least one of 14 common aeroallergens (dust mite mix, rat and 
mouse epithelia, dog hair/dander, cat dander, American and German cockroach, three 
pollens (Eastern Oak mix, grass mix, ragweed mix) and four molds (Helminthosporium, 
Alternariam, Penicillium and Aspergillus)) from skin prick tests. 
Urinary 1-OHPG  
Spot urine samples were analyzed for urinary 1-OHPG concentrations using 
immunoaffinity chromatography (IAC) and synchronous fluorescence spectroscopy 
(SFS), as previously described (Strickland et al. 1994). Urine samples (2ml) were treated 
with 0.1N HCl (90°C, 60 min), neutralized, and loaded onto Sep-pak C18 cartridges 
(Waters). After washing with 30% methanol, the relatively non-polar metabolites were 
eluted with 4 ml of 80% methanol and the volume of eluate is reduced to 0.5ml by 
evaporation on a Speedvac. The concentrated samples were diluted to 4ml with 15mM 
phosphate buffered saline (PBS) and loaded onto immunoaffinity columns prepared with 
0.8ml cyanogen bromide activated sepharose 4B (Sigma) coupled with monoclonal 




1986). We have previously shown that 1-OHPG binds to these columns (Strickland et al. 
1994). After washing the columns three times with 4 ml 15 mM PBS, bound compounds 
were eluted with 2 ml of 40% methanol in three fractions. Eluate fractions were analyzed 
by SFS with a Perkin-Elmer LS50 fluorescence spectrometer. The excitation-emission 
monochromators are driven synchronously with a wavelength difference of 34 nm. Under 
these conditions 1-OHPG produces a characteristic fluorescence excitation maximum at 
347 nm with emission maximum at 381 nm (Strickland et al. 1994). Fluorescence 
intensity was used to quantify 1-OHPG; in our laboratory the limit of detection was about 
0.03 pmol/ml. This level of sensitivity is sufficient to detect urinary 1-OHPG in >90% of 
subjects with low-level exposure to PAHs (such as in the U.S.), and in 100% of subjects 
with high exposure. The coefficient of variation of the assay is typically 6-10% 
(interbatch) in our laboratory.  
Urinary Creatinine  
Creatinine concentrations were determined using a modified version of the Jaffe 
reaction using the Creatinine Assay Kit (Cayman Chemical Company; Ann Arbor, MI). 
Briefly, 150 µl of alkaline picrate solution was added to wells containing 15 µl creatinine 
standard or urine samples in duplicate, and the solution was mixed for 10 minutes. The 
absorbance of the solution (due to the reaction between the alkaline picrate and urinary 
creatinine metabolites) was read at 450-500 nm using a Biotek ELx800 Absorbance 
Microplate Reader. 5 µl of acid solution was then added to the assay and the absorbance 
was read again at 450-500 nm, 20 minutes after mixing. The difference in color intensity 




creatinine levels were determined using a creatinine standard curve, which was estimated 
in each batch from analysis of the standard creatinine. 
Urinary isoprostane 
Isoprostane (8-iso-Prostaglandin F2α) was measured in urine using the 
OxiSelectTM 8-iso-Prostaglandin F2α ELISA Kit (Cell Biolabs Inc., San Diego, 
California, USA). Briefly, 100μl of diluted Anti-8-iso-PGF2α was added to the antibody 
coated plate and incubated for 1 h at 25°C on an orbital shaker. The wells were then 
washed five times with 300 μl 1X Wash buffer per well to remove the antibody solution. 
55 μl of sample and 55 μl of 8-iso-PGF2α-HRP conjugate were mixed in microtubes and 
approximately 100 μl of the mixture was transferred to the wells. After an hour at 25°C, 
the wells were washed five times with 300 μl 1X Wash buffer per well. 100 μl of 
Substrate Solution was added to each well and incubated at room temperature for 10-30 
minutes on an orbital shaker. The enzyme reaction was stopped by adding 100 μl of Stop 
Solution to each well. Absorbance was read at 450nm (primary wave length) using a 
microplate reader. 
Complete blood counts 
Peripheral blood total cell counts and differential counts were done using an 
automated counter. 
Chemokines and cytokines in serum and nasal lavage fluid 
Cytokine and chemokine (IL-6, IL-8, IL-10, IL-13, eotaxin, MIP-1α, GRO, 
RANTES, CCL20, GRO-α, and ECP) concentrations in the sample supernatants were 
determined by enzyme-linked immunosorbent assay (ELISA) using MilliplexTM 




in a 96 well multiscreen filter plate, 25 µL sample in duplicate was incubated with 25µL 
antibody coated beads overnight at 4°C on a plate shaker.  Plates were then washed two 
times on a vacuum apparatus and 25 µL of secondary antibody was added and incubated 
at room temperature for 1 hour on while shaking.  Finally, 25 µL of streptavidin-RPE was 
added directly to the secondary antibody and incubated for 30 minutes at room 
temperature with shaking.  Plates were then washed two more times and 100 µL of sheath 
fluid was added.  Plates were shaken for 5 minutes and then read using luminex 
technology on the Bio-PlexTM (Bio-Rad, Hercules, CA). Concentrations were calculated 
from standard curves using recombinant proteins and expressed as pg or ng/ml.   
Serum and nasal lavage GRO and GRO-α 
Plates were coated with capture antibodies (Ab) overnight at 4°C. Plates were 
then washed three times with 175 µl wash, and blocked with 1% BSA/PBS for 1 h at 
room temperature.  Samples and standards were loaded and incubated for 2 hours at room 
temperature. Plates were then washed again. Secondary Ab was added and incubated at 
room temperature for 1 h. Plates were washed again.  Streptavidin-HRP was added and 
incubated for 30 minutes, in the dark at room temperature. Plates were then washed again 
and developed with a 1:1 mixture of Color A and Color B. Plates were read at 450nm 
with a 595nm background subtraction. 
Serum and nasal lavage ECP 
Samples were loaded onto pre-coated plates and incubated at room temperature 
for 1 h. Plates were washed four times with 300 µl wash. Conjugate reagent was added 




was added and incubated at room temperature for 10 minutes and then stopped with 
H2SO4. Plates were then read at 450nm with a 595nm background subtraction. 
Nasal epithelial RNA 
Nasal epithelial cells were collected by using a Rhinoprobe curette and 
immediately lysed in 100 mL lysis solution provided with the RNAqueous-micro kit 
(Ambion, Austin, Tex). Lysed nasal samples were stored at -80°C before RNA isolation. 
Briefly, 50 µL 100% ethanol was added to 100 µL lysate and vortexed thoroughly. 
Lysate/ethanol mixture was loaded onto a microfilter cartilage assembly (column) and 
centrifuged for 30 seconds at 13,000g. The filter column was washed once with 180 µL 
wash and twice with 180 µL wash II. Finally, the filter column was spun at 13,000g 
without adding any wash buffer. RNA was eluted in 20 µL (10 µL x 2) elution buffer and 
quantified by using a NanoDrop 2000c spectrophotometer (Thermo Scientific, Rockford, 
Ill). 
cDNA synthesis and real-time PCR 
Total RNA was extracted from cells by using the RNeasy kit (QIAGEN). RNA 
samples were reverse-transcribed by using a high-capacity cDNA reverse-transcription 
kit following the manufacturer’s instructions. A 50-ng cDNA template was used for each 
real-time reaction with ABI 7000. Primer and probes used for this study are inventoried 
by Applied Biosystems, span the exon junction, and do not detect genomic DNA. The 
sequences for these primers and probes are proprietary of Applied Biosystems. An 
aliquot of diluted cDNA was used to measure human NQO1 (Hs00168547_m1), HMOX1 
(Hs1110250_m1), GCLM (Hs00157694_m1), GCLC (Hs00155249_m1), TFF2 




and probe mixes from Applied Biosystems. β-Actin (Hs99999903_m1) was used for 
normalization. The sequences for these primers and probes are proprietary to Applied 
Biosystems. The assays were performed using the ABI 7000 TaqMan system (Applied 
Biosystems). 
Statistical analysis 
Summary statistics were reported for urinary 1-OHPG concentrations. 1-OHPG 
concentrations and all continuous biomarker values (except MIP-1α) were log-
transformed to adjust for skewed distributions. Multivariate linear regressions with 
generalized estimating equations (GEE) were used to assess associations between the 
primary predictor (e.g. urinary 1-OHPG) and outcome (dependent) variables (i.e. urinary 
isoprostane; and nasal lavage, serum, and whole blood mediators, chemokines and 
cytokines) while adjusting for repeated measurements (i.e. visit) and possible 
confounders. Explanatory variables were considered possible confounders if the ß-
coefficient changed by more than 10% after inclusion of the exposure variable (e.g. 1-
OHPG) in the model or if the variable was significantly associated with the exposure or 
outcome. Our final models for multivariate linear regression with GEE were adjusted for 
age, race, gender, season, caregiver educational attainment and GSTM1 genotype). 
Urinary 1-OHPG was adjusted for urinary creatinine by including creatinine 
concentrations in the model as an independent variable (Barr et al. 2005). Age, 1-OHPG, 
urinary isoprostane, serum biomarkers, whole blood biomarkers, mRNA, and nasal 
lavage eosinophil, neutrophil, white blood cell count, IL-8 and GRO were measured as 
continuous variables; race, gender, and nasal lavage IL-6, IL-13, ECP, CCL20, eotaxin 




education was measured as an ordinal variables. Two-tailed p-value<0.05 was used to 
determine statistical significance. Effect modification was assessed using pairwise 
interaction terms for independent variables (e.g. the product of 1-OHPG concentrations 
and GSTM1 genotype) and interaction terms were considered statistically significant at p-
value<0.1. We used only the two baseline values for each study subject in our analyses. 
1-OHPG concentrations were reported as µmol/mol creatinine. Missing values were not 
included in analyses. All data were analyzed using STATA 11.1 (College Station, TX). 
Sensitivity analyses 
Multivariate linear regression (MLR) was performed without GEE analysis to test 
whether adjusting for repeated measurements resulted in over-correction (Supplemental 
Tables 4-2 to 4-4). There were fewer significant associations using MLR without GEE, 
suggesting that accounting for intra-individual variation was important for these analyses. 
We therefore reported MLR with GEE as our primary analysis. In addition, we included 
number of days between visit in the MLR with GEE model as an independent variable 
(Supplemental Table 4-6). Multivariate linear regression with GEE analyses with the 
number of days between visits included in the model as an independent variable yielded 
similar results to crude analyses (excluding the number of days between visits variable), 
suggesting that the washout period (minimum 7 days) was sufficient and intra-individual 
differences based on time between visits were not influential in associations between 









Most of the participants in the Nasal Challenge to Indoor Pollutants study were 
women (75%), African American (84%), between 18 and 50 years of age (mean: 30 years 
of age), had at least a high school diploma (66%) and resided in households with annual 
incomes of less than $25,000 (70%) (Table 4-1). All participants were atopic asthmatics, 
and most experienced asthma symptoms (66%) and used rescue medication (72%) during 
the two weeks prior the baseline visit. Over two thirds of the participants (69%) were able 
to express the GSTM1 protein (GSTM1-present genotype), and about a third (31%) were 
unable to express the GSTM1 protein (GSTM1-null genotype). 
Predictors of 1-OHPG 
1-OHPG concentrations were analyzed in 60 spot urine samples, and urinary 
creatinine (Cr) was measured to adjust for differences in urine dilutions (Table 4-2, 
Figure 4-1). Urinary 1-OHPG had an arithmetic mean (standard deviation (SD)) of 2.54 
(4.51) pmol/ml, geometric mean (GM) of 0.78 pmol/ml, median (interquartile range 
(IQR)) of 0.87 (0.20-2.71) pmol/ml, 95th percentile of 11.3 pmol/ml, and range of 0.05-
22.76 pmol/ml. Six samples (10%) were below the limit of detection (LOD) of 0.05 
pmol/ml. Urinary 1-OHPG concentration (pmol/ml) was divided by urinary creatinine 
(µmol/ml) to adjust for urine dilution differences, and were reported as µmoles 1-OHPG 
per mole creatinine (µmol/mol creatinine). Urinary 1-OHPG was positively associated 
with urinary creatinine (ß=0.478, p=0.001; 95% CI [0.198-0.757]), age (ß=0.051, 
p=0.024; 95% CI [0.007-0.095]), but not associated with gender, race, education or 




regression analysis, urinary 1-OHPG was associated with age (ß=0.031, p=0.036; 95% CI 
[0.002-0.060]), and having a HS diploma (compared to some HS education) (ß=1.082, 
p=0.003; 95% CI [0.361-1.803]) (Table 4-3). Seasonally, 1-OHPG was lowest in spring 
(which was used as the reference), and significantly higher in the summer (ß=1.398, 
p=0.017; 95% CI [0.252-2.545]) and the winter (ß=1.832, p<0.001; 95% CI [0.992-
2.671]), compared to spring. GSTM1 genotype also predicted urinary 1-OHPG. 
Participants with the GSTM1-present genotype (able to produce the GSTM1 enzyme) had 
significantly higher 1-OHPG concentrations (ß=0.795, p=0.031; 95% CI [0.071-1.519]) 
than participants with GSTM1-null genotype (cannot produce the GSTM1 enzyme), using 
multivariate analysis (Table 4-3, Figure 4-1). 
1-OHPG and inflammatory effects 
Overall, urinary 1-OHPG was associated with significant decreased serum IL-10 
(ß=-0.052, p=0.027; 95% CI [-0.098-(-0.008)]), and CCL-20 (ß=-0.128, p=0.010; 95% CI 
[-0.225-(-0.031)]), decreased PBMC (ß=-0.128, p=0.010; 95% CI [-0.225-(-0.031)]) and 
decreased IL-33 mRNA from nasal epithelium (ß=-0.101, p=0.024; 95% CI [-0.142-(-
0.010)]) in atopic asthmatic adults (Table 4-4). Urinary 1-OHPG was also associated with 
significant increases in nasal lavage eosinophil percent (ß=0.013, p=0.008; 95% CI 
[0.003-0.023]). However, urinary 1-OHPG was not associated with oxidative stress 
(urinary isoprostane), induction of antioxidant and cytokine mRNA (NQO1, HO-1, 
GCLM, GCLC, TFF2, and IL-33) in nasal epithelium cells, serum inflammatory 
cytokines (IL-6, IL-8 and IL-13), serum inflammatory chemokines (eotaxin, GRO, GRO-
α, MIP-1α, and RANTES), serum ECP, and nasal lavage cytokines and chemokines 





Urinary 1-OHPG was independently associated with increased oxidative stress, as 
measured by urinary isoprostane in GSTM1-null participants (ß=0.237, p=0.015; 95% CI 
[0.046-0.428]) using multivariate linear regression analysis with GEE and adjusting for 
possible confounders (Table 4-5 and Supplemental Table 4-5 (full table)). Urinary 1-
OHPG was also associated with significant increases in serum biomarkers of 
inflammation, including ECP, GRO, GRO-α, IL-8 and RANTES, in GSTM1-null 
participants. Local inflammation, as measured by total white blood cells in nasal lavage 
fluid, was significantly associated with elevated urinary 1-OHPG in GSTM1-null 
participants. 1-OHPG was also significantly associated with both increased peripheral 
blood inflammatory biomarkers: lymphocytes, and monocytes (both activated with 
PMA), and decreased peripheral blood polymorphonuclear leukocytes (PMN) in GSTM1-
null participants (Table 4-5 and Supplemental Table 4-5). 
GSTM1-present genotype 
Among GSTM1-present participants, urinary 1-OHPG was associated with an up-
regulation of nasal epithelium NQO1 and GCLC mRNA (Table 4-5 and Supplemental 
Table 4-5).1-OHPG was associated with local inflammation, specifically significantly 
increased nasal lavage eosinophil percent in GSTM1-present participants. Urine 1-OHPG 
was also associated with significant decreases in peripheral blood mononuclear cells 
(PBMC), PMA activated polymorphonuclear leukocytes (PMN) and monocytes, and 
significant decreases in serum IL-6 and CCL20 in GSTM1-present individuals (Table 4-5 





GSTM1 effect modification 
Overall, biomarkers of oxidative stress, inflammation and antioxidant responses 
did not differ by GSTM1 genotype, except with nasal lavage ECP, which was 
significantly higher in GSTM1-null individuals compared to GSTM1-present individuals 
(p=0.060) (Supplemental Table 4-1). GSTM1 genotype modified the associations 
between 1-OHPG and urinary isoprostane, with stronger associations in GSTM1-null 
subjects compared to GSTM1-present subjects (p-interaction=0.002) (Table 4-5; Figures 
4-2 and 4-3). Associations between 1-OHPG and the up-regulation of GCLC mRNA 
were also significantly stronger in participants with GSTM1-null genotype than with 
GSTM1-present genotype (p-interaction=0.024). GSTM1 genotype also modified 
associations between urinary 1-OHPG and IL-33 mRNA in nasal epithelial cells, with 
associations in opposite directions (p-interaction<0.001). Urinary 1-OHPG was inversely 
associated with IL-33 mRNA in GSTM1-null participants, whereas 1-OHPG was 
positively associated with IL-33 mRNA induction in GSTM1-present participants. 
GSTM1 genotype also modified associations between urinary 1-OHPG and serum 
chemokines. GSTM1-null participants had significantly stronger positive associations 
between 1-OHPG and serum GRO and GRO-α than GSTM1-present participants (p-
interaction=0.075 and 0.004, respectfully). GSTM1 genotype also modified associations 
between urinary 1-OHPG and peripheral blood biomarkers. GSTM1-null participants had 
significantly stronger positive associations between 1-OHPG and peripheral blood 
lymphocytes than GSTM1-present participants (p-interaction<0.001). GSTM1 genotype 
also modified the associations between 1-OHPG and PBMC (p-interaction=0.002) and 




interaction=0.002). These 1-OHPG-peripheral blood biomarker associations were in 
opposite directions depending on the GSTM1 genotype. 1-OHPG was positively 
associated with PBMC, monocytes and PMN in GSTM1-null participants, whereas 1-






Participants in our study (non-smoking atopic adults with active asthma) had 
twice the geometric mean, and about 2-4-fold higher median urinary 1-OHPG 
concentrations than the US average for adults (Table 4-6). The GM of 1-OHPG 
concentration in our study (0.07 µmol/mol Cr) was also similar to a cross-sectional study 
of the South Korean population in 2008 (0.07 µmol/mol Cr) (Sul et al. 2012), but over 
two-fold higher than non-smoking Swedish adults (median: 0.03 µmol/mol Cr) (Levin et 
al. 1995), and South Korean university students (GM: 0.03 µmol/mol Cr) (Kim H et al. 
2001). The high levels of PAH internal dose in our study may be attributed to elevated 
PAH exposures from living in an urban environment, including exposures to indoor 
sources (e.g. SHS and heating) and ambient sources (e.g. vehicular exhaust, industrial 
activity, and by-products from the burning of fossil fuels). 
GSTM1 and 1-OHPG 
In our study, urinary 1-OHPG was significantly higher in GSTM1-present 




associations, with higher urinary 1-OHP(G) concentrations in GSTM1-present individuals 
(Gabbani et al. 1996; Schoket et al. 2001; Lee et al. 2002; Petchpoung et al. 2011), while 
other studies have reported higher urinary 1-OHP(G) concentrations in GSTM1-null 
individuals (Pan et al. 1998; Nan et al. 2001; Alexandrie et al. 2000; Lee et al. 2003; 
Chuang et al. 2007; Lee et al. 2009; Islami et al. 2012) or no associations between 1-
OHP(G) and GSTM1 genotype (Hemminki et al. 1997; Merlo et al. 1998; Nerukhar et al. 
2000; Adonis et al. 2003; Apostoli et al. 2003; Yang et al. 2003; Wu et al. 2004; Bosso et 
al. 2006; Moretti et al. 2007). The GSTM1-present genotype was associated with higher 
1-OHPG in multivariate regression analysis only, suggesting an independent relationship 
between 1-OHPG and GSTM1-present genotype–that is observable only after adjustment 
for possible confounding variables. Similarly, Lee et al. (2002) reported significantly 
higher 1-OHPG levels in multivariate analyses of GSTM1-present participants who were 
smokers, suggesting that gene-environment interactions may modulate PAH internal dose 
analysis.  
Urinary 1-OHPG concentrations also may be influenced by phase I enzymes 
(CYP1A1, CYP1A2, CYP1B1), which hydrolyze PAHs to epoxides, quinones and semi-
quinones, prior to detoxification by glutathione (GSH), glucuronide and sulfate 
conjugation (Alexandrie et al. 2000). Cytochrome P450 (CYP) enzyme activity, which 
can be modified due to polymorphisms may also be associated with phase II enzyme (e.g. 
GSTM1 and UDP glucuronosyl transferase (UGT)) activity. CYP1A1 polymorphisms, 
such as CYP1A1 MspI T6235C (TC (*1/*2) and CC (*2/*2)) variant alleles, or CYP1A1 
exon 7 Ile462Val (Ile/Val (*1/*3) and Val/Val (*3/*3)) variant alleles, confer increased 




activity may lead to increases in activated oxidative PAH intermediates which are 
subsequently conjugated through glucuronidation and excreted in urine (as 1-OHPG). 
(Nerurkar et al. 2000; Petchpoung et al. 2011). A study of Thai bus drivers reported 
higher 1-OHPG in workers with CYP1A1*2 and CYP1A1*3 variant alleles and higher 1-
OHP in workers with GSTM1-present genotype compared to GSTM1-null genotype, in 
workers exposed to DEP (Petchpoung et al. 2011). In a Swedish aluminum plant, workers 
with CYP1A1 Ile/Val and GSTM1-null variant alleles had significantly higher 1-OHP 
concentrations than workers with other CYP1A1/GSTM1 allele combinations, suggesting 
gene-environment interaction in workers with dual polymorphisms (Alexandrie et al. 
2000). Adonis et al. (2003) also reported similar increases in urinary 1-OHP in Chilean 
diesel revision plant workers with CYP1A1*2/ GSTM1-null variant alleles compared to 
those with CYP1A1/GSTM1 wild type alleles. The mechanism for increased 1-OHPG in 
GSTM1-present individuals is unknown. Based on the reported metabolic pathways for 
PAHs, phase II conjugation by UGT and GSTs are not in the same pathway, and 
glucuronide conjugation does not directly involve GSTs (ATSDR 1995; Rihs et al. 2005; 
IARC 2010). Based on this metabolic pathway, the role of GSTM1 in directly 
conjugating PAH metabolites to urinary glucuronide metabolites may therefore be 
limited, and the absence of the GSTM1 enzyme (as with GSTM1-null individuals) would 
therefore be expected to make little difference in 1-OHPG excretion. UGT and GST may, 
however, compete with each other for conjugating reactive PAH intermediates. In 
addition, gene interactions between GST and UGT may modulate phase II PAH 
metabolism (such as induction of UGT by GST to adapt to elevated levels of PAH 




interactions (e.g. increased glucuronidation) may be reflected in urinary internal dose 
glucuronide biomarkers. Further studies investigating interactions between phase I 
(CYP1A1, CYP1B1, CYP1A2), phase II (GSTM1, GSTP1, GSTT1, UGT, NQO1), and 
other xenobiotic metabolism enzyme genes, and gene-environment interactions are 
therefore necessary to examine the influences of genetic polymorphisms on 
susceptibility, biological effects, and the body burden of PAHs and other xenobiotics.  
1-OHPG and inflammatory markers 
In our study of atopic asthmatic adults, urinary 1-OHPG was independently 
associated with increased nasal lavage eosinophil percent. Local eosinophilic 
inflammation is a hallmark of allergic inflammatory responses. Similar eosinophilic 
inflammatory responses to PAH exposures have been reported in epidemiological studies, 
including increased ECP, RANTES, monocyte chemoattactant protein-3 (MCP-3), and 
MIP-1α in nasal lavage fluids after nasal instillation with DEP, in mostly atopic adults 
(Diaz-Sanchez 1998; Diaz-Sanchez 2000). Increased allergic inflammation in participants 
with high PAH exposures may also suggest synergism between inhaled PAHs and 
aeroallergens. Animal and human studies have shown adjuvant effects by PAHs on 
allergic inflammation when co-exposed to aeroallergens (such as OVA, ragweed, and 
keyhole limpet hemocyanin (KLH)), including increases in allergen specific 
immunoglobulin E (IgE), IL-8 levels and a skewing toward Th2-type responses (Takano 
et al. 1995; Miyabara et al. 1998; Diaz-Sanchez et al. 1999;). IgE, IL-8, and Th2-related 
cytokines and chemokines promote eosinophil production, development and survival, and 




In our study, 1-OHPG was also independently associated with increased whole 
blood eosinophils and neutrophils activated by PMA, suggesting that PAHs are 
associated with systemic eosinophilic and neutrophilic inflammation. Serum cytokines 
(IL-10 and IL-33) and chemokines (CCL20), however, were inversely associated with 
urinary 1-OHPG, suggesting that PAHs may also suppress some systemic Th2-type 
inflammatory responses. Specifically, PAH exposures may be related to decreased Th2 
lymphocyte proliferation and differentiation (IL-10) (Pandya et al. 2002; Matsumoto et 
al. 2004), decreased Th2 maintenance and Th2-type cytokine production (IL-33) 
(Finkelman et al. 2010; Smith 2010), and decreased dendritic cell development (CCL20) 
(Reibman et al. 2002). Indeed, PAHs have shown immunosuppressive properties. In vitro 
and animal studies have reported associations between PAHs and decreased B-cell and T-
cell production and function, and decreased PBMCs (ATSDR 1995; IARC 2010; 
Zaccaria and McClure 2013). PAHs may therefore be associated with local eosinophilic 
inflammation, however, associations with systemic inflammatory pathways may be more 
complicated, with concurrent associations between PAHs and immunotoxicity, and Th1 
or Th2-related inflammatory responses. Systemic inflammation may therefore reflect 
heterogeneous inflammatory immune responses to exposures to various exogenous 
substances, including air pollutants (such as PAH, PM, DEP, ozone, NO2), allergens, and 
biological pathogens (such as viruses, endotoxin and fungi). In observational studies such 
as our study, inflammatory immune responses to myriad exogenous exposures may not 
produce clear patterns of systemic inflammation associated with Th1 or Th2-specific 
cytokine profiles or adaptive immune (eosinophil mediated) or innate immune (neutrophil 




pathways, and to interactions with many xenobiotics (e.g. PAHs and aeroallergens) will 
likely be reflected in varying degrees of associations between internal dose biomarkers 
and pluripotent cytokines, chemokines and inflammatory mediators measured in serum 
and whole blood. 
GSTM1 genotype 
In our study, PAH internal dose was associated with increased allergic 
inflammation among GSTM1-null participants. Urinary 1-OHPG was independently 
associated with increased systemic oxidative stress in GSTM1-null individuals only. 
These positive associations between elevated PAH exposures and increased oxidative 
stress in GSTM1-null individuals, and effect modification by GSTM1 genotype (with a 
more pronounced PAH-systemic oxidative stress association in GSTM1-null individuals) 
support the concept of inflammation involving increased oxidative stress in persons with 
less antioxidant capacity. PAH toxicity through oxidative stress and inflammation-
mediated pathways have been well characterized (Casillas et al. 1999; Fahy et al. 1999; 
Diaz-Sanchez et al. 2000; Nel et al. 2001; Pandya et al. 2002; Li et al. 2009; Cho and 
Moon 2010; Dozor et al. 2010).  
Elevated PAH internal dose was associated with significant increases in systemic 
eosinophil-mediated inflammation (i.e. increases in serum RANTES, ECP, GRO, GRO-α 
and IL-8), increased peripheral blood monocytes and lymphocytes, and increased local 
inflammation (nasal lavage white blood cell count (WBCC)) in GSTM1-null participants 
this study. Studies of nasal provocations with combinations of PAH rich pollutants (i.e. 
DEP and SHS) and allergens showed similar modifications by GSTM1 genotype, with 




histamine (related to Th2-type responses) among GSTM1-null subjects (Gilliland et al. 
2004). Similarly, individuals exposed to SHS and challenged with ragweed showed 
significantly higher IgE in GSTM1-null compared to GSTM1-present individuals 
(Gilliland et al. 2006). The chemokine, RANTES is integral to eosinophilic inflammation 
and is associated with Th2-related cytokine proliferation, and histamine release from 
basophils. It can activate eosinophils to release ECP, a granular protein that causes 
epithelial shedding (Turner and Foreman 1999; Diaz-Sanchez et al. 2000). IL-8 and 
GRO-α are pro-inflammatory CXC chemokines that are associated with neutrophil 
chemotaxis and degranulation, and leukocyte activation and migration (Fahy et al. 1999; 
Salvi et al. 2000). In vitro studies have also shown PAHs to be potent inducers of pro-
inflammatory IL-8 mRNA and protein production (Fahy et al. 1999; Bommel et al. 2000), 
and have shown that GSTM1 genotype modulates DEP induced IL-8 expression, such 
that cells that were GSTM1 deficient (null) showed increased IL-8 expression compared 
to cells with GSTM1 protein production (Wu et al. 2012b). Therefore, our study, an 
observational study with atopic asthmatic adults, supports the PAH exposure-allergic 
inflammatory response mechanism and suggests increased susceptibility for individuals 
who lack GSTM1 enzyme activity.  
GSTM1-present  
PAH internal dose was independently associated with antioxidant mRNA 
induction (NQO1 and GCLC) in nasal epithelium cells among GSTM1-present 
individuals. Glutamate cysteine ligase (GCL), an antioxidant enzyme, is the rate-limiting 
enzyme in GSH synthesis (Dickenson et al. 2004). Induction of GCLC as part of the 




the conjugation of reactive oxidative PAH intermediates by GSH to a stable, more 
excretable PAH metabolite. The absence of GSTM1 enzymes may therefore directly 
influence GSH levels, by suppressing GCLC expression. Our study, however found 
associations between 1-OHPG and induction of GCLC mRNA in both GSTM1-null 
individuals (although not significant) and significantly in GSTM1-present individuals. 
Our findings therefore suggest an up-regulation of GCLC in response to increased 
oxidative stress associated with PAH exposures, with possible modulations by gene 
interactions between GSTM1 and GCLC conferring further up-regulation. We also 
hypothesized that PAH internal dose would be associated with induction of nuclear factor 
(erythroid-derived 2)–like 2 (Nrf2) related antioxidant enzymes (such as HO-1 and NQO-
1) in GSTM1-null individuals, because lack of a GSTM1 enzyme may lead to increased 
ROS and trigger induction of other antioxidants. However, in our study, elevated PAH 
internal dose was independently associated induction of nasal epithelium NQO1 mRNA 
in GSTM1-present participants, suggesting that exposures to PAHs resulting in increased 
local oxidative stress and reactive oxidant intermediates (e.g. quinones and epoxides) 
may be sufficient to elicit increased antioxidant and phase II metabolism responses. 
Indeed, the responses to increased ROS, involves induction of Nrf2 mediated antioxidant 
genes (e.g. NQO1 and SOD1), phase II (GST) genes, and the transcription factor, 
antioxidant response element (ARE). Under this mechanism, antioxidant responses to 
exogenous electrophilic compounds are regulated by the Keap1/Nrf2 pathway, under 
which Nrf2 translocates to the nucleus, binds to the ARE, and facilitates the transcription 
of antioxidant enzymes (e.g. NQO1, HO-1 and SOD-1) as well as phase II enzymes 




induction of the antioxidant NQO1 in nasal epithelial cells of GSTM1-present individuals 
may therefore suggest a sufficient response, locally, to oxidative stress. 
PAH internal dose was also independently associated with decreased systemic 
eosinophilic inflammation (decreased whole blood monocytes and PMN with PMA 
activation, and serum CCL20 and IL-6) in GSTM1-present individuals. These inverse 
associations may reflect sufficient antioxidant responses, including increased induction of 
Nrf2 related antioxidants, and increased phase II conjugation, in GSTM1-present subjects 
with elevated PAH exposures. Antioxidant and anti-inflammatory responses in GSTM1-
present participants are supported by associations between PAH internal dose and these 
protective responses that are in opposite directions depending on GSTM1 genotype. 
Overall, our study shows inverse associations between PAHs and inflammatory 
biomarkers in GSTM1-present individuals, and significantly higher inflammation in 
individuals who cannot produce the GSTM1 enzyme (GSTM1-null participants) 
compared to GSTM1-present participants. Our findings are therefore consistent with 
increased ROS in GSTM1-null individuals compared to GSTM1-present individuals, 
specifically that the inability to produce the GSTM1 enzyme may reduce antioxidant 
capacity. Mechanisms for reduced antioxidant capacity in GSTM1-null individuals are 
also supported by positive PAH internal dose-anti-inflammation associations in GSTM1-
present individuals, reflecting sufficient anti-inflammatory responses in GSTM1-present 
individuals. GSTM1-null asthmatics may therefore be more susceptible to the deleterious 
effects of oxidative stress, inflammation and asthma exacerbation due to reduced 
antioxidant capacity. Recent studies using exogenous antioxidant supplementation 




administration of sulforaphane, a potent antioxidant found in broccoli sprouts (Reidl et al. 
2009), have shown promise in abrogating the oxidative stress-inflammation pathways by 
increasing antioxidant and phase II enzymes through the Keap1/Nrf2 pathway. Further 
studies focusing on countering oxidative stress may therefore be important to reducing 
inflammation related to asthma pathogenesis and exacerbation. 
Strengths  
To our knowledge, this is the only study that examines associations between 
internal dose of PAHs (measured by urinary 1-OHPG concentrations) and oxidative 
stress, antioxidant gene induction, and inflammatory biomarkers in various biospecimens 
in atopic asthmatic adults in Baltimore City. The participants were examined at two 
visits, which allowed us to assess repeated measurements and account for intra-individual 
differences. Assessment of GSTM1 genotype allowed us to examine genetic inter-
individual differences in internal dose of PAHs and oxidative stress and inflammatory 
response outcomes. This study also adds to the growing literature on effects of PAHs on 
oxidative stress and inflammation in atopic asthmatics. This study also focuses on a 
vulnerable population of predominantly African American adults of low SES in 
Baltimore with concomitantly high air pollutant exposures and prevalent asthma. 
Limitations 
One drawback to our study is small sample size (32 participants), and only 9 of 
the participants had the GSTM1-null polymorphism. We also did not apportion routes of 
exposure (e.g. inhalation and ingestion) for PAHs. Dietary intake of PAHs from eating 
roasted, charbroiled or smoked foods may account for a significant portion of total PAH 




monohydroxylated metabolites of low molecular weight PAHs (predominantly found in 
gas phase), including 2-naphthol (naphthalene), 3-hydroxyphenanthrene (phenanthrene) 
and 9-hydroxyflurorene (fluorine) may give a better assessment of internal dose from 
inhaled PAHs. We also did not measure other air pollutants and biological inhalants (such 
as ozone, NO2, endotoxin and aeroallergen) or assess viral infections. These possible co-
exposures are associated with inflammation and asthma exacerbation, and may confound 
the relationships found in our analyses. We did not measure anti-allergen 
immunoglobulin (e.g. total serum IgE, anti-mouse IgE, anti-cockroach IgE, anti-dust mite 
IgE, etc.). Exposure assessments and early effect biomarker analyses would allow us to 
better assess the influence of allergens and allergic immune responses to inflammation 
and asthma exacerbations. Not all gene-environment interactions, with polymorphic 
genes, were assessed in this study. Polymorphisms in phase I (e.g. CYP1A1, CYP1A2) 
and phase II enzymes (e.g. GSTP1, GSTT1, UGT and NAT2) may be influential in 
explaining inter-individual differences in PAH metabolism, and subsequent 1-OHPG 
excretion and local and systemic inflammation. The study cohort was comprised of atopic 
asthmatic adults, mostly African American descent, of mostly low socioeconomic status 
in Baltimore, and may therefore not be generalizable to asthmatic populations or people 
not living in urban environments of low socioeconomic status. 
Conclusion 
In conclusion, PAH internal dose in our study of non-smoking atopic asthmatic 
adults was higher than the US national average and international studies of adults. 
GSTM1 genotype modulated oxidative stress and inflammatory responses with increased 




increased ROS in GSTM1-null participants (due to decreased antioxidant capacity, and 
possible gene-gene and gene-environment interactions). Internal dose PAHs are also 
associated with increased oxidative stress and increased systemic inflammation in 
GSTM1-null participants. The inflammatory responses have a predominantly eosinophilic 
and Th2-related cytokine profile. However, immune responses to many exogenous 
exposures (including PAHs, SHS, ozone, NO2, PM, aeroallergens, endotoxin and viruses) 
are complex and may include concurrent associations with eosinophilic, neutrophilic, and 
Th1 and Th2-related inflammatory immune responses. PAH exposures were associated 
with oxidative stress and inflammatory responses, with implications for deleterious 
outcomes (e.g. asthma exacerbation) due to increased ROS and reactive PAH 
intermediates. Future studies may reduce asthma morbidity through interventions focused 
on reducing exposures and early biological effects. These strategies may include 
behavioral (e.g. smoking cessation), engineering (e.g. air filtration), policy (e.g. reduction 
in vehicular and industrial emissions) interventions, thereby reducing exposures to PAHs; 
and abrogation of oxidative stress and reactive oxidative compounds through 
supplementation with exogenous antioxidants (such as, Vitamin C and Vitamin E), or 





TABLES AND  FIGURES 
Table 4-1. Descriptive characteristics of the Nasal Challenge to Indoor Particulate Matter 
Study 
 



















Participant characteristics, total (n=32) No. (%) 
Female   24 (75) 
Age, years 30 (18-50)* 
Race  
    African American 27 (84) 
    White 5 (17) 
Education attainment  
    Less than high school 11 (34) 
    HS diploma 8 (25) 
    College or higher 13 (41) 
Income (n=27)  
    ≤$25,000 19 (70) 
    >$25,000  8 (30) 
GSTM1 genotype (n=29)  
    GSTM1-null 9 (31) 
    GSTM1-present 20 (69) 
Asthma symptoms 2 weeks prior to baseline visit 21 (66) 
Rescue Medication use in 2 weeks prior to baseline visit 23 (72) 







1-OHPG (pmol/ml)  
GSTM1-present 
1-OHPG (pmol/ml)  
Number of samples 60 60 17 39 
Arithmetic Mean (SD) 2.54 (4.51) 0.18 (0.26) 1.22 (1.26) 2.47 (4.18) 
Geometric Mean 0.78 0.07 0.58 0.80 
Median (IQR) 0.87 (0.20-2.71) 0.10 (0.02-0.21) 0.60 (0.21-1.99) 0.80 (0.19-3.12) 
95%ile 11.3 0.65 4.28 10.13 
Range 0.06-22.76 0.003-1.49 0.06-4.29 0.06-22.76 








Bivariate analyses  β Std. Err. z P-value [95% Conf. Interval] 
Urinary creatinine 0.478 0.143 3.35 0.001 0.198 0.757 
Age 0.051 0.022 2.25 0.024 0.007 0.095 
Gender -0.395 0.592 -0.67 0.504 -1.555 0.765 
Race 0.264 0.689 0.38 0.702 -1.086 1.614 
Education 0.317 0.293 1.08 0.280 -0.258 0.892 
Season 0.402 0.166 2.42 0.016 0.076 0.729 
GSTM1 genotype 0.319 0.497 0.64 0.521 -0.655 1.293 
       
       
Multivariate analysis       
Urinary creatinine 0.235 0.139 1.68 0.090 -0.039 0.508 
Age 0.031 0.015 2.09 0.036 0.002 0.060 
Gender -0.233 0.528 -0.44 0.659 -1.268 0.802 
Race 0.105 0.436 0.24 0.810 -0.750 0.960 
Visit 0.381 0.323 1.18 0.237 -0.251 1.014 
Educational attainment       
    Less than HS (reference) - - - - - - 
    HS diploma 1.082 0.368 2.94 0.003 0.361 1.803 
    College or higher 0.626 0.485 1.29 0.196 -0.324 1.576 
Season       
    Spring (reference) - - - - - - 
    Summer 1.398 0.585 2.39 0.017 0.252 2.545 
    Fall 0.631 0.614 1.03 0.304 -0.572 1.835 
    Winter 1.832 0.428 4.27 <0.001 0.992 2.671 
GSTM1 genotype       
    GSTM1-null (reference) - - - - - - 
    GSTM1-present 0.795 0.369 2.15 0.031 0.071 1.519 




Figure 4-1. Adjusted mean of urinary 1-OHPG concentration, by GSTM1 genotype 
 





Table 4-4. Associations between urinary 1-OHPG and biomarkers of oxidative stress, gene 




Urinary oxidative stress biomarker β P>z [95% CI]  β P>z [95% CI] 
Log Urinary isoprostane  0.025 0.104 -0.005 0.055  0.026 0.181 -0.012 0.063 
Nasal epithelium mRNA           
Log NQO1 0.008 0.818 -0.059 0.074  0.051 0.084 -0.007 0.109 
Log HO-1 0.035 0.423 -0.050 0.120  0.017 0.576 -0.044 0.078 
Log GCLM -0.010 0.566 -0.046 0.025  0.009 0.690 -0.034 0.052 
Log GCLC -0.017 0.512 -0.066 0.033  0.035 0.435 -0.053 0.124 
Log TFF2 -0.014 0.626 -0.068 0.041  0.024 0.589 -0.064 0.112 
Log IL-33 -0.061 0.111 -0.136 0.014  -0.101 0.031 -0.194 -0.009 
Serum cytokines and chemokines          
Log Serum IL-6 -0.017 0.199 -0.042 0.009  -0.027 0.157 -0.064 0.010 
Log Serum IL-8 -0.014 0.438 -0.050 0.022  -0.009 0.654 -0.050 0.031 
Log Serum IL-10 -0.026 0.111 -0.058 0.006  -0.052 0.027 -0.098 -0.006 
Log Serum IL-13 -0.001 0.839 -0.012 0.010  0.006 0.665 -0.023 0.036 
Log Serum CCL20 -0.102 0.066 -0.210 0.007  -0.128 0.010 -0.225 -0.031 
Log Serum ECP 0.002 0.928 -0.048 0.052  0.006 0.879 -0.068 0.080 
Log Serum eotaxin 0.022 0.115 -0.005 0.050  0.011 0.546 -0.026 0.048 
Log Serum GRO 0.002 0.919 -0.028 0.031  0.015 0.384 -0.019 0.049 
Log Serum GRO-α 0.020 0.378 -0.024 0.064  0.038 0.068 -0.003 0.079 
Log Serum MIP-1α -0.016 0.356 -0.050 0.018  -0.017 0.249 -0.046 0.012 



















































aAdjusted for urinary creatinine 
bAdjusted for urinary creatinine, age, race, gender, GSTM1 genotype, and educational attainment 





















Nasal lavage biomarkers          
Log Nasal lavage IL-6 0.119 0.198 -0.062 0.299  *    
Log Nasal lavage IL-8 -0.012 0.784 -0.099 0.075  -0.019 0.532 -0.079 0.041 
Log Nasal lavage IL-10 -0.011 0.369 -0.034 0.013  -0.017 0.486 -0.064 0.030 
Log Nasal lavage IL-13 0.031 0.651 -0.102 0.164  0.037 0.721 -0.167 0.241 
Log Nasal lavage ECP -0.028 0.795 -0.240 0.184  0.148 0.323 -0.145 0.441 
Log Nasal lavage CCL20 -0.061 0.598 -0.286 0.165  -0.041 0.660 -0.224 0.142 
Log Nasal lavage eotaxin  0.017 0.842 -0.151 0.185  *    
Log Nasal lavage GRO 0.004 0.916 -0.076 0.085  0.020 0.518 -0.041 0.082 
Log Nasal lavage GRO-α 0.018 0.611 -0.050 0.085  0.037 0.114 -0.009 0.083 
Log Nasal lavage MIP-1α -0.007 0.929 -0.162 0.148  *    
Log Nasal lavage RANTES  0.023 0.218 -0.014 0.061  *    
Log Nasal lavage neutrophil count -0.026 0.223 -0.068 0.016  0.010 0.834 -0.085 0.105 
Log Nasal lavage neutrophil percent 0.018 0.115 -0.004 0.041  0.043 0.121 -0.011 0.097 
Log Nasal lavage eosinophil percent -0.002 0.688 -0.011 0.008  0.013 0.008 0.003 0.023 
Log Nasal lavage white blood cell count -0.031 0.090 -0.066 0.005  -0.002 0.946 -0.070 0.066 
Whole blood biomarkers          
Log PBMC no PMA 0.049 0.307 -0.044 0.142  -0.076 0.024 -0.142 -0.010 
Log PBMC with PMA 0.005 0.795 -0.032 0.042  -0.034 0.383 -0.111 0.043 
Log Monocytes no PMA 0.061 0.096 -0.011 0.134  -0.037 0.276 -0.104 0.030 
Log Monocytes with PMA -0.009 0.624 -0.047 0.028  -0.057 0.092 -0.124 0.009 
Log Lymphocytes no PMA 0.041 0.463 -0.068 0.150  -0.009 0.832 -0.089 0.071 
Log Lymphocytes with PMA 0.016 0.784 -0.100 0.133  -0.035 0.612 -0.169 0.100 
Log PMN no PMA 0.018 0.540 -0.040 0.076  0.039 0.432 -0.058 0.136 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4-2. Associations between urinary 1-OHPG and urinary, nasal lavage and peripheral 








Figure 4-3. Associations between urinary 1-OHPG and serum cytokines, chemokines and 





























Study Location Cohort characteristics Mean Median (IQR) 
Nasal Challenge Study Baltimore City Atopic asthmatic adults AM (SD): 0.18 (0.26) 0.10 (0.02-0.21) 
   GM: 0.07  
NHANES II (1999-2000) US General population, adults GM: 0.037 0.036 
NHANES III (2001-2002) US General population, adults GM: 0.023 0.021 
NHANES IV (2003-2004) US General population, adults GM: 0.041 0.038 
Kim et al. 2001 South Korea Non-smoking university students GM: 0.03  
Kim et al. 2001 South Korea Non-smoking shipyard workers GM: 0.18  
Levin et al. 1995 Sweden Non-smoking adults GM: 0.03  









We investigated the links between internal dose of PAHs and biological responses 
associated with asthma using biomarkers of oxidative stress and immune response in 
cohorts of children and adults living in the inner city of Baltimore. We quantified PAH 
internal dose in this cohort of children by measuring urinary 1-hydroxypyrene-
glucuronide (1-OHPG), and assessed associations between PAH internal dose and early 
effect biomarkers of oxidative damage, and inflammatory responses in cohorts of both 
children and adults, and assessed associations between PAH internal dose and asthma 
related symptoms in the cohort of asthmatic children, accounting for possible 
confounders. 
Urinary 1-OHPG concentrations among asthmatic children and adults in the 
DISCOVER, Asthma-Diet, and Nasal Challenge to Indoor Particulate Matter studies 
were higher than the US national average and many international studies, reflecting the 
disproportionate burden of exposures to environmental toxicants for inner city, 
predominantly African American communities of low SES. We hypothesized that 
spending time in the home would be associated with increased urinary 1-OHPG due to 
exposures to indoor air pollutants (such as PM). Our study, however, found that residing 
in a non-smoking home conferred a “protective” effect for 1-OHPG concentrations 
compared to residing in a smoking household. Exposures to SHS may therefore 
contribute to urinary 1-OHPG concentration. Most children in our study resided in homes 
with cigarette smoking at some time during the monitoring period, highlighting the 




was not associated with biomarkers of oxidative stress in children (urinary MDA), atopic 
asthmatic adults with the GSTM1-null polymorphism showed increased oxidative stress 
and increased local and systemic inflammatory responses to internal dose of PAHs, 
suggesting that lack of the GSTM1 enzyme may confer increased susceptibility to early 
biological effects related to asthma exacerbation. In children, internal dose of PAHs was 
associated with increased systemic inflammation (e.g. eosinophilia), with atopic 
asthmatic children reporting significantly higher inflammatory responses than non-atopic 
asthmatic children. These results suggest an adjuvant type effect of inflammatory 
responses in children sensitized to allergens, and likely co-exposed to these allergens and 
PAHs. PAH exposures were also associated with increased nighttime asthma symptoms 
and ß-agonist use. PAH exposures have shown consistent associations with inflammatory 
responses in children and adults, and have been associated with increased risk of asthma 
symptoms in children. These results support the proposed mechanism of activated PAHs 
causing increased oxidative stress, leading to increased inflammation and subsequently 
asthma exacerbation. The adjuvant activity of PAHs on allergen-mediated inflammatory 
responses are also supported by our findings, as atopic asthmatic children had more 
pronounced inflammatory responses to elevated PAHs than non-atopic asthmatic 
children.  
Public health relevance and implications 
The medical and social burden of asthma is considerable, with a disproportionate 
impact on vulnerable groups including young children, African-Americans and those 
living in the inner city. Exposure to air particulate matter is associated with asthma 




characterized. It has been proposed that combustion products in PM may exacerbate 
asthma symptoms in atopic asthmatics. This is a major problem for inner city residents 
where the indoor environment can be a strong contributor to asthma. We used urinary 
biomarkers of PAH exposure, a major combustion product constituent of fine PM, to 
explore the hypothesis that combustion products play a role in childhood asthma 
exacerbation in the urban environment.  
This study helps to determine the importance of PAH exposure in understanding 
the mechanisms of asthma exacerbation in children and adults living in an urban 
environment. This information will be useful in designing and implementing preventive 
interventions to reduce childhood asthma exacerbation and severity. 
Based on our findings, future studies to reduce asthma morbidity from PAH 
exposures could focus on interventions focused on reducing exposures and early 
biological effects. These strategies may include behavioral (e.g. smoking cessation), 
engineering (e.g. air filtration), and policy (e.g. reduction in vehicular and industrial 
emissions) interventions, thereby reducing exposures to PAHs. Another approach could 
be abrogation of oxidative stress and reactive oxidative compounds through 
supplementation with exogenous antioxidants (such as, Vitamin C and Vitamin E), or 
oral administration of compounds, such as sulforaphane, to stimulate antioxidant 
pathways and phase II enzymes. A multifaceted approach featuring further mechanistic, 
observational, intervention and clinical studies focused on PAH exposures and the 
continuum of biological and physiological responses associated with the development of 
asthma and asthma exacerbation, as well as studies incorporating exposures to other 




(such as SES, environmental justice, and healthcare utilization) may be necessary to 
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Supplemental Table 2-2 Comparisons, correlations and multivariate linear regression analyses 

































 * Adjusted for urinary creatinine 






Coef. (β) Std. Err. z P-value [95% Conf. Interval] 
  Age 0.123 0.018 6.98 <0.001 0.088 0.158 
  Gender (reference: girls) -0.013 0.068 -0.19 0.852 -0.145 0.120 
  Season -0.036 0.026 -1.41 0.159 -0.086 0.014 
  Atopic status -0.074 0.076 -0.97 0.334 -0.224 0.076 
  BMI percentile (continuous) 0.002 0.001 1.91 0.056 0.000 0.004 
  Asthmatic status (reference: non-asthmatic) -0.267 0.073 -3.64 <0.001 -0.411 -0.123 
  Caregiver’s education -0.042 0.035 -1.22 0.223 -0.110 0.026 
       
Comparison: Urinary Creatinine (day 3 vs. day 7)      
 z p-value     
Wilcoxon sign-rank test 2.74 0.006     
Comparisons: 1-OHPG/Cr (day 3 vs. day 7)    
 AM (SD) GM Median (IQR) n 
1-OHPG/Cr all samples 0.19 (0.22) 0.111 0.13 (0.06-0.25) 359 
1-OHPG/Cr day 3 0.16 (0.19) 0.085 0.11 (0.05-0.21) 255 
1-OHPG/Cr day 7 0.18 (0.22) 0.092 0.11 (0.05-0.23) 339 
Wilcoxon sign-rank test (day 3 vs day 7) p=0.422    
     
Correlations: (Log) 1-OHPG/Cr (day 3 vs. day 7)    
 r p-value   
Pearson’s correlation coefficient 0.20 0.003   
Pearson’s correlation coefficient (Log) 0.27 <0.001   
Spearman’s rho 0.34 <0.001   
     
Multivariate Linear Regression: Log 1-OHPG/Cr (day 3 vs day7)  
 β P>z [95% CI] 
Crude* 0.190 0.003 0.065 0.316 




Supplemental Table 2-3. Geometric means and medians of creatinine adjusted 1-OHPG 





























Supplemental Table 2-5. Predictors of indoor PM2.5, PM10, PM2.5-10 concentrations 
 Geometric mean Median (IQR) 
Winter 0.088 0.12 (0.04-0.23) 
Spring 0.091 0.11 (0.05-0.22) 
Summer  0.081 0.10 (0.05-0.23) 
Fall  0.096 0.13 (0.05-0.22) 
 
β P>z [95% CI] 
Time with windows open -0.065 0.485 -0.248 0.118 
Gas stove -0.250 0.205 -0.637 0.137 
Types of heating     
    Radiator -0.134 0.374 -0.430 0.162 
    Forced air 0.004 0.975 -0.254 0.262 
Type of curb     
    Parking lot 0.220 0.243 -0.149 0.588 
    Arterial street 0.032 0.850 -0.299 0.363 
    Side street -0.175 0.180 -0.432 0.081 
Curb distance  0.012 0.820 -0.093 0.117 
Log PM2.5          
 β P>z [95% CI]      
Smoking in the home 0.275 0.001 0.119 0.431      
Average cigarettes per day 0.037 <0.001 0.023 0.051      
Time with windows open 0.037 0.522 -0.076 0.151      
Stove use 0.106 0.173 -0.047 0.259      
Burning candles or incense 0.059 0.580 -0.149 0.267      
Burned something on stove 0.097 0.381 -0.120 0.314      
          
Log PM10          
 β P>z [95% CI]      
Smoking in the home 0.306 <0.001 0.162 0.450      
Average cigarettes per day 0.030 <0.001 0.018 0.041      
Time with windows open -0.008 0.890 -0.117 0.102      
Stove use 0.115 0.087 -0.017 0.247      
Burning candles or incense 0.033 0.671 -0.120 0.186      












































Supplemental Table 2-7. Associations between average time spent in the home and urinary  
1-OHPG concentrations, adjusting for indoor PM2.5, PM2.5-10, and PM10 
          
Log PM2.5-10  All PM2.5-10 samples   Without PM2.5-10 outlier* 
 β P>z [95% CI]  β P>z [95% CI] 
Smoking in the home 0.148 0.117 -0.037 0.332  0.176 0.064 -0.011 0.362 
Average cigarettes per day 0.005 0.563 -0.011 0.020  0.006 0.487 -0.010 0.021 
Time with windows open -0.136 0.071 -0.283 0.011  -0.110 0.146 -0.259 0.038 
Stove use 0.182 0.044 0.005 0.359  0.158 0.072 -0.014 0.330 
Burning candles or incense 0.129 0.227 -0.081 0.340  0.150 0.159 -0.059 0.358 
Burned something on stove 0.240 0.084 -0.032 0.512  0.101 0.500 -0.193 0.396 
Correlations between indoor air nicotine and PM2.5 and urinary 1-OHPG/Cr  
 Correlation coefficient p-value 
Log air nicotine vs. log PM2.5 (Pearson’s r) 0.550 <0.001 
Air nicotine vs. PM2.5 (Spearman’s rho) 0.530 <0.001 
Log air nicotine vs. log 1-OHPG/Cr (Pearson’s r) 0.107 0.046 
Air nicotine vs. 1-OHPG/Cr (Spearman’s rho) 0.115 0.031 
Predictors indoor air nicotine concentrations (MLR with GEE)    
 β P>z [95% CI]    
Smoking in the home 1.037 <0.001 0.703 1.371    
Average cigarettes per day 0.083 <0.001 0.055 0.110    
Log PM2.5 (dependent variable) 0.795 <0.001 0.467 1.124    
 Crude*  Adjusted** 
Adjusting for indoor PM2.5 β P>z [95% CI]  β P>z [95% CI] 
Average time in the home, all samples -0.020 0.238 -0.054 0.013  -0.017 0.360 -0.052 0.019 
Average time in the home days 0-2 (urine day 3) -0.020 0.252 -0.053 0.014  -0.019 0.272 -0.052 0.015 
Average time in the home days 4-6 (urine day 7) -0.047 0.012 -0.083 -0.010  -0.054 0.002 -0.089 -0.019 
          
Adjusting for indoor PM2.5-10          
Average time in the home, all samples 0.140 0.027 0.016 0.264  0.148 0.029 0.015 0.281 
Average time in the home days 0-2 (urine day 3) 0.113 0.297 -0.100 0.326  0.084 0.430 -0.125 0.294 
Average time in the home days 4-6 (urine day 7) 0.173 0.018 0.030 0.315  0.201 0.007 0.055 0.347 
          
Adjusting for indoor PM2.5-10 without outlier          
Total urine 0.121 0.057 -0.003 0.245  0.117 0.074 -0.011 0.246 
Urine collected on Day 3 0.113 0.297 -0.100 0.326  0.083 0.437 -0.127 0.293 




* Adjusted for urinary creatinine 





Supplemental Table 2-8. Associations between average time spent in the home and urinary  
1-OHPG, stratified by PM2.5, and adults smoking in the home 
 
Associations between average time in the home and urinary 1-OHPG, stratified by PM2.5 (dichotomized at median: 21.3 
μg/m3) 
 
Associations between average time in the home and urinary 1-OHPG, stratified by adults smoking in the home 





Supplemental Table 2-9. Geometric mean and median for time spent in the home and time spent 








          
Adjusting for indoor PM10          
Average time in the home, all samples -0.019 0.233 -0.051 0.012  -0.012 0.496 -0.046 0.022 
Average time in the home days 0-2 (urine day 3) -0.028 0.097 -0.061 0.005  -0.025 0.142 -0.058 0.008 
Average time in the home days 4-6 (urine day 7) -0.031 0.087 -0.066 0.004  -0.032 0.064 -0.065 0.002 
 
Low PM2.5  High PM2.5  
 
β P>z [95% CI]  β P>z [95% CI] P-int 
Avg. time in the home all samples -0.019 0.462 -0.070 0.032  -0.050 0.040 -0.099 -0.002 0.809 
Avg. time in the home days 0-2 (urine day 3) -0.013 0.560 -0.056 0.031  -0.067 0.001 -0.106 -0.027 0.291 
Avg. time in the home days 4-6 (urine day 7) -0.104 <0.001 -0.153 -0.056  -0.018 0.488 -0.070 0.033 0.003 
 
No smoking  Smoking  
 
β P>z [95% CI]  β P>z [95% CI] P-int 
Avg. time in the home all samples -0.013 0.612 -0.065 0.039  -0.024 0.261 -0.065 0.018 0.758 
Avg. time in the home days 0-2 (urine day 3) -0.033 0.135 -0.075 0.010  -0.013 0.566 -0.056 0.030 0.628 
Avg. time in the home days 4-6 (urine day 7) -0.092 <0.001 -0.144 -0.040  -0.001 0.966 -0.044 0.043 0.012 
 Hours spent in the home  Hours spent outdoors 
 Geometric mean  Median (IQR)   Geometric mean  Median (IQR)  
Winter 15.0 16.0 (14.2-17.1)  1.2 0.9 (0.6-1.8) 
Spring 14.6 15.0 (13.4-16.2)  2.4 2.9 (1.3-4.7) 
Summer 16.2 16.8 (14.0-20.2)  2.0 2.4 (0.7-4.6) 
Fall 14.6 15.0 (13.5-17.0)  1.6 1.9 (0.7-3.4) 




Supplemental Table 2-10. Comparison of time spent in the home, indoors elsewhere, and outdoors 
(hours) on weekdays and during the weekend 
 









Supplemental Table 2-11. Associations between average time spent outdoors and urinary  
1-OHPG, adjusting for indoor PM2.5 concentrations 
* Adjusted for urinary creatinine 















Hours spent in the 
home   
Hours spent indoors  
(vehicles, other buildings, etc.)  Hours spent outdoors 
Weekdays (median (IQR)) 15.4 (13.6-17.1)  6.2 (2.8-8)  2.0 (0.8-3.9) 
Weekends (median (IQR)) 18.0 (13.5-21.5)  1.5 (0-7.0)  1.5 (0-4.5.0) 
Wilcoxon sign-rank test p<0.001  p<0.001  p=0.792 
 Hours outdoors on weekdays  Hours outdoors on weekends  
Boys (median (IQR)) 2.0 (0.8-4.3)  1.5 (0-4.0) 
Girls (median (IQR)) 1.4 (0.6-3.4)  1.5 (0-5.0) 
Wilcoxon rank-sum test p=0.009  p=0.301 
 Crude*  Adjusted** 
All Samples β P>z [95% CI]  β P>z [95% CI] 
Average time outdoors all samples -0.012 0.663 -0.064 0.040  -0.005 0.867 -0.060 0.050 
Average time outdoors days 0-2 (urine day 3) -0.006 0.881 -0.081 0.069  0.004 0.915 -0.077 0.086 
Average time outdoors days 4-6 (urine day 7) 0.032 0.211 -0.018 0.081  0.044 0.107 -0.009 0.097 
          
By Gender          
  Boys          
Average time outdoors all samples -0.020 0.620 -0.100 0.059  -0.022 0.611 -0.105 0.062 
Average time outdoors days 0-2 (urine day 3) -0.025 0.597 -0.119 0.068  -0.026 0.604 -0.126 0.073 
Average time outdoors days 4-6 (urine day 7) 0.086 0.011 0.019 0.153  0.081 0.018 0.014 0.148 
          
  Girls          
Average time outdoors all samples 0.013 0.718 -0.057 0.083  0.016 0.683 -0.062 0.095 
Average time outdoors days 0-2 (urine day 3) 0.025 0.695 -0.101 0.151  0.045 0.538 -0.098 0.188 




Supplemental Table 2-12. Associations between average time spent outdoors and urinary  
1-OHPG, adjusting for indoor air nicotine concentrations 
* Adjusted for urinary creatinine 





Supplemental Table 2-13.  Associations between time spent outdoors and urinary 1-OHPG 
concentrations by season, and effect modification by season 
 











Adjusted for urinary creatinine, gender, age, atopic status, season, caregiver’s education 
 
Effect modification of seasons on associations between time spent outdoors and urinary 1-OHPG 
concentrations 
aAdjusted for urinary creatinine, gender, age, atopic status, season, caregive 
b Adjusted for indoor PM2.5, urinary creatinine, gender, age, atopic status, season, caregiver’s education 






 Crude*  Adjusted** 
All Samples β P>z [95% CI]  β P>z [95% CI] 
Avg. time outdoors all samples -0.002 0.924 -0.050 0.046 
 
0.013 0.634 -0.041 0.067 
Avg. time outdoors days 0-2 (urine day 3) -0.003 0.920 -0.067 0.061 
 
0.014 0.718 -0.063 0.092 
Avg. time outdoors days 4-6 (urine day 7) 0.030 0.197 -0.016 0.075 
 
0.051 0.043 0.002 0.100 
          
By Gender          
  Boys          
Avg. time outdoors all samples -0.004 0.917 -0.071 0.064 
 
0.009 0.826 -0.070 0.088 
Avg. time outdoors days 0-2 (urine day 3) -0.024 0.477 -0.091 0.043 
 
-0.022 0.600 -0.105 0.061 
Avg. time outdoors days 4-6 (urine day 7) 0.088 0.004 0.028 0.149 
 
0.099 0.002 0.037 0.162 
          
  Girls          
Avg. time outdoors all samples 0.046 0.046 0.046 0.046 
 
0.025 0.524 -0.051 0.101 
Avg. time outdoors days 0-2 (urine day 3) 0.046 0.046 0.046 0.046 
 
0.057 0.432 -0.086 0.200 
Avg. time outdoors days 4-6 (urine day 7) 0.046 0.046 0.046 0.046 
 
-0.018 0.574 -0.082 0.045 
All Samples β P>z [95% CI] 
Winter -0.038 0.638 -0.198 0.121 
Spring 0.029 0.516 -0.059 0.118 
Summer  0.147 0.003 0.048 0.246 
Fall -0.067 0.181 -0.164 0.031 
 Associations between 1-OHPG and interactions between season and time spent outdoors 
 P-value
a P-value b P-value c 
Winter x time spent outdoors 0.060 0.047 0.078 
Spring x time spent outdoors 0.946 0.926 0.925 
Summer x time spent outdoors 0.001 <0.001 <0.001 






























a  Less data on first day of monitoring period (day 0, Saturday). Interviews may not have been conducted or children may not have been home. 
b Due to ripped membrane, equipment malfunction or PM2.5 > PM10 






Total n=359 n % Missing total % Missing girls % Missing boys 
Indoor PM2.5 concentrationsb 309 14 14 13 
Indoor PM10 concentrationsb 308 14 14 15 
Indoor PM2.5-10 concentrationsc 280 22 21 23 
Indoor air nicotine concentrations 346 4 3 4 
Time spent indoors/outdoors Day 0a 282 21 20 23 
Time spent indoors/outdoors Day 1 325 9 8 11 
Time spent indoors/outdoors Day 2 332 8 8 7 
Time spent indoors/outdoors Day 3 341 5 4 6 
Time spent indoors/outdoors Day 4 343 4 4 5 
Time spent indoors/outdoors Day 5 337 6 6 6 
Time spent indoors/outdoors Day 6 340 5 4 6 
Average time indoors/outdoors days 0-6a 273 24 23 25 
Average time indoors/outdoors days 0-2a 277 23 22 24 
Average time indoors/outdoors days 4-6 331 8 7 8 
Smoking in the home days 0-6a 288 20 20 20 
Smoking in the home days 0-2a 296 17 16 19 
Smoking in the home days 4-6 332 8 8 7 
Playing sports outdoors on days 0-6a 258 28 27 30 
Playing sports outdoors on days 0-2a 272 24 22 26 




APPENDIX D: Supplemental Tables for Chapter 3 
 
Supplemental Table 3-1. Associations between urinary 1-OHPG concentrations and ß-agonist 
use during the day 
*Adjusted for urinary creatinine 





Supplemental Table 3-2. Associations between urinary 1-OHPG concentrations and having 
trouble breathing during the day 
*Adjusted for urinary creatinine 
**Adjusted for urinary creatinine, air nicotine (continuous), age, gender, season, and caregiver's education 
 Crude*  Adjusted** 
1-OHPG conc. Day 3 OR P>z [95% CI]  OR P>z [95% CI] 
 ß-agonist use during previous 4 days (0-3) 1.720 0.027 1.062 2.785  1.811 0.040 1.028 3.190 
 ß-agonist use during previous 3 days (1-3) 1.184 0.544 0.685 2.047  1.335 0.347 0.731 2.440 
 ß-agonist use during previous 2 days (2-3) 1.051 0.861 0.600 1.842  1.282 0.453 0.671 2.450 
 ß-agonist use during next 2 days (4-5) 1.346 0.375 0.698 2.598  1.754 0.146 0.823 3.742 
 ß-agonist use during next 4 days (4-6) 1.344 0.345 0.727 2.482  1.707 0.140 0.839 3.474 
 ß-agonist use any day (0-6) 1.646 0.059 0.980 2.764  1.732 0.075 0.946 3.169 
          
1-OHPG conc. day 7          
 ß-agonist use during previous 2 days (5-6) 0.853 0.543 0.511 1.424  0.962 0.892 0.546 1.693 
 ß-agonist use during previous 3 days (4-6) 1.020 0.937 0.626 1.662  1.152 0.624 0.655 2.025 
 ß-agonist use any day (0-6) 0.880 0.631 0.522 1.483  0.088 0.774 -0.512 0.688 
          
1-OHPG conc. average of samples          
 ß-agonist use on days 0-3 1.076 0.755 0.680 1.702  1.119 0.672 0.665 1.883 
 ß-agonist use on days 4-6 1.136 0.653 0.653 1.976  1.301 0.412 0.694 2.442 
 ß-agonist use on days 0-6 1.068 0.787 0.662 1.726  1.165 0.580 0.678 2.002 
 Crude*  Adjusted** 
1-OHPG conc. day 3 OR P>z [95% CI]  OR P>z [95% CI] 
 Trouble breathing during previous 4 days (0-3) 1.500 0.087 0.943 2.387  1.534 0.084 0.944 2.491 
 Trouble breathing during previous 3 days (1-3) 1.595 0.102 0.912 2.789  1.719 0.108 0.887 3.332 
 Trouble breathing during previous 2 days (2-3) 1.349 0.304 0.762 2.386  1.615 0.160 0.827 3.153 
 Trouble breathing during next 2 days (4-5) 1.117 0.645 0.697 1.790  1.074 0.787 0.640 1.802 
 Trouble breathing during next 4 days (4-6) 1.139 0.597 0.704 1.842  1.055 0.844 0.618 1.803 
 Trouble breathing any day (0-6) 1.480 0.088 0.943 2.323  1.426 0.146 0.884 2.303 
          
1-OHPG conc. day 7          
 Trouble breathing during previous 2 days (5-6) 0.795 0.313 0.509 1.242  0.674 0.165 0.386 1.177 
 Trouble breathing during previous 3 days (4-6) 0.887 0.602 0.567 1.390  0.776 0.376 0.443 1.360 
 Trouble breathing any day (0-6) 0.867 0.509 0.568 1.324  -0.156 0.533 -0.647 0.335 
          
1-OHPG conc. average of samples          
 Trouble breathing on days 0-3 1.252 0.288 0.828 1.893  1.331 0.224 0.839 2.109 
 Trouble breathing on days 4-6 0.935 0.782 0.583 1.501  0.902 0.721 0.511 1.591 




Supplemental Table 3-3. Associations between urinary 1-OHPG concentrations and 
















*Adjusted for urinary creatinine 





Supplemental Table 3-4. Associations between urinary 1-OHPG concentrations and being 
bothered by asthma during the day 
*Adjusted for urinary creatinine 











 Crude*  Adjusted** 
1-OHPG concentrations day 3 OR P>z [95% CI]  OR P>z [95% CI] 
   Unscheduled doctor's visit days 0-7 1.785 0.413 0.446 7.150  1.860 0.424 0.407 8.495 
          
1-OHPG concentrations day 7          
   Unscheduled doctor's visit days 0-7 0.564 0.401 0.148 2.145  0.284 0.143 0.053 1.528 
          
1-OHPG concentrations average of samples          
   Unscheduled doctor's visit days 0-7 0.609 0.455 0.166 2.236  0.327 0.156 0.070 1.529 
 
Crude*  Adjusted** 
1-OHPG conc. day 3 OR P>z [95% CI]  OR P>z [95% CI] 
 Bothered by asthma during previous 4 days (0-3) 1.358 0.224 0.829 2.225  1.375 0.263 0.787 2.403 
 Bothered by asthma during previous 3 days (1-3) 1.547 0.128 0.882 2.715  1.696 0.109 0.888 3.237 
 Bothered by asthma during previous 2 days (2-3) 1.414 0.248 0.785 2.547  1.713 0.121 0.868 3.383 
 Bothered by asthma during next 2 days (4-5) 1.059 0.814 0.658 1.704  0.966 0.898 0.573 1.631 
 Bothered by asthma during next 4 days (4-6) 0.977 0.919 0.621 1.537  0.860 0.549 0.524 1.410 
 Bothered by asthma on days 0-6 1.204 0.464 0.733 1.977  1.071 0.802 0.628 1.826 
          
1-OHPG conc. day 7          
 Bothered by asthma during previous 2 days (5-6) 0.753 0.215 0.480 1.180  0.601 0.073 0.344 1.050 
 Bothered by asthma during previous 3 days (4-6) 0.836 0.464 0.517 1.351  0.707 0.238 0.398 1.257 
 Bothered by asthma days (0-6) 0.861 0.519 0.545 1.358  -0.236 0.365 -0.747 0.274 
          
1-OHPG conc. average of samples          
 Bothered by asthma on days 0-3 1.204 0.386 0.791 1.833  1.244 0.384 0.760 2.037 
 Bothered by asthma on days 4-6 0.873 0.572 0.546 1.397  0.773 0.378 0.437 1.369 




Supplemental Table 3-5. Associations between urinary 1-OHPG concentrations and limited 
activity due to asthma during the day 
*Adjusted for urinary creatinine 






 Crude*  Adjusted** 
1-OHPG conc. day 3 OR P>z [95% CI]  OR P>z [95% CI] 
 Limited activity during previous 4 days (0-3) 1.282 0.371 0.744 2.209  1.341 0.347 0.727 2.476 
 Limited activity during previous 3 days (1-3) 1.464 0.198 0.819 2.618  1.687 0.127 0.862 3.300 
 Limited activity during previous 2 days (2-3) 1.379 0.305 0.746 2.549  1.706 0.162 0.807 3.604 
 Limited activity during next 2 days (4-5) 0.962 0.882 0.580 1.596  0.933 0.816 0.519 1.676 
 Limited activity during next 4 days (4-6) 0.942 0.811 0.574 1.545  0.907 0.737 0.513 1.603 
 Limited activity on any day (0-6) 1.077 0.789 0.624 1.859  1.047 0.880 0.578 1.895 
          
1-OHPG conc. day 7          
 Limited activity during previous 2 days (5-6) 0.895 0.632 0.570 1.406  0.868 0.613 0.502 1.500 
 Limited activity during previous 3 days (4-6) 0.920 0.746 0.554 1.526  0.938 0.831 0.518 1.696 
 Limited activity on any day (0-6) 1.105 0.696 0.669 1.827  0.133 0.647 -0.435 0.701 
          
1-OHPG conc. average of samples          
 Limited activity on days 0-3 1.473 0.090 0.941 2.306  1.550 0.109 0.907 2.650 
 Limited activity on days 4-6 1.039 0.883 0.627 1.719  1.106 0.748 0.597 2.048 




Effect Modification by atopic status 
 
Supplemental Table 3-6. Atopic status as an effect modifier of associations between urinary  
1-OHPG concentrations and waking due to asthma symptoms during the night or in the early 
morning 




Supplemental Table 3-7. Atopic status as an effect modifier of associations between urinary  
1-OHPG concentrations and ß-agonist use during the night or in the morning 
Adjusted for creatinine, air nicotine (continuous), age, gender, season, and caregiver's education  
 Non-Atopic  Atopic  
1-OHPG conc. day 3 β P>z [95% CI]  β P>z [95% CI] P-int 
 Woken by asthma during previous 4 nights (0-3) 0.048 0.283 -0.040 0.136  0.079 0.064 -0.005 0.162 0.789 
 Woken by asthma during previous 3 nights (1-3) 0.048 0.254 -0.035 0.131  0.066 0.057 -0.002 0.134 0.752 
 Woken by asthma during previous 2 nights (2-3) 0.008 0.709 -0.035 0.051  0.028 0.168 -0.012 0.068 0.753 
 Woken by asthma during next 2 nights (4-5) -0.006 0.486 -0.024 0.011  0.021 0.143 -0.007 0.049 0.908 
 Woken by asthma during next 4 nights (4-7) 0.038 0.181 -0.018 0.094  0.038 0.135 -0.012 0.089 0.658 
 Woken by asthma any night (0-7) 0.110 0.002 0.040 0.180  0.091 0.094 -0.015 0.197 0.184 
           
1-OHPG conc. day 7           
 Woken by asthma during previous 2 nights (6-7) 0.026 0.278 -0.021 0.074  -0.003 0.813 -0.031 0.024 0.152 
 Woken by asthma during previous 3 nights (5-7) 0.060 0.161 -0.024 0.143  0.003 0.888 -0.039 0.046 0.210 
 Woken by asthma during previous 4 nights (4-7) 0.075 0.108 -0.017 0.166  0.026 0.403 -0.035 0.088 0.370 
 Woken by asthma any night (0-7)) 0.010 0.793 -0.068 0.089  0.049 0.322 -0.048 0.146 0.939 
           
1-OHPG conc. average of samples           
 Woken by asthma on nights 0-3 0.037 0.385 -0.046 0.120  0.052 0.180 -0.024 0.129 0.979 
 Woken by asthma on nights 4-7 0.075 0.100 -0.014 0.165  0.056 0.210 -0.031 0.143 0.809 
 Woken by asthma on nights 0-7 0.077 0.216 -0.045 0.198  0.108 0.138 -0.035 0.250 0.881 
 Non-Atopic  Atopic  
1-OHPG conc. day 3 β P>z [95% CI]  β P>z [95% CI] P-interaction 
 ß-agonist use during previous 4 days (0-3) 0.082 0.170 -0.035 0.200  0.072 0.124 -0.020 0.164 0.497 
 ß-agonist use during previous 3 days (1-3) 0.062 0.158 -0.024 0.148  0.069 0.080 -0.008 0.146 0.395 
 ß-agonist use during previous 2 days (2-3) 0.008 0.709 -0.035 0.051  0.028 0.168 -0.012 0.068 0.753 
 ß-agonist use during next 2 days (4-5) -0.006 0.486 -0.024 0.011  0.021 0.143 -0.007 0.049 0.908 
 ß-agonist use during next 4 days (4-7) -0.032 0.440 -0.112 0.049  0.074 0.070 -0.006 0.155 0.644 
 ß-agonist use any day (0-7) 0.171 0.035 0.012 0.330  0.139 0.104 -0.028 0.307 0.141 
           
1-OHPG conc. day 7           
 ß-agonist use during previous 2 days (6-7) 0.026 0.278 -0.021 0.074  -0.003 0.813 -0.031 0.024 0.152 
 ß-agonist use during previous 3 days (5-7) -0.018 0.560 -0.081 0.044  0.008 0.785 -0.051 0.068 0.850 
 ß-agonist use during previous 4 days (4-7) -0.002 0.955 -0.067 0.063  0.003 0.948 -0.076 0.081 0.675 
 ß-agonist use any day (0-7) -0.050 0.075 -0.197 0.096  0.036 0.608 -0.101 0.172 0.948 
           
1-OHPG conc. average of samples           
 ß-agonist use on days 0-3 0.025 0.589 -0.065 0.114  0.069 0.260 -0.051 0.189 0.968 
 ß-agonist use on days 4-7 -0.010 0.804 -0.087 0.067  0.041 0.471 -0.070 0.151 0.722 




Supplemental Table 3-8. Atopic status as an effect modifier of associations between urinary  
1-OHPG concentrations and ß-agonist use during the day 





Supplemental Table 3-9. Atopic status as an effect modifier of associations between urinary  
1-OH PG concentrations and having trouble breathing during the day  
 Adjusted for urinary creatinine, air nicotine (continuous), age, gender, season, and caregiver's education 
 
 
 Non-Atopic  Atopic  
1-OHPG conc. day 3 β P>z [95% CI]  β P>z [95% CI] P-interaction 
 ß-agonist use during previous 4 days (0-3) 0.021 0.757 -0.113 0.155  0.066 0.302 -0.059 0.192 0.855 
 ß-agonist use during previous 3 days (1-3) -0.005 0.900 -0.084 0.074  0.046 0.346 -0.050 0.141 0.720 
 ß-agonist use during previous 2 days (2-3) 0.003 0.937 -0.068 0.074  0.026 0.425 -0.038 0.090 0.761 
 ß-agonist use during next 2 days (4-5) -0.003 0.867 -0.041 0.035  0.029 0.367 -0.034 0.092 0.779 
 ß-agonist use during next 4 days (4-6) 0.022 0.643 -0.070 0.113  0.021 0.658 -0.071 0.112 0.535 
 ß-agonist use any day (0-6) 0.033 0.786 -0.204 0.269  0.066 0.553 -0.152 0.284 0.761 
           
1-OHPG conc. day 7           
 ß-agonist use during previous 2 days (5-6) -0.027 0.231 -0.072 0.017  -0.016 0.452 -0.059 0.026 0.955 
 ß-agonist use during previous 3 days (4-6) -0.028 0.338 -0.086 0.029  -0.014 0.661 -0.075 0.047 0.896 
 ß-agonist use any day (0-6) -0.241 0.007 -0.418 -0.065  0.002 0.978 -0.143 0.147 0.520 
           
1-OHPG conc. average of samples           
 ß-agonist use on days 0-3 -0.044 0.442 -0.156 0.068  0.084 0.248 -0.059 0.227 0.486 
 ß-agonist use on days 4-6 -0.022 0.494 -0.084 0.040  -0.011 0.812 -0.106 0.083 0.716 
 ß-agonist use on days 0-6 -0.113 0.330 -0.340 0.114  0.037 0.755 -0.197 0.272 0.952 
 Non-Atopic  Atopic  
1-OHPG conc. day 3 β P>z [95% CI]  β P>z [95% CI] P-int 
 Trouble breathing during previous 4 days (0-3) 0.033 0.492 -0.061 0.127  0.046 0.386 -0.058 0.149 0.506 
 Trouble breathing during previous 3 days (1-3) -0.032 0.316 -0.095 0.031  0.059 0.151 -0.021 0.139 0.147 
 Trouble breathing during previous 2 days (2-3) -0.022 0.277 -0.062 0.018  0.042 0.168 -0.018 0.101 0.101 
 Trouble breathing during next 2 days (4-5) -0.021 0.326 -0.063 0.021  0.014 0.557 -0.033 0.061 0.400 
 Trouble breathing during next 4 days (4-6) -0.051 0.288 -0.146 0.043  0.015 0.665 -0.052 0.081 0.375 
 Trouble breathing any day (0-6) -0.012 0.915 -0.225 0.202  0.035 0.656 -0.118 0.187 0.495 
           
1-OHPG conc. day 7           
 Trouble breathing during previous 2 days (5-6) -0.011 0.690 -0.065 0.043  -0.003 0.916 -0.057 0.051 0.591 
 Trouble breathing during previous 3 days (4-6) 0.000 0.994 -0.076 0.076  0.004 0.910 -0.071 0.080 0.581 
 Trouble breathing any day (0-6) -0.094 0.334 -0.283 0.096  0.100 0.347 -0.108 0.307 0.439 
           
1-OHPG conc. average of samples           
 Trouble breathing on days 0-3 0.012 0.821 -0.088 0.111  0.123 0.114 -0.030 0.276 0.202 
 Trouble breathing on days 4-6 -0.019 0.728 -0.128 0.090  0.022 0.705 -0.090 0.133 0.440 




Supplemental Table 3-10. Atopic status as an effect modifier of associations between urinary  
1-OHPG concentrations and being bothered by asthma during the day 





Supplemental Table 3-11. Atopic status as an effect modifier of associations between urinary  
1-OHPG concentrations and limited activity due to asthma symptoms during the day 
   Adjusted for urinary creatinine, air nicotine (continuous), age, gender, season, and caregiver's education 
 
 
 Non-Atopic  Atopic  
1-OHPG conc. day 3 β P>z [95% CI]  β P>z [95% CI] P-int 
 Bothered by asthma during previous 4 days (0-3) 0.081 0.219 -0.048 0.210  0.038 0.509 -0.075 0.152 0.924 
 Bothered by asthma during previous 3 days (1-3) 0.044 0.465 -0.073 0.161  0.053 0.237 -0.035 0.141 0.876 
 Bothered by asthma during previous 2 days (2-3) 0.012 0.700 -0.049 0.073  0.037 0.219 -0.022 0.096 0.818 
 Bothered by asthma during next 2 days (4-5) -0.027 0.241 -0.071 0.018  0.016 0.490 -0.030 0.063 0.648 
 Bothered by asthma during next 4 days (4-6) -0.053 0.272 -0.148 0.042  0.010 0.782 -0.060 0.080 0.567 
 Bothered by asthma any day (0-6) 0.060 0.604 -0.167 0.286  0.022 0.794 -0.145 0.190 0.975 
           
1-OHPG conc. day 7           
 Bothered by asthma during previous 2 days (5-6) -0.026 0.348 -0.079 0.028  -0.007 0.780 -0.057 0.043 0.575 
 Bothered by asthma during previous 3 days (4-6) -0.027 0.491 -0.103 0.050  -0.002 0.957 -0.072 0.068 0.543 
 Bothered by asthma any day (0-6) -0.103 0.329 -0.310 0.104  0.091 0.365 -0.106 0.287 0.474 
           
1-OHPG conc. average of samples           
 Bothered by asthma on days 0-3 0.040 0.563 -0.095 0.175  0.117 0.128 -0.034 0.267 0.288 
 Bothered by asthma on days 4-6 -0.026 0.640 -0.135 0.083  0.008 0.872 -0.092 0.108 0.609 
 Bothered by asthma on days 0-6 0.020 0.895 -0.275 0.315  0.154 0.237 -0.102 0.411 0.301 
 Non-Atopic  Atopic  
1-OHPG conc. day 3 β P>z [95% CI]  β P>z [95% CI] P-interaction 
 Limited activity during previous 4 days (0-3) 0.081 0.219 -0.048 0.210  0.038 0.509 -0.075 0.152 0.924 
 Limited activity during previous 3 days (1-3) 0.044 0.465 -0.073 0.161  0.053 0.237 -0.035 0.141 0.876 
 Limited activity during previous 2 days (2-3) 0.012 0.700 -0.049 0.073  0.037 0.219 -0.022 0.096 0.818 
 Limited activity during next 2 days (4-5) -0.027 0.241 -0.071 0.018  0.016 0.490 -0.030 0.063 0.648 
 Limited activity during next 4 days (4-6) -0.053 0.272 -0.148 0.042  0.010 0.782 -0.060 0.080 0.567 
 Limited activity on any day (0-6) 0.060 0.604 -0.167 0.286  0.022 0.794 -0.145 0.190 0.975 
           
1-OHPG conc. day 7           
 Limited activity during previous 2 days (5-6) -0.026 0.348 -0.079 0.028  -0.007 0.780 -0.057 0.043 0.575 
 Limited activity during previous 3 days (4-6) -0.027 0.491 -0.103 0.050  -0.002 0.957 -0.072 0.068 0.543 
 Limited activity on any day (0-6) -0.103 0.329 -0.310 0.104  0.091 0.365 -0.106 0.287 0.474 
           
1-OHPG conc. average of samples           
 Limited activity on days 0-3 0.040 0.563 -0.095 0.175  0.117 0.128 -0.034 0.267 0.288 
 Limited activity on days 4-6 -0.026 0.640 -0.135 0.083  0.008 0.872 -0.092 0.108 0.609 




APPENDIX E: Supplemental Tables for Chapter 4 
 
Supplemental Table 4-1. Descriptive statistics for urine, serum, whole blood, nasal lavage, and 
nasal epithelium mRNA biomarkers, stratified by GSTM1 genotype 





Overall GSTM1-null GSTM1-present  
 
Median (IQR) Median (IQR) Median (IQR) p-value* 
Urinary biomarkers     
1-OHPG (pmol/ml) 0.87 (0.20-2.71) 0.60 (0.21-1.99) 0.80 (0.19-3.12) 0.509 
1-OHPG (umol/mol Cr) 0.10 (0.02-0.22) 0.10 (0.03-0.15) 0.11 (0.02-0.24) 0.599 
Isoprostane (pg/ml) 3365(3574-5094) 3313 (2541-4937) 3321 (2570-5139) 0.866 
Isoprostane (ug/g Cr) 2702 (1964-3393) 2874 (2261-3929) 2493 (1636-3952) 0.742 
Nasal epithelium mRNA     
NQO1 50 (28.4-108.3) 50.12 (32.1-108.3) 53.0 (28.8-102.5) 0.959 
HO-1 9.04 (5.72-18.03) 8.66 (6.20-18.33) 9.45 (5.06-15.40) 0.938 
GCLM 14.39(7.07-26.84) 9.39 (5.25-18.04) 17.35 (7.20-26.84) 0.468 
GCLC 82.7 (31.4-978.5) 51.6 (26.3-811.2) 359.5 (48.3-978.5) 0.378 
TFF2 238.9 (111.5-1205) 225.7 (54.6-890.0) 252.1 (54.6-1387.5) 0.559 
IL-33 6915 (2054-50708) 2789 (1259-63339) 15159 (2489-50048) 0.223 
Serum cytokines and chemokines (pg/ml)    
IL-6  0.32 (0.32-1.33) 0.32 (0.32-1.99) 0.32 (0.32-4.33) 0.962 
IL-8 8.82 (5.18-12.73) 6.89 (5.84-13.79) 9.34 (4.81-12.73) 0.925 
IL-10 0.32 (0.32-0.32) 0.32 (0.32-0.32) 0.32 (0.32-4.97) 0.439 
IL-13 0.32 (0.32-0.32) 0.32 (0.32-0.32) 0.32 (0.32-0.32) 0.748 
CCL20 10.49 (032-38.28) 6.66 (0.32-49.89) 10.57 (0.32-35.60) 0.921 
ECP 7.24 (5.11-14.89) 7.28 (3.76-25.72) 7.24 (5.32-14.19) 0.955 
eotaxin 61.93 (41.14-99.96) 55.95 (43.5-86.42) 58.73 (32.01-104.8) 0.910 
GRO 1379 (804-2175) 1429 (1002-2215) 1345 (758-2180) 0.460 
GRO-α 188.7 (666.6-367.6) 134.6 (87.2-351.2) 120.4 (30.2-322.2) 0.776 
MIP-1 α 13.80 (8.10-21.47) 13.87 (5.56-24.32) 14.21 (8.74-20.21) 0.835 
Nasal lavage biomarkers (pg/ml)    
IL-6 0.32 (0.32-0.32) 0.32 (0.32-0.32) 0.32 (0.32-0.32) 0.925 
IL-8 72.78 (45.74-137.6) 75.72 (45.74-78.9) 76.23 (52.0-212.8) 0.440 
IL-10 0.32 (0.32-0.32) 0.32 (0.32-0.32) 0.32 (0.32-0.32) 0.651 
IL-13 0.32 (0.32-0.97) 0.32 (0.32-0.82) 0.32 (0.32-1.33) 0.635 
ECP 0.32 (0.32-3.28) 3.28 (3.16-3.68) 0.32 (0.32-3.23) 0.060 
CCL20 0.32 (0.32-3.02) 1.61 (0.32-2.31) 0.78 (0.32-3.75) 0.806 
eotaxin 1.6 (1.6-1.6) 1.6 (1.6-1.6) 1.6 (1.6-1.6) 0.308 
GRO 343.9 (234.9-541.2) 304.3 (226.6-346) 399.3 (299.2-871.0) 0.123 
GRO-α 654.5 (359.2-1054) 472.0 (325.9-1054) 708.4 (600.9-1508) 0.328 
MIP-1α 0.32 (0.32-4.21) 0.32 (0.32-2.31) 1.31 (0.32-6.64) 0.202 
Neutrophil count 77 (55-96) 80 (71-96) 73 (55-97) 0.817 
Neutrophil percent 0.78 (0.58-0.91) 0.78 (0.69-0.92) 0.73 (0.57-0.91) 0.696 
Eosinophil count 0 (0-2) 1 (0-3) 0 (0-2) 0.364 
Eosinophil percent 0 (0-0.3) 0.1 (0-0.3) 0 (0-0.02) 0.380 




Supplemental Table 4-2. Associations between urinary 1-OHPG and biomarkers of oxidative 




Urinary biomarkers β P>z [95% CI]  β P>z [95% CI] 
Log Isoprostane  0.025 0.176 -0.012 0.062  0.026 0.328 -0.027 0.078 
mRNA for antioxidant genes         
Log NQO1 0.005 0.889 -0.068 0.078  0.040 0.467 -0.071 0.151 
Log HO-1 0.002 0.951 -0.075 0.080  0.010 0.833 -0.084 0.103 
Log GCLM -0.011 0.719 -0.071 0.049  0.002 0.968 -0.091 0.095 
Log GCLC -0.022 0.697 -0.137 0.092  0.031 0.712 -0.140 0.203 
Log TFF2 -0.016 0.777 -0.132 0.099  0.020 0.827 -0.162 0.201 
Log IL-33 -0.062 0.405 -0.211 0.087  -0.086 0.436 -0.309 0.137 
Whole blood biomarker         
Log PBMC no PMA 0.055 0.220 -0.034 0.144  -0.004 0.947 -0.136 0.128 
Log PBMC with PMA 0.006 0.862 -0.061 0.072  -0.022 0.653 -0.118 0.075 
Log Monocytes no PMA 0.062 0.166 -0.027 0.152  -0.003 0.962 -0.134 0.128 
Log Monocytes with PMA -0.010 0.741 -0.071 0.051  -0.052 0.245 -0.140 0.037 
Log Lymphocytes no PMA 0.041 0.407 -0.057 0.140  0.007 0.925 -0.139 0.153 
Log Lymphocytes with PMA 0.017 0.736 -0.081 0.114  -0.019 0.792 -0.166 0.128 
Log PMN no PMA 0.020 0.643 -0.065 0.104  0.040 0.519 -0.084 0.163 
Log PMN with PMA -136.8 0.421 -475.1 201.4  -0.029 0.440 -0.106 0.047 
Log Eosinophil no PMA -0.019 0.869 -0.248 0.211  0.047 0.877 -0.562 0.655 
Log Eosinophil with PMA 0.060 0.651 -0.207 0.328  0.146 0.512 -0.304 0.595 
Log Neutrophil no PMA 0.015 0.801 -0.103 0.132  0.017 0.916 -0.305 0.338 
Log Neutrophil with PMA -0.005 0.890 -0.081 0.070  0.057 0.527 -0.126 0.240 
Serum cytokines and chemokines         
Log CCL20 -0.110 0.203 -0.280 0.061  -0.087 0.470 -0.329 0.154 
Log ECP 0.004 0.898 -0.063 0.072  0.000 0.995 -0.102 0.101 
Log Eotaxin 0.058 0.012 0.013 0.103  0.018 0.505 -0.035 0.071 
Log GRO -0.006 0.768 -0.046 0.034  0.027 0.285 -0.023 0.078 
Log GRO-α -0.073 0.120 -0.167 0.020  -0.076 0.377 -0.247 0.095 
Log IL-6 -0.053 0.327 -0.162 0.055  -0.106 0.193 -0.268 0.056 
Log IL-8 -0.025 0.517 -0.103 0.052  -0.016 0.784 -0.130 0.099 
Log IL-10 -0.064 0.227 -0.168 0.041  -0.136 0.048 -0.271 -0.001 
Log IL-13 -0.014 0.790 -0.116 0.089  -0.015 0.852 -0.172 0.143 
MIP-1α -0.035 0.503 -0.139 0.069  -0.024 0.755 -0.175 0.128 
Log RANTES -0.001 0.945 -0.030 0.028  0.006 0.732 -0.028 0.039 
Nasal lavage biomarkers         
Log Nasal lavage IL-6 1.126 0.145 0.960 1.321  *    
Log Nasal lavage IL-8 -0.015 0.654 -0.082 0.052  0.003 0.947 -0.089 0.095 
Log Nasal lavage IL-10 -0.013 0.587 -0.060 0.035  -0.020 0.602 -0.100 0.060 
Log Nasal lavage IL-13 1.029 0.681 0.898 1.180  1.040 0.803 0.762 1.421 




aAdjusted for urinary creatinine 
bAdjusted for urinary creatinine, age, race, gender, GSTM genotype, and educational attainment 





Supplemental Table 4-3. Associations between urinary 1-OHPG and biomarkers of oxidative 
stress, gene induction, and inflammation, stratified by GSTM1 genotype (without GEE analysis) 
Log Nasal lavage CCL20 0.948 0.469 0.820 1.096  0.949 0.663 0.749 1.202 
Log Nasal lavage eotaxin 1.016 0.891 0.809 1.276  *    
Log Nasal lavage GRO -0.001 0.982 -0.059 0.057  0.020 0.596 -0.059 0.100 
Log Nasal lavage GRO-α 0.001 0.981 -0.070 0.072  0.030 0.468 -0.054 0.114 
Nasal lavage MIP-1α 0.993 0.917 0.867 1.136  1.233 0.464 0.704 2.160 
Nasal lavage RANTES 1.032 0.812 0.796 1.338  *    
Log Nasal lavage neutrophil count -0.026 0.404 -0.088 0.036  0.011 0.859 -0.116 0.139 
Nasal lavage neutrophil percent 0.016 0.466 -0.028 0.061  0.040 0.394 -0.053 0.133 
Nasal lavage eosinophil percent -0.001 0.895 -0.017 0.015  -0.001 0.968 -0.037 0.035 
Log Nasal lavage WBCC -0.031 0.177 -0.076 0.014  -0.006 0.905 -0.107 0.095 
 
GSTM1-null  GSTM1-present 
 
Urinary biomarkers β P>z [95% CI] 
 
β P>z [95% CI] P-interaction 
Log Isoprostane  0.307 0.008 0.100 0.514  0.019 0.517 -0.039 0.077 0.008 
mRNA from antioxidant genes          
Log NQO1 0.146 0.728 -0.807 1.098  0.042 0.519 -0.090 0.174 0.634 
Log HO-1 -0.243 0.426 -0.923 0.437  0.008 0.878 -0.097 0.113 0.355 
Log GCLM -0.170 0.674 -1.085 0.745  -0.003 0.954 -0.103 0.098 0.444 
Log GCLC 0.863 0.229 -0.685 2.411  0.045 0.556 -0.111 0.201 0.042 
Log TFF2 1.053 0.348 -1.476 3.581  0.035 0.691 -0.145 0.215 0.358 
Log IL-33 -1.244 0.394 -4.480 1.993  -0.051 0.474 -0.196 0.095 0.597 
Whole blood biomarkers          
Log PBMC no PMA 0.434 0.335 -0.531 1.399  0.005 0.948 -0.137 0.147 0.166 
Log PBMC with PMA 0.299 0.379 -0.432 1.031  -0.025 0.623 -0.127 0.077 0.319 
Log Monocytes no PMA 0.257 0.569 -0.717 1.232  -0.001 0.988 -0.137 0.135 0.201 
Log Monocytes with PMA 0.256 0.457 -0.481 0.992  -0.056 0.154 -0.134 0.022 0.041 
Log Lymphocytes no PMA 0.667 0.179 -0.368 1.703  0.005 0.946 -0.157 0.168 0.131 
Log Lymphocytes with PMA 0.468 0.233 -0.359 1.294  -0.027 0.748 -0.199 0.145 0.584 
Log PMN no PMA 0.089 0.782 -0.617 0.796  0.051 0.471 -0.093 0.196 0.383 
Log PMN with PMA 0.230 0.372 -0.325 0.786  -0.038 0.341 -0.119 0.043 0.114 
Log Eosinophil no PMA -2.117 0.375 -8.008 3.775  0.046 0.892 -0.650 0.741 0.675 
Log Eosinophil with PMA -0.283 0.741 -2.768 2.201  0.156 0.575 -0.414 0.726 0.869 
Log Neutrophil no PMA -0.524 0.733 -4.497 3.449  -0.006 0.973 -0.381 0.369 0.952 
Log Neutrophil with PMA -1.077 0.340 -3.838 1.684  0.039 0.658 -0.143 0.222 0.742 
Serum cytokines and chemokines          
Log CCL20 1.843 0.003 0.785 2.900  -0.103 0.373 -0.337 0.130 0.011 




Adjusted for urinary creatinine, age, gender, race, season, and educational attainment 




Log Eotaxin -0.014 0.878 -0.217 0.189  0.025 0.416 -0.038 0.088 0.594 
Log GRO 0.285 0.016 0.067 0.504  0.015 0.603 -0.043 0.073 0.111 
Log GRO-α 0.511 0.004 0.209 0.813  -0.151 0.116 -0.342 0.040 0.022 
Log IL-6 0.193 0.631 -0.683 1.068  -0.083 0.221 -0.220 0.053 0.302 
Log IL-8 0.656 0.016 0.157 1.155  -0.001 0.982 -0.122 0.119 0.181 
Log IL-10 0.318 0.286 -0.315 0.951  -0.113 0.127 -0.261 0.034 0.601 
Log IL-13 0.765 0.158 -0.360 1.890  -0.002 0.979 -0.143 0.139 0.299 
MIP-1α -0.767 0.244 -2.159 0.624  0.050 0.400 -0.070 0.170 0.232 
Log RANTES 0.119 0.014 0.031 0.207  0.006 0.764 -0.033 0.045 0.830 
Nasal lavage biomarkers          
Log Nasal lavage IL-8 0.714 0.298 -1.492 2.920  0.008 0.899 -0.129 0.145 0.843 
Log Nasal lavage IL-10 *     -0.022 0.603 -0.112 0.069  
Log Nasal lavage IL-13 *     0.940 0.776 0.612 1.442  
Log Nasal lavage ECP *     1.074 0.652 0.789 1.462  
Log Nasal lavage CCL20 *     0.391 0.116 0.121 1.261  
Log Nasal lavage GRO 0.553 0.232 -0.850 1.956  0.006 0.912 -0.111 0.123 0.430 
Log Nasal lavage GRO-α 0.329 0.480 -1.312 1.969  0.009 0.858 -0.098 0.116 0.073 
Nasal lavage MIP-1α *     0.957 0.920 0.407 2.252 0.508 
Log Nasal lavage neutrophil count 0.353 0.131 -0.142 0.849  -0.017 0.792 -0.151 0.117 0.282 
Nasal lavage neutrophil percent 0.177 0.302 -0.206 0.560  0.024 0.648 -0.084 0.133 0.658 
Nasal lavage eosinophil percent 0.021 0.303 -0.025 0.068  -0.002 0.936 -0.048 0.044 0.757 




Supplemental Table 4-4. Comparison between multivariate linear regression models without and 
with GEE analysis (model: associations between urinary 1-OHPG and biomarkers of oxidative 
stress, gene induction, and inflammation) 
 MLR without GEE (full model)  MLR with GEE (full model) 
Urinary oxidative stress biomarker β P>z [95% CI]  β P>z [95% CI] 
Log isoprostane  0.026 0.328 -0.027 0.078  0.026 0.181 -0.012 0.063 
mRNA           
Log NQO-1 0.040 0.467 -0.071 0.151  0.051 0.084 -0.007 0.109 
Log HO-1 0.010 0.833 -0.084 0.103  0.017 0.576 -0.044 0.078 
Log GCLM 0.002 0.968 -0.091 0.095  0.009 0.690 -0.034 0.052 
Log GCLC 0.031 0.712 -0.140 0.203  0.035 0.435 -0.053 0.124 
Log TFF2 0.020 0.827 -0.162 0.201  0.024 0.589 -0.064 0.112 
Log IL-33 -0.086 0.436 -0.309 0.137  -0.101 0.031 -0.194 -0.009 
Serum cytokines and chemokines          
Log Serum IL-6 0.659 0.187 0.355 1.223  -0.027 0.157 -0.064 0.010 
Log Serum IL-8 -0.016 0.784 -0.130 0.099  -0.009 0.654 -0.050 0.031 
Log Serum IL-10 -0.136 0.048 -0.271 -0.001  -0.052 0.027 -0.098 -0.006 
Log Serum IL-13 -0.015 0.852 -0.172 0.143  0.006 0.665 -0.023 0.036 
Log Serum CCL20 -0.087 0.470 -0.329 0.154  -0.128 0.010 -0.225 -0.031 
Log Serum ECP 0.000 0.995 -0.102 0.101  0.006 0.879 -0.068 0.080 
Log Serum eotaxin 0.018 0.505 -0.035 0.071  0.011 0.546 -0.026 0.048 
Log Serum GRO 0.027 0.285 -0.023 0.078  0.015 0.384 -0.019 0.049 
Log Serum GRO-α -0.076 0.377 -0.247 0.095  0.038 0.068 -0.003 0.079 
Log Serum MIP-1α -0.024 0.755 -0.175 0.128  -0.017 0.249 -0.046 0.012 
Log Serum RANTES 0.006 0.732 -0.028 0.039  0.008 0.194 -0.004 0.021 
Nasal Lavage biomarkers          
Log Nasal lavage IL-8 0.003 0.947 -0.089 0.095  -0.019 0.532 -0.079 0.041 
Log Nasal lavage IL-10 -0.020 0.602 -0.100 0.060  -0.017 0.486 -0.064 0.030 
Log Nasal lavage IL-13  1.040 0.803 0.762 1.421  0.037 0.721 -0.167 0.241 
Log Nasal lavage ECP  1.152 0.340 0.861 1.542  0.148 0.323 -0.145 0.441 
Log Nasal lavage CCL20  0.949 0.663 0.749 1.202  -0.041 0.660 -0.224 0.142 
Log Nasal lavage GRO 0.020 0.596 -0.059 0.100  0.020 0.518 -0.041 0.082 
Log Nasal lavage GRO-α 0.030 0.468 -0.054 0.114  0.037 0.114 -0.009 0.083 
Log Nasal lavage MIP-1α 1.233 0.464 0.704 2.160  *    
Log Neutrophil count 0.011 0.859 -0.116 0.139  0.010 0.834 -0.085 0.105 
Neutrophil percent 0.040 0.394 -0.053 0.133  0.043 0.121 -0.011 0.097 
Eosinophil percent -0.001 0.968 -0.037 0.035  0.013 0.008 0.003 0.023 
Log White blood cell count -0.006 0.905 -0.107 0.095  -0.002 0.946 -0.070 0.066 
Whole blood biomarkers          
Log PBMC no PMA -0.004 0.947 -0.136 0.128  -0.076 0.024 -0.142 -0.010 
Log PBMC with PMA -0.022 0.653 -0.118 0.075  -0.034 0.383 -0.111 0.043 
Log Monocytes no PMA -0.003 0.962 -0.134 0.128  -0.037 0.276 -0.104 0.030 
Log Monocytes with PMA -0.052 0.245 -0.140 0.037  -0.057 0.092 -0.124 0.009 




Adjusted for urinary creatinine, age, gender, race, season, and educational attainment 










Log Lymphocytes with PMA -0.019 0.792 -0.166 0.128  -0.035 0.612 -0.169 0.100 
Log PMN no PMA 0.040 0.519 -0.084 0.163  0.039 0.432 -0.058 0.136 
Log PMN with PMA -0.029 0.440 -0.106 0.047  -0.034 0.217 -0.087 0.020 
Log Eosinophils no PMA 0.047 0.877 -0.562 0.655  0.012 0.943 -0.319 0.343 
Log Eosinophils with PMA 0.146 0.512 -0.304 0.595  0.314 0.023 0.043 0.586 
Log Neutrophils no PMA 0.017 0.916 -0.305 0.338  -0.079 0.274 -0.219 0.062 



























































































































































































































































































































































































































































































      
 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplemental Table 4-6. Associations between urinary 1-OHPG and biomarkers of oxidative 
stress, gene induction, and inflammation with time between visits (days) in the modela 
 
GSTM1-null  GSTM1-present 
 
Urinary biomarkers β P>z [95% CI] 
 
β P>z [95% CI] P-int 
Log Isoprostane (w/o outlier)  0.306 0.013 0.080 0.532  0.019 0.529 -0.041 0.078 0.010 
mRNA for antioxidant enzymes          
Log NQO-1 0.148 0.732 -0.861 1.157  0.047 0.477 -0.088 0.182 0.531 
Log HO-1 -0.241 0.445 -0.964 0.481  -0.007 0.886 -0.101 0.088 0.750 
Log GCLM -0.167 0.675 -1.096 0.762  -0.003 0.950 -0.107 0.101 0.459 
Log GCLC 0.868 0.226 -0.705 2.441  0.057 0.448 -0.097 0.212 0.022 
Log TFF2 1.019 0.388 -1.754 3.792  0.051 0.550 -0.124 0.227 0.186 
Log IL-33 -1.231 0.366 -4.310 1.848  -0.048 0.519 -0.200 0.105 0.544 
Whole blood biomarkers          
Log PBMC no PMA 0.484 0.356 -0.656 1.624  0.006 0.936 -0.140 0.152 0.181 
Log PBMC with PMA 0.319 0.420 -0.548 1.186  -0.029 0.576 -0.133 0.075 0.399 
Log Monocytes no PMA 0.264 0.588 -0.799 1.327  0.003 0.967 -0.137 0.143 0.203 
Log Monocytes with PMA 0.254 0.493 -0.550 1.057  -0.057 0.161 -0.137 0.024 0.055 
Log Lymphocytes no PMA 0.594 0.294 -0.625 1.813  0.014 0.862 -0.151 0.179 0.109 
Log Lymphocytes with PMA 0.404 0.366 -0.568 1.376  -0.010 0.907 -0.181 0.161 0.388 
Log PMN no PMA -0.029 0.937 -0.833 0.776  0.043 0.552 -0.103 0.190 0.531 
Log PMN with PMA 0.077 0.768 -0.507 0.661  -0.038 0.353 -0.122 0.045 0.143 
Log Eosinophil no PMA -1.609 0.601 -10.399 7.180  0.001 0.997 -0.704 0.706 0.672 
Log Eosinophil with PMA 0.245 0.808 -3.573 4.064  0.152 0.595 -0.438 0.743 0.870 
Log Neutrophil no PMA 0.077 0.968 -5.562 5.715  -0.014 0.940 -0.402 0.374 0.951 
Log Neutrophil with PMA -0.296 0.779 -3.366 2.773  0.028 0.753 -0.157 0.214 0.749 
Serum cytokines and chemokines          
Log CCL20 1.768 0.006 0.652 2.884  -0.134 0.233 -0.360 0.091 0.021 
Log ECP 0.300 0.209 -0.207 0.808  0.006 0.905 -0.096 0.108 0.067 
Log Eotaxin 0.010 0.909 -0.186 0.206  0.025 0.435 -0.040 0.090 0.597 
Log GRO 0.257 0.020 0.051 0.463  0.026 0.304 -0.025 0.078 0.022 
Log GRO-α 0.506 0.008 0.175 0.837  -0.132 0.162 -0.320 0.056 0.022 
Log IL-6 0.340 0.300 -0.368 1.048  -0.076 0.273 -0.215 0.063 0.236 
Log IL-8 0.694 0.016 0.171 1.217  0.000 1.000 -0.124 0.124 0.173 
Log IL-10 0.431 0.074 -0.052 0.915  -0.114 0.135 -0.266 0.038 0.599 
Log IL-13 0.910 0.083 -0.149 1.969  0.021 0.745 -0.110 0.153 0.138 
MIP-1α -0.584 0.330 -1.880 0.713  0.040 0.504 -0.080 0.160 0.183 
Log RANTES 0.113 0.024 0.019 0.206  0.008 0.679 -0.031 0.048 0.673 
Nasal lavage biomarkers          
Log Nasal lavage IL-8 0.714 0.298 -1.492 2.920  0.057 0.440 -0.103 0.218 0.824 
Log Nasal lavage IL-10 *     -0.024 0.643 -0.140 0.091 0.739 
Log Nasal lavage IL-13 *     1.190 0.607 0.613 2.310 0.404 
Log Nasal lavage ECP *     1.041 0.917 0.486 2.229 0.136 




ajMultivariate linear regression model (without GEE analysis) adjusted for urinary creatinine, age, gender, race, season, and educational 
attainment 










Log Nasal lavage GRO 0.553 0.232 -0.850 1.956  0.050 0.431 -0.087 0.186 0.402 
Log Nasal lavage GRO-α 0.329 0.480 -1.312 1.969  0.064 0.230 -0.049 0.177 0.074 
Log Neutrophils 0.364 0.154 -0.194 0.923  -0.030 0.650 -0.166 0.106 0.346 
Log Neutrophil percent 0.066 0.425 -0.129 0.261  0.009 0.697 -0.037 0.054 0.841 
Log Eosinophil percent 0.021 0.360 -0.032 0.074  0.013 0.469 -0.023 0.048 0.366 
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